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Summary
Neurodegenerative diseases are a growing burden in the modern ageing societies. Especially
Alzheimer’s disease (AD)—the most common form of dementia—has gained lot of attention
lately. Although several drugs are available to enhance the life-quality of people with AD,
none of them can stop the progression or cure this disease. Therefore new medications for
treatment and prevention are needed. Medicinal plants are a rich source for drug leads and
active compounds. Furthermore, plant extracts are potential multitarget drugs that can be
particularly useful for diseases with complex pathology like AD. Therefore, in the present
work plants from Traditional Chinese Medicine (TCM) were tested for their efficacy against
two prominent pathological markers in AD: beta-amyloid (Aβ) aggregates and oxidative
damage.
For the present study the model organism Caenorhabditis elegans was deployed. In a
screening of 55 TCM plant extracts on a C. elegans strain expressing human Aβ peptide in
muscles, several extracts that could reduce Aβ aggregation were identified. From those the
three most active ones were chosen for further evaluation. The methanol extract of Gly-
cyrrhiza uralensis proved to have the best characteristics for therapeutic use. Additionally
to the reduction of Aβ aggregates by 30 %, this extract could also counteract Aβ toxicity
in a paralysis assay by increasing the mean time of paralysis (PT50) by 1.8 h and showed
antioxidant activity in the heat shock protein (HSP) expression assay.
The major compounds in the G. uralensis extract were identified via LC-MS/MS. Four
substances—glycyrrhizic acid (GA), glycyrrhetinic acid (GRA), liquiritigenin (LG), and iso-
liquiritigenin (ILG)—were chosen as possible active compounds. From those ILG showed
the strongest activity by reducing Aβ aggregation by 26 % and counteracting Aβ toxicity
in paralysis assay (1.2 h delay in PT50). It also affected serotonergic neurotransmission
in C. elegans with neuronal Aβ expression. Furthermore, significant antioxidant activity
was shown in the HSP expression assay, and the survival of worms under oxidative stress
was increased by 82 % after treatment with ILG. This compound could induce nuclear
translocation of the transcription factor DAF-16 that is responsible for stress resistance
and longevity in C. elegans. The mechanism of action of ILG in counteracting Aβ toxicity
could therefore involve hormesis and modulation of serotonergic neurotransmission.
The present work also reports for the first time the effect of Carlina acaulis against Aβ
toxicity and its antioxidant activity in vivo. The dichloromethane extract of this plant de-
layed the Aβ-induced paralysis by 1.6 h. GLC-MS analysis identified Carlina oxide as the
main compound in this extract. Carlina oxide alone was not as active as the extract in paral-
ysis assay, but it was responsible for the antioxidant activity. Both the extract and Carlina
oxide were active in the HSP expression assay and could induce DAF-16 delocalisation. The
mechanism of action for C. acaulis against Aβ toxicity still needs further study, although
hormetic effects and the antioxidant activity may contribute to this effect.
The plants and compounds identified in this study should be considered for further inves-
tigation in vertebrate models. Especially their bioavailability and drug safety need broader
attention. The initial results reported here suggest G. uralensis, C. acaulis, and ILG as
possible candidates for prevention or treatment of AD. Their positive effects counteracting
protein aggregation and oxidative stress might also be useful against other neurodegenera-
tive diseases and for healthy ageing in general.
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Zusammenfassung
Neurodegenerative Erkrankungen werden immer mehr zu einer größeren Last in der zeitgenössi-
schen, alternden Gesellschaft. Besonders die Alzheimer Erkrankung (AD) – die am häufigsten vor-
kommende Demenzart – wurde diesbezüglich in den letzten Jahren in den Fokus gerückt. Obwohl
mehrere Medikamente zur Verbesserung der Lebensqualität der Menschen mit AD zur Verfügung
stehen, kann keines dieser den Krankheitsverlauf anhalten oder die Patienten heilen. Daher besteht
Bedarf an neuen Medikamenten zur Behandlung und Prävention. Arzneipflanzen stellen eine reich-
haltige Quelle für Leitsubstanzen und Wirkstoffe dar. Darüber hinaus sind Pflanzenextrakte in der
Lage mit mehreren Targets zu interagieren, was bei einer komplexen Pathologie wie die der AD von
Vorteil sein kann. Daher wurden in der vorliegenden Arbeit Pflanzen aus der Traditionellen Chine-
sischen Medizin (TCM) auf ihre Wirksamkeit an zwei prominenten pathologischen Markern von AD
– Beta-Amyloid (Aβ)-Aggregate und oxidativer Schaden – getestet.
Für die vorliegende Arbeit wurde der Modellorganismus Caenorhabditis elegans benutzt. In einem
Screening von 55 Extrakten aus TCM Pflanzen an einer C. elegans Linie, die das menschliche Aβ-
Peptid in den Muskeln exprimiert, wurden mehrere Extrakte gefunden, die die Aβ-Aggregation
hemmten. Von diesen wurden die drei Effektivsten für weitere Untersuchungen ausgewählt. Der
Methanolextrakt aus Glycyrrhiza uralensis erwies sich als der am besten Geeigneteste für eine Be-
handlung. Zusätzlich zu der Hemmung der Aβ-Aggregation um 30 % konnte dieser Extrakt auch
die Toxizität von Aβ in einem Paralyse-Test herabsetzen, wobei die mittlere Zeit zur Paralyse (PT50)
um 1,8 h verlängert wurde, und zeigte antioxidative Wirkung in dem Hitzeschock-Protein (HSP)-
Expressions-Test.
Die Hauptbestandteile des G. uralensis Extrakts wurden mittels LC-MS/MS identifiziert. Vier
Substanzen – Glycyrrhizinsäure (GA) , Glycyrrhetinsäure (GRA) , Liquiritigenin (LG) und Isoliquiri-
tigenin (ILG) – wurden als mögliche Wirkstoffe ausgewählt. Von diesen zeigte ILG die höchste Akti-
vität, indem es die Aβ-Aggregation um 26 % hemmte und der Aβ-Toxizität in dem Paralyse-Test ent-
gegenwirkte (1,2 h Verzögerung in PT50). ILG beeinflusste auch die serotonerge Signalübertragung
in C. elegans mit neuronaler Aβ-Expression. Darüber hinaus konnte eine signifikante Aktivität in
dem HSP-Expressions-Test gezeigt sowie die Überlebensrate von Würmern unter oxidativem Stress
durch die Behandlung mit ILG um 82 % erhöht werden. Diese Substanz konnte die Translokation
des Transkriptionsfaktors DAF-16, der für Stressresistenz und Langlebigkeit in C. elegans zuständig
ist, in den Zellkern induzieren. Der Wirkmechanismus von ILG gegen Aβ-Toxizität könnte daher
eine Hormesis und die Modulation der serotonergen Signalübertragung mit einschließen.
In der vorliegenden Arbeit wurde auch zum ersten mal eine Wirkung von Carlina acaulis gegen
die Aβ-Toxizität und seine antioxidative Wirkung in vivo aufgezeigt. Der Dichlormethanextrakt
von dieser Pflanze verzögerte die Aβ-induzierte Paralyse um 1,6 h. Eine GLC-MS Analyse identi-
fizierte Carlinaoxid als den Hauptbestandteil dieses Extraktes. Carlinaoxid als Reinsubstanz zeigte
in dem Paralyse-Test eine geringere Wirksamkeit als der Extrakt, aber war für die antioxidative
Wirkung verantwortlich. Der Extrakt und das Carlinaoxid waren beide wirksam in dem HSP-
Expressions-Test und induzierten die DAF-16 Delokalisation. Der Wirkmechanismus von C. acaulis
gegen Aβ-Toxizität bedarf weiterer Untersuchungen, obwohl hormetische Effekte und die antioxida-
tive Wirkung dazu beitragen können.
Die Pflanzen und Reinstoffe, die sich in dieser Arbeit als wirksam gezeigt haben, sollten für wei-
tere Untersuchungen an Vertebraten in Betracht gezogen werden. Besonders die Bioverfügbarkeit
und Arzneimittelsicherheit benötigen umfassende Aufmerksamkeit. Die Ergebnisse dieser Arbeit
machen G. uralensis, C. acaulis und ILG zu möglichen Kandidaten für Prävention und Behandlung
von AD. Ihre positive Wirkungen auf Proteinaggregation und oxidativen Stress könnten auch gegen
andere neurodegenerative Erkrankungen sowie für ein gesundes Altern allgemein hilfreich sein.
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1 Introduction
1.1 Alzheimer’s disease
Alzheimer’s disease (AD) was first described by Alois Alzheimer as a presenile dementia
he observed in one of his patients, Auguste D. The 51 year old woman suffered from loss
of memory, confusion, auditory hallucinations, and anxiety (Alzheimer, 1907). After the
death of his patient, Alzheimer examined her brain. He found an uniform atrophy of the
brain accompanied by fibrillar inclusions in the neurons—neurofibrillary tangles—and an-
other kind of extracellular inclusions, that became known as senile plaques. The plaques
are mostly found in the isocortex, whereas the neurofibrillary tangels first appear in the
entorhinal cortex, then in limbic areas, and only in late stages of the disease affect also the
isocortex (Braak & Braak, 1991). Memory dysfunction is the most common early symptom
in AD. It is usually accompanied by a complex mixture of several other cognitive deficits
and neuropsychiatric comorbidities that are partly related to the brain areas affected by the
pathology (Lyketsos et al., 2011; Peña-Casanova et al., 2012).
The senile plaques can be divided, based on their morphology, into diffuse plaques and
classical cored plaques. All of them contain a protein known as beta-amyloid (Aβ) and vari-
able other constituents (reviewed in Armstrong, 2009). The cored plaques are characterized
by dense cores consisting of fibrillar Aβ and are often accompanied by dystrophic neurites
(then also called neuritic plaques). Due to the insolubility of Aβ fibrils in most common
solvents it was possible to isolate and purify them (Selkoe et al., 1986) and the protein was
first sequenced by Masters et al. (1985). Comparison of the sequences of the protein forming
the plaque cores and an amyloid from cerebral blood vessels from AD patients (Glenner &
Wong, 1984b) showed that also the latter inclusions contain Aβ. The neurofibrillary tangles
proved to be more difficult to purify, but by immunochemical methods they were shown to
contain the protein tau (Grundke-Iqbal et al., 1986a).
In the beginning of 20th century only a few presenile cases of AD caught the attention of
physicians like A. Alzheimer, but as the disease became better known, it was also detected
in many old patients. Today age is considered the most important risk factor for AD. In only
about 4 % of the cases the symptoms occur before the age of 65 (Alzheimer’s Association,
2015). A small portion of this early onset AD is caused by genetic mutations in genes related
to Aβ (see section 1.1.1) and has an autosomal dominant heredity. In these cases the people
affected can be as young as 30 years. In the much more common late onset AD no single
gene is responsible for the condition (see section 1.1.4).
AD comprises 60–80 % of all dementia cases (Alzheimer’s Association, 2015). About 5 %
of people over the age of 60 worldwide suffer from AD, and since the population of many
countries is ageing, the number of people with AD is predicted to triple until 2050 (Prince
& Jackson, 2009). Although AD is the most common form of dementia and has been known
and studied for over a century, it is still not clear what causes this syndrome. Figure 1.1
shows some of the proteins and cellular processes found to contribute to the pathology. These
factors and their interplay as well as approaches for diagnosis and treatment are described
in following sections.
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Figure 1.1: Overview of some cellular defects in AD. Next to Aβ overload and tau hyperphosphory-
lation also mitochondrial dysfunction, oxidative stress, neuroinflammation, and other abnormal-
ities are found in AD brains, ultimately leading to neuronal damage and cell death. The arrows
point to possible causative connections between them. APOE: apolipoprotein E; APP: amyloid
precursor protein; Aβ: beta-amyloid; ROS: reactive oxygen species.
1.1.1 β-Amyloid
Extracellular depositions of Aβ are one pathological hallmark of AD. Soon after the se-
quencing of this peptide, the gene coding for it was discovered and located on chromosome
21 (Goldgaber et al., 1987; Kang et al., 1987; Robakis et al., 1987). Aβ is a cleavage product
of a type I transmembrane protein called amyloid precursor protein (APP) (Koo & Squazzo,
1994). APP is a glycosylated protein with a length of 695–770 amino acids that is expressed
in several cell types with the highest expression rate in neurons (Beyreuther et al., 1993;
Dyrks et al., 1988; Weidemann et al., 1989). There predominantly the splicing form with 695
amino acids is found, and it is concentrated in synapses (Kang & Müller-Hill, 1990; Schu-
bert et al., 1991). Although the exact function of APP is still not clear, the different cleavage
products of it have both trophic and toxic effects and are essential to the development of an
organism (reviewed in Nhan et al., 2015).
APP can be cleaved by different secretases (Fig. 1.2). α-Secretase has its cleavage site
within the Aβ peptide between Lys-16 and Leu-17 (Esch et al., 1990). Different zinc bind-
ing metalloproteinases from a disintegrin and metalloproteinase (ADAM) family have α-
secretase activity, especially ADAM10 (reviewed in Lichtenthaler, 2011). This cleavage re-
sults in a soluble APP ectodomain (sAPPα) and a C-terminal membrane bound peptide of 83
amino acids (C83). The latter can be further cleaved to p3 peptide and APP intracellular C-
terminal domain (AICD) by γ-secretase, a complex of presenilin (PSEN), nicastrin, anterior
pharynx defective 1 (APH1), and presenilin enhancer (PEN2) (Edbauer et al., 2003; Kim-
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Figure 1.2: APP processing and mutations. The Aβ fragment is marked in red and its sequence
is shown on the right together with possible mutations in or adjacent to this peptide (red:
pathogenic; green: protective).
berly et al., 2003). Alternatively the full length APP can be cleaved by β-site APP-cleaving
enzyme 1 (BACE1), which leads to the production of sAPPβ and C99 (Hussain et al., 1999;
Lin et al., 2000; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999). Subsequent cleav-
age of C99 by γ-secretase leads to the release of Aβ peptide and AICD. The C83 or C99
fragments can also be cleaved by caspases, resulting in C31 (the last 31 amino acids of the
C-terminus of APP) and by subsequent γ-secretase cleavage in Jcasp (Gervais et al., 1999).
For a more detailed review on APP processing see Zhang et al. (2011).
The secretases and APP are transmembrane proteins. They are produced in endoplasmic
reticulum, transported to Golgi for maturation, and from there sent to plasma membrane.
Regulation of this trafficking has an impact on Aβ generation, depending on the colocalisa-
tion of APP with the different secretases. The α-secretase is active at the plasma membrane,
where mostly sAPPα is produced (Parvathy et al., 1999). BACE1 can cleave APP in the en-
doplasmic reticulum, in trans-Golgi network, at the plasma membrane where it competes
with α-secretase, and in endosomes (Chyung & Selkoe, 2003; Cook et al., 1997; Kinoshita
et al., 2003; Vassar et al., 1999). Since BACE1 has its pH optimum at 4–5.5, the intracellu-
lar acidic compartments account for most of its activity (Knops et al., 1995; Lin et al., 2000;
Sinha et al., 1999; Vassar et al., 1999). γ-Secretase complex needs complete assembly and
maturation, it is first active at the plasma membrane and also has an acidic pH optimum
(Kaether et al., 2006; Pasternak et al., 2003). Therefore, Aβ peptides are mostly generated
in the endosome, where APP and its C-terminal fragments are sorted after internalisation
to be recycled to the plasma membrane or degraded, and in lysosomes (Haass et al., 1992;
Koo & Squazzo, 1994; Pasternak et al., 2003; Yamazaki et al., 1996). In damaged neurons
also the autophagic vacuoles have been shown to be a site of Aβ generation (Yu et al., 2005).
APP, BACE1, and γ-secretase localize to lipid rafts—membrane microdomains that are rich
in cholesterol and sphingolipids (Riddell et al., 2001; Vetrivel et al., 2004). The interactions
of secretases and APP with membrane lipids and cholesterol can modulate secretion of Aβ,
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but also its aggregation and clearance as reviewed by Walter & van Echten-Deckert (2013).
The Aβ peptide has a length of 37–43 amino acids due to the multiple cleavage sites of
γ-secretase (Qi-Takahara et al., 2005). The most abundant form under normal conditions is
Aβ1–40, followed by a smaller amount of Aβ1–42. Also N-terminal truncated forms (Aβx–40/42)
and other C-termini can be found in small amounts (Miller et al., 1993; Vigo-Pelfrey et al.,
1993). These peptides can aggregate into oligomers, protofibrils, and finally fibrils that
deposit into plaques. Diffuse and cored plaques contain mostly Aβ1/x–42, plaques in the walls
of leptomeningeal and intracortical blood vessels (a sign of cerebral amyloid angiopathy
often found in AD brains) contain both Aβ1/x–40 and Aβ1/x–42 (Gowing et al., 1994; Gravina
et al., 1995; Iwatsubo et al., 1994; Miller et al., 1993; Roher et al., 1993a,b). Monomeric Aβ
is naturally unfolded in aqueous solutions. In solid plaque cores, fibrils of Aβ with a cross-β
structure are found. The formation of fibrils is dependent on pH, solvent, and concentration
of the peptide. Aβ1–42 has a higher tendency to aggregate into fibrils because of a more
stable β-sheet formation, and it is the first aggregate forming species in the course of AD
(Barrow et al., 1992; Burdick et al., 1992; Iwatsubo et al., 1994). This process probably starts
with an intraneuronal aggregation (Capetillo-Zarate et al., 2012; Gouras et al., 2000; Ling
et al., 2014). The N-truncated forms and the p3 peptide (Aβ17–x) are found in diffuse plaques
and tend to aggregate more rapidly than the full length Aβ (Gowing et al., 1994; Kumar-
Singh et al., 2000; Pike et al., 1995). These species, Aβ with pyroglutamate at positions 3
or 11, and phosphorylated peptides are found in later stages of AD (Rijal Upadhaya et al.,
2014).
Several missense mutations have been found in the APP gene in families with herita-
ble AD or cerebral haemorrhage. Most of the pathogenic mutations are located near the
secretase cleavage sites (Fig. 1.2). The Swedish mutation (Mullan et al., 1992) is a dou-
ble mutation affecting two amino acid residues near the β-cleavage site (K670N/M671L,
positions given for APP770 transcript) that increases the production of both Aβ1–40 and
Aβ1–42 (Citron et al., 1992; Scheuner et al., 1996). Recently a mutation at codon 673 has
been shown to be protective against AD by inhibiting the β-cleavage (Jonsson et al., 2012).
Many of the other mutations are located near the γ-secretase cleavage sites (Ancolio et al.,
1999; Chartier-Harlin et al., 1991; De Jonghe et al., 2001; Eckman et al., 1997; Goate et al.,
1991; Guardia-Laguarta et al., 2010; Kumar-Singh et al., 2000; Murrell et al., 1991, 2000;
Pasalar et al., 2002; Terreni et al., 2002) and increase the Aβ1–42/Aβ1–40 ratio (De Jonghe
et al., 2001; Eckman et al., 1997; Guardia-Laguarta et al., 2010; Scheuner et al., 1996).
Two mutations lying at the cytoplasmic transmembrane junction at the residues 723 and
724 of APP770 have a similar effect (Kwok et al., 2000; Theuns et al., 2006). Consistent
with the notion that γ-secretase cleavage plays an important role in familial AD, there
are 207 pathogenic mutations in PSEN1 gene and 13 in PSEN2 (AD & FTD Mutation
Database (http://www.molgen.vib-ua.be/ADMutations, accessed on 20/11/2015), Cruts et al.,
2012). PSENs also play a role in cellular processes independent of Aβ such as calcium ho-
moeostasis, endocytosis, and autophagy that are found to be impaired in both familial and
sporadic AD (reviewed in Smolarkiewicz et al., 2013). Mutations lying inside the Aβ se-
quence are associated with cerebral amyloid angiopathy and cerebral haemorrhage, but in
some cases also AD symptoms were accompanied with the vascular ones (Giaccone et al.,
2002; Grabowski et al., 2001; Hendriks et al., 1992; Kamino et al., 1992; Levy et al., 1990;
Nilsberth et al., 2001; Obici et al., 2005; Rossi et al., 2004). Some of these mutations lead
to differences in APP processing, others affect the aggregation kinetics of the Aβ peptide
(Haass et al., 1994; Nilsberth et al., 2001; Watson et al., 1999). Additionally to these muta-
tions, duplication of the APP gene can lead to AD symptoms as seen in people with Down’s
syndrome, a condition arising from trisomy of chromosome 21 (Glenner & Wong, 1984a).
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Aβ-fibrils were first thought to be the toxic species, but due to the lack of correlation be-
tween plaques and cognitive decline (Gómez-Isla et al., 1997; Lue et al., 1999; Snowdon,
2003) and evidence that oligomers of Aβ are far more toxic than the fibrils (Lambert et al.,
1998; Walsh et al., 2002), most of the recent research has concentrated on low molecular
weight aggregates. The oligomers are heterogeneous and sensitive to solution conditions,
which complicates the study of these aggregates (Benilova et al., 2012). The exact size
or structure of the toxic Aβ species is not yet known, as an example globular or annu-
lar oligomers that interact with membranes are shown to be toxic (Sebollela et al., 2014;
Tsigelny et al., 2014). It is also not clear how these oligomers exert their toxicity. Since
Ca2+ levels are raised in affected neurons and Aβ is known to interact with membranes, it
has been suggested that the oligomers can increase membrane permeability unspecifically
(Kayed et al., 2004) or by forming pores that are selective for Ca2+ (Arispe, 2004; Durell
et al., 1994; Lin et al., 2001a). This mechanism would lead to unspecific toxicity in all cells.
Another hypothesis states that there is a ‘toxin receptor’ that allows the oligomers to target
a specific population of cells at the presynaptic sites. Many such receptors for Aβ oligomers
have been proposed (reviewed in Dinamarca et al., 2012). One of them is the prion pro-
tein (PrP) that can activate FYN proto-oncogene (FYN), a cytoplasmic tyrosin kinase (Chin
et al., 2004; Lacor et al., 2004; Laurén et al., 2009; Um et al., 2012). Binding to PrP or other
possible receptors leads to exitotoxicity, aberrant morphology with loss of dendritic spines,
and decreases in long term potentiation (Lacor et al., 2007; Laurén et al., 2009; Um et al.,
2012). Some of the possible mechanisms are discussed in a recent review by Viola & Klein
(2015). For effects of Aβ on oxidative stress, mitochondrial dysfunction, and inflammation
in AD see section 1.1.3.
The Aβ peptides can be cleared from brain by several routes. The observation of de-
greased Aβ clearance in patients with late onset AD (Mawuenyega et al., 2010) has pointed
out a possible defect in one of these pathways as a cause for this most common form of AD.
One important way of clearance is the active transport of Aβ over the blood brain barrier.
Transport from the brain into blood is mediated by P-glycoprotein (Cirrito et al., 2005), low
density lipoprotein receptor-related protein 1 (LRP1) (Shibata et al., 2000), and low density
lipoprotein receptor (Castellano et al., 2012). The latter two are dependent on apolipoprotein
E (APOE) (Castellano et al., 2011), a major risk factor for late onset AD (see section 1.1.4).
Aβ can also be transported in the other direction, from blood to brain, dependent on ad-
vanced glycosylation end product-specific receptor (RAGE) (Deane et al., 2003). This raises
the possibility that part of the Aβ burden in brain actually originates in systemic circula-
tion. Changed levels and localization of LRP1 and RAGE in AD brains probably contribute
to the pathogenesis (Donahue et al., 2006). Another minor pathway for Aβ clearance is
the perivascular drainage of interstitial fluid. This can also explain the arterial deposition
of Aβ in cerebral amyloid angiopathy (Weller et al., 1998). Along this pathway Aβ is re-
moved by perivascular macrophages, whereas microglia and peripheral macrophages have
only a minor role in phagocytotic Aβ clearance (Hawkes & McLaurin, 2009; Mildner et al.,
2011). Aβ can be taken up by cells and transported to lysosomes, where Aβ1–40 is rapidly
degraded. Aβ1–42 is more resistant to degradation and tends to accumulate (Burdick et al.,
1997). This can lead to lysosomal dysfunction and release of the contents of lysosomes into
cytosol (Yang et al., 1998). Microglia, neurons, astrocytes, and cells of the blood vessels syn-
thesise a variety of enzymes that are able to degrade Aβ (reviewed in Miners et al., 2011).
The most important ones among them are insulin degrading enzyme (Qiu et al., 1998) and
neprilysin, a membrane bound protein that can be released into extracellular space and ac-
counts for the most Aβ degrading activity in vivo (Iwata et al., 2000). The activity of these
enzymes is up-regulated in ageing brain and in AD, probably as a physiological response to
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increased Aβ level. However, since these enzymes also have a variety of other substrates,
the up-regulation can lead to detrimental effects like vasoconstriction and reduced cerebral
blood flow (Miners et al., 2014). Others have also reported decreased levels of neprilysin
(reviewed in Grimm et al., 2013) and the ability of insulin degrading enzyme to process Aβ
may be compromised due to brain insulin resistance (see section 1.1.4).
The mutations found in APP, causing autosomal dominant AD, and the observation of dif-
fuse plaques before any other abnormal lesions or neuronal damage led to the formulation
of amyloid cascade hypothesis (Hardy & Allsop, 1991; Hardy & Higgins, 1992). According to
its original version the aggregation of Aβ is the first event in the pathogenesis of AD. The
plaques then exert their toxic effects on neurons and lead to tau aggregation and neuronal
death, eventually causing dementia. During the next decades new findings essentially sup-
ported this hypothesis with the replacement of Aβ fibrils by oligomers as the toxic species
and addition of synaptic dysfunction as an early event in the pathology (Ferreira & Klein,
2011; Hardy & Selkoe, 2002; Selkoe, 2002). Opponents of this hypothesis have argued that
there is no correlation between plaque load and cognitive decline; the cell culture and mouse
models, used to produce most of the evidence supporting Aβ as the cause for AD, have little
resemblance with in vivo disease conditions; and there are evidence that Aβ is in fact pro-
tective, produced as a response to cellular stress (Herrup, 2015; Lee et al., 2004; Perry et al.,
2000). More controversy arose when the first drugs based on lowering the amount of Aβ
failed to improve the cognitive function of patients in clinical trials. Alternatives and mod-
ifications to the amyloid cascade hypothesis have been proposed (Armstrong, 2014; Ethell,
2010; Pimplikar, 2009; Small & Duff, 2008). Others argue that the damage made by Aβ
may be irreversible. Therefore, possible treatments should be tested earlier in course of the
disease, before the patients develop severe pathology and overt symptoms (Karran et al.,
2011; Musiek & Holtzman, 2015; Tam & Pasternak, 2012). To test this theory, biomarkers
to detect early stages of the disease are needed (see section 1.1.4). Nevertheless, the amyloid
cascade hypothesis is still the predominant explanation for the aetiology of AD.
1.1.2 Tau
Tau tangles are the other prominent aggregates in AD. Tau is a microtubule-associated
protein (MAP) that is necessary for tubulin assembly and stabilisation of microtubules (Bré
& Karsenti, 1990; Fellous et al., 1977; Panda et al., 1995; Weingarten et al., 1975). Micro-
tubules are part of the cytoskeleton that give differentiated cells their typical shape. They
are also involved in movement, outgrowth of axons in developing neurons, and polarized
transport of vesicles. There are several MAPs that regulate the dynamic equilibrium of
microtubules with monomeric tubulin and they are specific for different cells and compart-
ments. Tau is found specifically in axons of neurons where microtubules are important for
both stability and axonal transport (Binder et al., 1985; Dotti et al., 1987).
The gene encoding tau is located on chromosome 17 (Neve et al., 1986) and gives rise
to 7 isoforms through alternative splicing. In peripheral nervous system a high molecular
weight isoform is found that contains an additional exon 4A (Couchie et al., 1992). The
other 6 isoforms are expressed in central nervous system and differ in splicing of exons 2,
3, and 10 (Goedert et al., 1989a,b). Exon 10 encodes one of the four possible tandem repeats
at the C-terminal portion of tau that, together with their flanking regions, act as tubulin
binding sites (Gustke et al., 1994; Himmler et al., 1989; Maccioni et al., 1989). Therefore,
isoforms lacking this exon have only three binding repeats, and their binding to microtubuli
is weaker. In early developmental stages only the shortest isoform lacking exons 2, 3, and
10 is expressed (Goedert et al., 1989a,b). Mutations in tau gene are not associated with AD,
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but they can lead to frontotemporal dementia (reviewed in Ghetti et al., 2015).
Tau protein can be posttranscriptionally modified. A number of these modifications af-
fect its interaction with microtubules and aggregation to neurofibrillary tangels (reviewed
in Fontaine et al., 2015). The best studied modification is phosphorylation at the tandem
repeats or residues flanking this region by different kinases (Lovestone & Reynolds, 1997;
Wang et al., 2007). This occurs in a healthy brain, varying at different ages, to regulate the
binding affinity of tau to microtubules (Lindwall & Cole, 1984a,b; Trinczek et al., 1995). In
AD brain tau is hyperphosphorylated and loses its ability to bind to microtubules (Grundke-
Iqbal et al., 1986b). In this form tau can aggregate into paired helical filaments and further
into the tangles found in AD brains (Bancher et al., 1989; Ihara et al., 1986; Kidd, 1963;
Luna-Muñoz et al., 2007). All tau isoforms found in adult brain are involved in formation of
paired helical filaments (Greenberg et al., 1992). The aggregation of tau can be prevented by
molecular chaperones that alter its binding to microtubules and prevent toxicity (Abisambra
et al., 2010; Dou et al., 2003; Patterson et al., 2011b; Voss et al., 2012).
By aggregating tau loses its function as stabilizer of microtubules, leading to dysfunctions
in cytoskeleton and axonal transport. Additionally to this loss of function effect, the soluble
tau oligomers or hyperphosphorylated monomers might gain a toxic function, similar to the
Aβ oligomers (Ding & Johnson, 2008). As for Aβ, it is also not clear for tau what kind of
oligomers mediate the toxicity (Cowan et al., 2012). However, they have been shown to ac-
cumulate in AD brain early in the disease progression and correlate with memory loss and
synapse dysfunction in tauopathy models (Berger et al., 2007; Lasagna-Reeves et al., 2011;
Patterson et al., 2011a; Sydow et al., 2011). Several mechanisms have been proposed to ex-
plain the toxicity of tau. A phosphatase-activating domain at the N-terminus, that becomes
accessible through conformation change in pathogenic tau, can inhibit kinesin dependent
axonal transport (Kanaan et al., 2011). Defects in mitochondrial distribution have been ob-
served probably as a consequence of dysfunctional axonal transport (Kopeikina et al., 2011),
and tau fragments contribute to mitochondrial dysfunction (see section 1.1.3). Tau can also
mediate some aspects of Aβ toxicity (Roberson et al., 2007). Aβ oligomers lead to activation
of kinases that phosphorylate tau, missorting of tau and other axonal proteins into den-
drites, elevated Ca2
+ levels, and destabilization of microtubules (Yu et al., 2012; Zempel &
Mandelkow, 2012; Zempel et al., 2010). Tau is necessary for postsynaptic targeting of FYN
that can phosphorylate a subunit of N-methyl-D-aspartate receptor (NMDAR) leading to its
anchoring at the postsynaptic sites. This causes exitotoxicity and seizures in AD models
(Ittner et al., 2010). Tau itself can also be phosphorylated by FYN that is activated by Aβ
via PrP (Larson et al., 2012). Phosphorylation by this and other kinases leads to aberrant
cell cycle re-entry that leads to cell death (Seward et al., 2013). It is not clear which of these
mechanisms is most relevant for AD.
It is widely accepted that tau pathology occurs downstream of Aβ in accordance with the
amyloid cascade hypothesis. What remains unclear are the mechanisms by which Aβ leads
to changes in tau. Aβ seems to activate kinases that lead to tau hyperphosphorylation like
discussed above and reviewed by Lloret et al. (2015). On the other hand, there are reports
that human tau can increase Aβ levels (Bright et al., 2015), suggesting a more complex
interaction between these proteins. While most of the treatment strategies today aim at
Aβ as the main culprit of the disease, some researchers argue that tau should be the target
(Crespo-Biel et al., 2012). Indeed, tau pathology correlates better with cognitive decline than
Aβ (Arriagada et al., 1992; Gómez-Isla et al., 1997), and tau knockout in APP expressing
mouse models rescues the memory deficits (Ittner et al., 2010; Roberson et al., 2007). Still,
neuronal and synapse loss are better correlates for cognitive decline than either Aβ or tau
tangles, suggesting the possibility of other pathogenic mechanisms. Oxidative stress and
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Figure 1.3: ROS production in mitochondria. The respiratory chain (complexes I–V; complex II not
shown) establish a pH gradient and use it to produce ATP. Aβ and tau can inhibit complex IV
and I, respectively, leading to excess superoxide production. Superoxide can react further to form
other ROS. Here shown the Fenton reaction with Fe2+ as catalyst. Aβ can facilitate the reduction
of Fe3+ to Fe2+, thereby indirectly affecting the formation of OH• (Smith et al., 2007).
mitochondrial dysfunction play an important role at the junction between Aβ and tau and
have an important role in disease progression as described in the next section.
1.1.3 Oxidative stress, mitochondrial dysfunction, and inflammation
Aerobic cells are constantly exposed to reactive oxygen species (ROS) generated by metabolic
processes. Low levels of ROS have a physiological signalling function and can protect cells
from serious damage (Ristow & Schmeisser, 2011; Yan, 2014). But when the level of oxida-
tive stress exceeds the antioxidant capacity of the cells, ROS become toxic. They can react
with different biomolecules like phospholipids, proteins, or nucleic acids, leading to ageing
and various diseases including AD (reviewed in Phaniendra et al., 2015). An excess of oxi-
dised proteins, lipids, and ribonucleic acid (RNA) is seen at early stages in AD brains (Abe
et al., 2002; Lovell et al., 1995; Markesbery & Lovell, 1998; Nunomura et al., 1999; Smith
et al., 1991; Williams et al., 2006). Deoxyribonucleic acid (DNA) oxidation, especially in mi-
tochondrial DNA, has also been found (Mecocci et al., 1994; Prasad Gabbita et al., 1998).
Taken together, this indicates prominent oxidative damage in AD brain that may have an
important role in the pathogenesis.
The major source of ROS in an eukaryotic organism are mitochondria. Mitochondria
produce adenosine triphosphate (ATP)—the main energy carrier in the body—by oxidative
phosphorylation. Thereby electrons are carried through four protein complexes of the elec-
tron transport chain that use the energy to establish a proton gradient (Fig. 1.3). At com-
plex IV molecular oxygen (O2) is reduced to water (H2O). Subsequently complex V uses
the proton gradient to produce ATP. If the electron transfer between complexes I–IV is in-
hibited, O2 can serve as an alternative electron receptor and a superoxide radical (O
•–
2 ) is
formed. O•–2 is detoxified by superoxide dismutase (SOD) which produces O2 and hydrogen
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peroxide (H2O2), another ROS that is further reduced to H2O by catalase or glutathione
peroxidase. If these ROS escape the cells defensive mechanism, they can either oxidise
biomolecules themselves or form the more reactive hydroxyl radical (OH•). This can hap-
pen via two reaction mechanisms, both of which depend on metal ions (Men+) like copper or
iron (reviewed in Halliwell & Gutteridge, 1984):
Fenton reaction: Men++H2O2 −−−→Me(n+1)++OH•+OH−
Haber-Weiss reaction: O•−2 +H2O2
Men+−−−−→OH•+OH−+O2
Imbalances in copper, iron, and zinc ions have been reported in AD brains, and these
metals are found in senile plaques (Deibel et al., 1996; Lovell et al., 1998). Copper can
bind to Aβ, especially under acidic conditions, and facilitate the formation of H2O2, possibly
followed by Fenton reaction (Atwood et al., 2000; Huang et al., 1999; Opazo et al., 2002). The
three histidine residues of Aβ are thereby involved in complexing the metal ion, whereas
Met35 and Tyr10 are important for the redox chemistry (Smith et al., 2007; Varadarajan
et al., 1999; Yatin et al., 1999). In nanomolar concentrations Aβ binding to copper exhibits
neurotrophic and antioxidant effects, although higher concentrations lead to pro-oxidant
activity (reviewed in Atwood et al., 2003). Binding of zinc to Aβ leads to aggregation of the
peptide and reduces its toxicity (Bush et al., 1994; Cuajungco et al., 2000). Zink can also bind
to tubulin, and dyshomeostasis of this metal can lead to depolymerisation of microtubules
(Craddock et al., 2012). The expression of APP is regulated by iron (Rogers et al., 2002), and
copper binding to APP increases Aβ production (Noda et al., 2013), further emphasising the
important role of metal ions in AD pathogenesis.
Mitochondrial dysfunction is seen in different neurodegenerative disorders, such as AD,
Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease (reviewed in
Lezi & Swerdlow, 2012). In AD interactions of Aβ with mitochondrial proteins can lead
to inhibition of the electron transport chain (Fig. 1.3), increased ROS levels, and apop-
tosis (Cha et al., 2012). The activity of complex IV is decreased in AD (Maurer et al.,
2000; Mutisya et al., 1994), possibly because of decreased expression and deletions in mito-
chondrial DNA (Krishnan et al., 2011; Rhein et al., 2009) or blockage of the translocases—
proteins needed for proper import of mitochondrial proteins encoded by nuclear DNA—by
APP (Devi et al., 2006). Furthermore, Aβ is taken up into mitochondria and is found in
the inner membrane, making a direct interaction with the complexes of the respiratory
chain or other mitochondrial proteins like Aβ-binding alcohol dehydrogenase (ABAD) pos-
sible (Hansson Petersen et al., 2008; Lustbader et al., 2004). Deficiency of complex IV is
dependent on Aβ, whereas tau oligomers decrease complex I levels. Both these effects are
synergistic in impairing mitochondrial membrane potential and ATP production (Amadoro
et al., 2012; Lasagna-Reeves et al., 2011; Quintanilla et al., 2014; Rhein et al., 2009). Ex-
posure to Aβ leads to higher ROS levels due to its interaction with mitochondrial proteins
(Hernandez-Zimbron et al., 2012; Lustbader et al., 2004). Additionally, increased fission and
decreased fusion of mitochondria have been observed in AD, resulting in changed morphol-
ogy (Baloyannis, 2011). Aβ can influence the expression of proteins involved in mitochon-
drial dynamics and this leads to altered transport of mitochondria in neurons (see also sec-
tion 1.1.2) that correlates with loss of dendritic spines (Calkins & Reddy, 2011; Wang et al.,
2009). Aβ can also support the expression of permeability transition pore, whereas tau
oligomers activate caspase 9, implicating both peptides in induction of apoptosis (Lasagna-
Reeves et al., 2011; Moreira et al., 2002). In normal cells dysfunctional mitochondria are
degraded via autophagy, but under pathological conditions this process is impaired and
leads to further damage of the cells (reviewed in Nixon & Yang, 2011; Schiavi & Ventura,
2014).
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Decreased ATP production due to mitochondrial dysfunction can lead to higher Aβ levels
(Scheffler et al., 2012; Velliquette et al., 2005), and phosphorylated tau has been detected
after inhibition of complex IV (Szabados et al., 2004). The evidence of defect mitochondria
in AD have led to the formulation of a ‘mitochondrial cascade hypothesis’ (Swerdlow et al.,
2014; Swerdlow & Khan, 2004). It states that mitochondrial dysfunction is the driving force
of sporadic late onset AD, leading to Aβ aggregation due to changes in electron transport
chain as well as tau phosphorylation and aggregation due to cell cycle re-entry. This hy-
pothesis includes the free radical theory of ageing (Harman, 1956), using it to explain the
late onset of sporadic AD. The ‘two hit’ hypothesis also states that oxidative stress has an
important role in AD pathogenesis, but according to this theory a second factor like mitotic
stress is needed to initiate the disease progression (Zhu et al., 2001, 2007, 2004).
Another possible source of ROS are activated immune cells, that use these reactive mole-
cules for fighting intruders like bacteria. Indeed, fibrillar Aβ can induce O•–2 production in
macrophages (Colton et al., 2000). Already Alzheimer observed microglia, the brain resident
immune cells, surrounding the senile plaques (Alzheimer, 1911). Aβ aggregates activate mi-
croglia that can bind and phagocytose Aβ via different membrane receptors (reviewed in Yu
& Ye, 2015) and recruit peripheral monocytes that also contribute to Aβ clearance in brain
parenchyma (Krabbe et al., 2013; Simard et al., 2006). In the course of the disease, however,
microglia exposed to Aβ lose this protective function and change to a more pro-inflammatory
form, releasing cytokines that further inhibit clearance of Aβ (Hickman et al., 2008; Krabbe
et al., 2013). Additionally, uptake of Aβ from the periphery by RAGE causes neurovascu-
lar stress and leads to further expression of cytokines (Deane et al., 2003). On the other
hand, chronic systemic inflammation has been shown to induce AD-like pathology in mice,
suggesting that inflammatory conditions can trigger excess Aβ production and initiate AD
(Krstic et al., 2012). The ROS and pro-inflammatory cytokines produced by microglia can ac-
tivate different signalling cascades in neurons and lead to damage of the cells. For example
the activation of kinases can lead to tau hyperphosphorylation (Kitazawa et al., 2011). The
role of neuroinflammation in the aetiology of AD is still under debate, but its association
with the disease is supported also by genetic studies discussed in the next section.
1.1.4 Risk factors and biomarkers
Since curing AD has proven to be a difficult task, more and more attention is paid to pre-
vention and early detection of the people at risk. The most important risk factor is high age,
followed by cerebrovascular disease, traumatic brain injury, cardiovascular disease, hyper-
tension, and metabolic disorders like type II diabetes or obesity. Mediterranean diet and
physical and mental activity, on the other hand, decrease the risk (reviewed in Mayeux &
Stern, 2012; Reitz & Mayeux, 2014). Metabolic disorders and AD could be linked together
via insulin resistance as proposed already decades ago (Hoyer, 1988; Hoyer et al., 1991).
Insulin has an important role in energy control and also in synaptic plasticity in central
nervous system (reviewed in Ma et al., 2015a). Signalling trough insulin and insulin-like
growth factor 1 (IGF-1) receptors promotes clearance of Aβ oligomers (Zhao et al., 2009) and
is linked to other stress signals involved in AD by different pathways (reviewed in Lourenco
et al., 2015). One of the hubs where several of these pathways converge is the transcrip-
tion factor forkhead box O (FOXO), that regulates the response of a cell to both oxidative
stress and glucose deprivation, but can lead to cell death and several processes implicated
in AD by prolonged activity (Manolopoulos et al., 2010). The evidence for the involvement
of insulin signalling in AD pathology has led to the notion that this disease can be seen as
a form of brain diabetes (Lourenco et al., 2015; Morgen & Frölich, 2015). According to a
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recent study, however, Aβ oligomers can induce peripheral glucose intolerance by a mech-
anism involving inflammation and endoplasmic reticulum stress in hypothalamus (Clarke
et al., 2015). Therefore, the role of insulin resistance and diabetes in AD pathology remains
a subject of further study.
The genetic background of familial AD is well known (see section 1.1.1), but the genetic
component of the more prevalent sporadic AD seems to be more complex. Several genome
wide association studies have been conducted to find risk genes, but most of the genes found
have only a weak association with the disease. Among those are genes coding for pro-
teins involved in lipid transport (APOE; clusterin), immune system (ATP-binding cassette
sub-family A member 7; complement component receptor 1; CD33; membrane-spanning
4-domains, subfamily A, members 6A and 4E; CD-2 associated protein), and endocyto-
sis (bridging integrator 1; phosphatidylinositol binding clathrin assembly protein; sortilin-
related receptor 1) (AlzGene database (http://www.alzgene.org/, accessed on 20/11/2015),
Bertram et al., 2007; Reitz & Mayeux, 2014). The strongest association, found in almost
all of these studies, is for APOE. There are three common alleles of the APOE gene: ε2, ε3,
and ε4. The ε4 allele is associated with higher risk for late onset AD (Corder et al., 1993;
Strittmatter et al., 1993), whereas ε2 is protective (Corder et al., 1994; Hardy et al., 1993).
APOE is responsible for cholesterol transport and homoeostasis in brain. Lower cholesterol
levels in microglia have been shown to enhance intracellular degradation of Aβ by facili-
tating endocytic trafficking (Lee et al., 2012a). Also the degradation by insulin degrading
enzyme is enhanced by lipidated APOE (Jiang et al., 2008). Additionally, APOE can directly
interact with Aβ and alter its aggregation properties (Arold et al., 2012; Garai et al., 2014;
LaDu et al., 2011).
The pathological diagnosis of AD relies on the extent of Aβ and tau pathology in the brain
of the patient (reviewed in Serrano-Pozo et al., 2011). In order to diagnose AD in living
patients, biomarkers and imaging techniques are needed together with cognitive tests to
separate AD from other dementias. Available biomarkers can be divided into two groups:
biochemical markers found in cerebrospinal fluid and imaging biomarkers. In cerebrospinal
fluid concentrations of Aβ and tau can be measured. Aβ1–42 is lower in patients with AD
whereas total and phosphorylated tau levels are higher than in controls. Especially the
ratios Aβ1–42/Aβ1–40 and Aβ1–42/phospho-tau have shown high predictive value for early
AD (reviewed in Lewczuk et al., 2014). Different imaging techniques can be applied for
the diagnosis (reviewed in Ahmed et al., 2014). Positron emission tomography using 18-F-
flourodeoxyglucose typically shows bilateral hypometabolism and hypoperfusion in the AD
brains. Specific tracers like Pittsburgh Compound B used with positron emission tomog-
raphy can visualize amyloid plaques in living patients. Additionally, structural magnetic
resonance imaging can detect brain atrophy. Using combinations of these biomarkers, it is
possible to strengthen the diagnosis made by cognitive testing and differentiate between dif-
ferent types of dementias. Still, there are many problems including availability and cost of
suitable instrumentation and insufficient standardisation of the acquisition methods, there-
fore these techniques are not everywhere used as a standard procedure for diagnosis. New
methods and markers, that would be easier to handle and have better sensitivity and selec-
tivity, are in development (Ahmed et al., 2014).
1.1.5 Treatment
The first prescription drug for AD was tacrine (Cognex®), an acetylcholine esterase in-
hibitor (AChEI) (Summers, 2006). The neurotransmitter acetylcholine (ACh) has an im-
portant role in forming the concious awareness, and impairment of the cholinergic system
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underlies symptoms of different dementias (Perry et al., 1999). In AD there is a lack of
ACh due to selective loss of cholinergic neurons (Davies & Maloney, 1976; Francis et al.,
1999). By inhibiting the enzyme that degrades ACh—acetylcholine esterase (AChE)—the
amount of this neurotransmitter in the synaptic cleft can be increased. Hence, the treatment
slows down the cognitive decline and helps to maintain activities of daily living. The usage
of tacrine was discontinued due to hepatotoxicity (e.g. Blackard et al., 1998), but newer
AChEI donepezil (Aricept®), rivastigmine (Exelon®), and galantamine (Reminyl®) are still
used in mild to moderate AD (Birks, 2006). For moderate to severe disease stages another
drug called memantine (Namenda®) is approved (Matsunaga et al., 2015). Memantine is
a non-competitive NMDAR antagonist, that counteracts the impaired glutamate signalling
and can protect neurons from excitotoxicity. Combinations of both drug types have shown
greater benefits in mild to moderate AD than one drug alone (Parsons et al., 2013). Still,
these treatments only counteract the symptoms and cannot halt the course of the disease.
Therefore, a lot of effort has been made to find new, more efficient drugs.
Most of the research in this area has concentrated on Aβ: substances that can inhibit Aβ
oligomerization (reviewed in Doig & Derreumaux, 2015), reduce its production, or facilitate
its clearance. An example of a small molecule that can reduce brain amyloid load, proba-
bly due to modulation of BACE1, and is currently tested in clinical trials is methylene blue
(Mori et al., 2014). BACE1 is the rate limiting enzyme for Aβ production and therefore a
logical drug target. Several small molecules that can inhibit BACE1 or modulate its activ-
ity have been found and some of them have reached phase III clinical trials (reviewed in
Evin & Hince, 2013; Vassar et al., 2014). However some adverse effects have been noticed
due to other targets of this enzyme and cross reactivity with other aspartyl proteases of
the same family like BACE2 or cathepsin D. Similar problems occurred with γ-secretase
inhibitors, where an increased risk of skin cancer and worsening of cognitive abilities have
been observed (reviewed in Mikulca et al., 2014). There the focus has shifted from inhibiting
the enzyme to modulating its activity in favour of the shorter Aβ species. These modula-
tors do not inhibit other functions of γ-secretase and therefore should have less side-effects
(D’Avanzo et al., 2015). For increasing the clearance of Aβ, immunotherapy is utilized (re-
viewed in Spencer & Masliah, 2014). Although the first clinical trials in this field failed due
to severe side effects and no change in cognitive abilities of the patients was observed, new
approaches for both active and passive immunization are hoped to lead to safer and more
effective treatment.
Failure of the first anti-Aβ drugs has triggered a search for new targets and treatment
possibilities. Immunotherapy against tau is considered along with antioxidant and anti-
inflammatory approaches, and a lot of other targets are explored (Geldenhuys & Darvesh,
2014). Since AD is an multi-factorial disease with many possible drug targets, a trend of
developing multi-target-directed-ligands has emerged. Also, prevention and early pharma-
cological intervention are gaining more and more attention (Sindi et al., 2015), although
there is still a lack of reliable biomarkers to identify those at risk in presymptomatic stages
(see section 1.1.4). In the search for new multitarget treatments and lead substances for
drugs traditional medicine, especially Traditional Chinese Medicine (TCM) (reviewed in Su
et al., 2014; Zeng et al., 2015), and natural products have received considerable attention.
Several natural products have been found to be effective: the AChEI galantamine was first
isolated from snowdrop (Galanthus spp. ) (Heinrich & Teoh, 2004); huperzin A, an AChEI
from Huperzia serrata, is in phase II clinical trials (Yang et al., 2013b); (−)-epigallocatechin
gallate (EGCG) (Camellia sinensis), curcumin (Curcuma longa), resveratrol, scyllo-inositol
(Cocos nucifera), and several flavonoids can modulate Aβ aggregation (reviewed in Bu et al.,
2015); the standardized Ginkgo biloba extract EGb761® has shown beneficial effects (Can-
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evelli et al., 2014; Gauthier & Schlaefke, 2014). Despite all these efforts, more research is
still needed to find an effective treatment for AD.
1.2 Medicinal plants
Phytotherapy is one of the oldest forms of medicine, known to mankind already for thou-
sands of years. The traditional practices differ by culture and region. Today we have access
to a lot of ethnobotanical information from around the world. Some of the plants used tra-
ditionally are scientifically proved to be effective and are still used in modern phytotherapy,
some others are used in alternative medicine or as food supplements. The basis of effec-
tiveness of medicinal plants are almost exclusively secondary metabolites—small molecules
produced by plants to protect themselves. These molecules can either directly interact with
a pharmaceutical target in human body or they can be used as leads for synthesis of active
compounds. Therefore, medicinal plants are interesting for both traditional medicine and
modern pharmaceutical research.
Plants produce secondary metabolites as a means to interact with their environment. In
order to reproduce, plants need the help of insects and animals for pollination and distri-
bution of their seeds. Therefore, they have developed molecules that attract these helpers.
They also have to protect their territory and resources from other plants, so they have devel-
oped phytotoxins. Plants do not have the ability to move away from their enemies. Hence,
they depend on their chemical defence system to protect themselves from phytopathogens
and herbivores. Upon an attack they produce phytoalexins—molecules that can ward off
the danger and send a warning to systemic tissues. As a reaction to this signal protective
secondary metabolites and proteins are produced for enhanced protection in whole plant,
leading to a systemic acquired resistance (Ahuja et al., 2012; Spoel & Dong, 2012). Next
to this induced expression of phytoalexins, many protective secondary metabolites are pro-
duced constitutively, stored, and released upon an attack. These molecules, that have an-
timicrobial, antifungal, antioxidant, and several other properties, are most interesting for
pharmaceutical research.
Secondary metabolites probably developed early in the evolution of plants and have been
refined through natural selection (Wink, 2003), giving them an advantage over de novo syn-
thesis of medical compounds. The chemical structures of these molecules are diverse, as are
their mechanisms of action. Some mimic molecules in animals and can interact with specific
receptors or enzymes (e.g. some alkaloids are similar to neurotransmitters and can activate
or inhibit neuroreceptors or re-uptake transporters), but most (e.g. polyphenols, terpenes)
have rather unspecific interactions with proteins, biomembranes, or nucleic acids (reviewed
in Wink, 2008). One plant usually produces various compounds to have the best protection
against as many different threats as possible. Hence, plant extracts are multitarget drugs
that can modulate several cellular processes and possibly even act on targets that have not
been identified yet.
Natural selection has not only helped the plants to perfect their toxins, the herbivores
have gone through an evolutionary adaptation process as well. Thereby, mutations to the
target proteins have led to resistance in some specialised herbivores. Other insects and
animals have developed several mechanisms to either store the toxins and use them for
their own protection or detoxify these phytochemicals. The latter option is mostly used by
vertebrates. Proteins in these organisms can be protected by chaperones like heat shock
proteins (HSPs); oxidative damage can be prevented by SOD, catalase, or other enzymes.
Additionally, the toxic compounds are actively modified in liver and excreted, or their in-
take is inhibited by ATP-binding cassette transporters in epithelia (Murugaiyah & Mattson,
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2015). Expression of protective proteins is controlled by transcription factors like nuclear
factor erythroid 2-like 2 (NRF2), heat shock factor 1 (HSF-1), or FOXO (Murugaiyah &
Mattson, 2015; Son et al., 2008). Small amounts of toxic compounds, that manage to cross
the epithelia, activate these transcription factors and trigger the transcription of the stress
resistance proteins that can protect the organism from the toxin that was ingested, but also
give it a wider resistance to many types of stress. This is the underlying mechanism of
hormesis—the phenomenon that small amounts of a compound can be beneficial, even if a
larger amount of the same substance is toxic (Calabrese, 2015; Mattson, 2008). Hormesis
is proposed as the mechanism of action for several phytochemicals including polyphenols
from green tea like EGCG (Murakami, 2014; Son et al., 2008). Also other types of stress
like exercise or caloric restriction lead to hormetic responses. Most interestingly, hormesis
is essential for healthy ageing and the health of nervous system (Murugaiyah & Mattson,
2015).
1.2.1 Phytotherapy in Traditional Chinese Medicine
TCM is one of the oldest medicine systems dating back more than 5000 years. Since at that
time there was no technology available to look inside a living body, TCM uses superficial
observations—ranging from voice quality to pulse feeling—to diagnose a condition. A dis-
ease is seen as an imbalance in yin and yang, the two basic forces in Taoism. Without the
modern knowledge about anatomy and physiology, the ancient healers used this philosophy
to describe the function of human body. In TCM the body is divided into Organs, whereby
‘Organ’ does not refer to an anatomical entity but is rather a concept of body parts and func-
tions that react together to certain changes in the body (for better distinction these Organs
are written with a capital letter). Each Organ is governed by one of the five elements—wood,
fire, earth, metal, water—and has either a yin- or yang-character depending on its function.
The normal functioning of the Organs is ensured by the flow of qi, often translated as ‘life
energy’. Qi flows through meridians—‘energy channels’ that belong to the Organs—thereby
nourishing all tissues. If the flow of qi is obstructed, the balance between yin and yang will
be disturbed and the person feels sick.
TCM uses different forms of therapy like acupuncture, tuina massage, qigong exercises,
and also phytotherapy. Using medicinal plants is common in different cultures and can be
rationalised by the physiological activity of secondary metabolites. TCM, however, has its
specific way of using plants. Each plant is described by its flavour—sour, bitter, sweet, acrid,
salty. These flavours correspond to the five elements and thereby indicate the effect of the
plant on different Organs. Some plants are processed, e.g. by roasting, to obtain the desired
effect. A phytotherapeutical drug always consists of at least four plants: emperor—the
plant with the main effect; minister—supports the effect of emperor; ambassador—guides
the effect to the right Organ; assistant—helps to treat secondary symptoms, harmonizes
the other plants, and reduces toxicity (Bürkland, 2014). This concept of using many plants
together in one drug is in contrast to western medicine, where one plant or, better still,
one pure compound is used. Extracting several plants together can, however, change the
composition of the extract, possibly leading to less toxicity and synergistic effects (Wang
et al., 2013b; Yang et al., 2009b).
One of the TCM herbs that has become popular also in western countries is Ginkgo biloba
L. (Ginkgoaceae) (Fig. 1.4). This dioecious tree can grow up to 35 m high, it has unique
fan-shaped leaves, and the female plants produce fruit-like seeds that smell like rancid but-
ter due to the high content of butyric acid (Van Wyk et al., 2015). In TCM originally the
seeds are used, only later the leaves have been also listed as a medicinal drug. The fleshy
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Figure 1.4: Ginkgo biloba
leaves with unripe seeds
(picture taken in the
botanical garden of Hei-
delberg University, July
2015) and some of its
compounds.
sarcotesta is removed and the gametophytes, also called ‘nuts’, are briefly steamed or boiled
before baking them dry. This drug, bái guo˘, affects the Lung qi. It is used against cough and
asthma, and it also reduces urination and leukorrhea (Qian, 2007). In western countries
Ginkgo leaves extract has become a popular food supplement because of its assumed mem-
ory enhancing properties. A standardized extract called EGb761® with controlled content
of flavonoid glycosides (25 %), terpene lactones (6 %), and ginkgolic acid (less than 5 ppm)
has been developed by Beaufor-Ipsen Pharma (Paris, France) and Dr. Willmar Schwabe
Pharmaceuticals (Karlsruhe, Germany). Many studies have demonstrated the antioxidant,
neuroprotective, anticancer, and other beneficial effects of this extract in different models
(reviewed in Mahadevan & Park, 2008; Smith & Luo, 2004), but the clinical value of it in
humans with cognitive disorders like AD is still under debate (Schneider, 2012).
Many other TCM herbs have been studied for their neuroprotective and anti-dementia
activities. Since in the TCM theory brain is considered as bone marrow and belongs to Kid-
ney, many Kidney nourishing preparations have been tested, although the overall results
have been inconclusive (Zeng et al., 2015). Examples for plants with an effect on Kidney
would be Alpinia oxyphylla (yì zhì), Cnidium monnieri (shé chuáng zı˘), Polygonum multi-
florum (hé sho˘u wu¯), Epimedium spp. (yín yáng huò), or Phellodendron spp. (huáng ba˘i)
(Qian, 2007). A. oxyphylla Miq. is a perennial herb from the family Zingiberaceae that is
native to Asia and Australia. Its capsular elliptic fruits, that are the medicinally used part,
contain terpenes, diarylheptanes, flavonoids, protocatechuic acid, and sterols (Fig. 1.5) (Li
et al., 2013b; Qing et al., 2012). Antioxidant, anti-inflammatory, and neuroprotective activi-
ties have been reported for this drug and its compounds (Qing et al., 2012; Shi et al., 2006;
Shui et al., 2006; Yu et al., 2003). It has also shown beneficial effects in models for AD and
Parkinson’s disease (Shi et al., 2014; Zhang et al., 2015). Other herbs like Coptis chinensis
(huáng lián), Evodia rutaecarpa (wú zhu¯ yú), Magnolia officinalis (hòu pò), Paeonia lact-
iflora (chì sháo), Panax ginseng (rén she¯n), or Verbena officinalis (ma˘ bia¯n ca˘o) have also
been studied regarding their possible benefits against AD in different model systems and
several secondary metabolites from different groups (alkaloids, polyphenols, saponins, and
others) have been identified as their active ingredients (reviewed in Su et al., 2014). Some
studies involving effects on Aβ are summarised in Table 1.1.
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Table 1.1: Activity against Aβ aggregation and toxicity of selected TCM plants.
Plant Drug Model Effect Reference
Alpinia galanga ethanol extract
of rhizome
mice treated with
Aβ25–35
memory enhancing,
antioxidant
Hanish Singh
et al. (2011)
Alpinia oxyphylla ethanol extract
of fruits
mice treated with
Aβ1–42
memory enhancing,
decreased Aβ1–42 levels,
inhibits AChE, antioxidant
Shi et al.
(2014)
5-hydroxy-
methylfurfural
mice treated with
Aβ1–42
memory enhancing,
decreased Aβ1–42 levels,
inhibits BACE1,
antioxidant
Liu et al.
(2014)
Camellia sinensis EGCG α-synuclein,
Aβ1–42, cell
culture
binds unfolded proteins,
inhibits fibrillisation, leads
to formation of non-toxic
oligomers
Ehrnhoefer
et al. (2008)
green tea
catechins
SAMP8 mice1 memory enhancing, reduced
levels of Aβ1–42 oligomers
Li et al.
(2009)
EGCG C. elegans reduced Aβ deposits and
oligomerisation, decreased
lipofuscin formation,
antioxidant
Abbas &
Wink (2010)
EGCG α-synuclein,
Aβ1–42, cell
culture
binds to amyloid fibrils,
remodels their structure
Bieschke
et al. (2010)
digested water
extract of green
tea
cell culture antioxidant, protective
against Aβ1–42 toxicity
Okello et al.
(2011)
EGCG metal-free and
metal-associated
Aβ1–40, cell
culture
higher antiamyloidogenic
activity in metal-associated
system, reduced Aβ toxicity,
produces ternary complexes
with metal-associated Aβ
Hyung et al.
(2013)
Centella asiatica extract PSAPP mice2 decreased Aβ1–40 and
Aβ1–42 in hippocampus,
antioxidant
Dhanasekaran
et al. (2009)
water extract Tg2576 mice3,
cell culture
memory enhancing,
neuroprotective against Aβ
toxicity, no change in Aβ
levels
Soumyanath
et al. (2012)
water extract,
caffeoylquinic
acids
cell culture antioxidant, normalizes
calcium homoeostasis,
attenuates mitochondrial
dysfunction
Gray et al.
(2015)
Continued on next page
1Naturally occurring mouse line with accelerated senescence and several features similar to AD.
2Doubly transgenic mice expressing APP with the Swedish mutation and PSEN1 with M146L mutation.
3Transgenic mice expressing APP with the Swedish mutation.
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Table 1.1 – Continued from previous page
Plant Drug Model Effect Reference
Cnidium monnieri osthole APP/PS1 mice4 memory enhancing,
enhanced neurogenesis in
dentate gyrus, neurotrophic
Liu et al.
(2015b)
Coptis chinensis berberine TgCRND8 mice5,
cell culture
memory enhancing,
decreased Aβ levels,
anti-inflammatory,
decreased phosphorylation
of APP and tau
Durairajan
et al. (2012)
Eleutherococcus
senticosus
water and
methanol
extracts of
rhizome
rat cortical
primary neuron
cultures treated
with Aβ25–35
protective against axonal
and dendritic atrophy,
against cell death, and
against synapse loss
Tohda et al.
(2008)
methanol
extract of
rhizome,
isolated
compounds
rat cortical
primary neuron
cultures treated
with Aβ25–35
protective against axonal
and dendritic atrophy
Bai et al.
(2011)
Epimedium
brevicornum
icariin APP/PS1-21 mice6 rescues nesting behaviour,
reduced Aβ deposition,
anti-inflammatory
Zhang et al.
(2014)
icariin Tg2576 memory enhancing, reduced
insoluble Aβ and APP
levels, increased
neurogenesis
Li et al.
(2015)
Evodia rutaecarpa evodiamine APP/PS1 mice,
SAMP8 mice
memory enhancing,
increased glucose uptake in
the brain,
anti-inflammatory
Yuan et al.
(2011)
Ginkgo biloba EGb761®,
flavonoids,
bilobalide,
ginkgolide B
rat hippocampal
primary cell
cultures treated
with Aβ25–35,
Aβ1–40, or Aβ1–42
protective against Aβ
toxicity, antioxidant
(flavonoids)
Bastianetto
et al. (2000)
EGb761®,
individual
compounds
cell culture,
C. elegans
antioxidant (especially
kaempferol and quercetin)
Smith & Luo
(2003)
EGb761®,
ginkgolides,
bilobalide,
flavonoids
C. elegans counteracts Aβ toxicity,
inhibits Aβ oligomerization,
antioxidant
Wu et al.
(2006)
ginkgolides A,
B, C, and
bilobalide
Aβ25–35 no specific interaction that
would modulate Aβ
aggregation
He et al.
(2008)
Continued on next page
4Doubly transgenic mice expressing APP with the Swedish mutation and PSEN1 with exon 9 deletion.
5Transgenic mice expressing APP with the Swedish mutation and V717F mutation.
6Doubly transgenic mice expressing APP with the Swedish mutation and PSEN1 with L166P mutation.
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Table 1.1 – Continued from previous page
Plant Drug Model Effect Reference
Ginkgo biloba EGb761® TgCRND8 mice,
cell culture
memory enhancing,
anti-inflammatory, induces
autophagy, reduces Aβ
deposits
Liu et al.
(2015d)
Glycyrrhiza
uralensis
water extract of
the root
mice treated with
Aβ25–35
memory enhancing,
antioxidant, reduces AChE
activity
Ahn et al.
(2006)
liquiritigenin rat hippocampal
primary neuron
cultures treated
with Aβ25–35
protects for apoptotic cell
death and Aβ-induced
toxicity, reduces Aβ1–40
secretion
Liu et al.
(2009)
ethanol extract
of the root,
isoliquiritigenin
rat cortical
primary neuron
cultures treated
with Aβ25–35
protective against apoptotic
cell death, interfere with
increases in calcium and
ROS concentration
Lee et al.
(2012b)
isoliquiritigenin
and its
synthetic
derivatives
Aβ1–42,
5-lipoxygenase
inhibit Aβ aggregation by
binding to the peptide,
inhibit 5-lipoxygenase
Chen et al.
(2013)
Magnolia
officinalis
magnolol,
honkiol
cell culture protective against apoptotic
cell death, interfere with
increases in calcium and
ROS concentration
Hoi et al.
(2010)
ethanol extract
of bark, 4-O-
methylhonkiol
mice treated with
Aβ1–42, cell
culture, Aβ1–42,
BACE1
memory enhancing,
protective against neuronal
cell death, antioxidant,
inhibited Aβ aggregation,
BACE1 activity, and BACE1
expression
Lee et al.
(2010a)
ethanol extract
of bark
Tg2576 memory enhancing,
decreases Aβ1–42 levels,
reduces expression of APP
and BACE1
Lee et al.
(2012c)
Paeonia lactiflora paeoniflorin rats treated with
Aβ1–42
memory enhancing,
antioxidant, protective
against apoptotic cell death,
interferes with increase in
calcium
Zhong et al.
(2009)
paeoniflorin microglial cell
culture treated
with Aβ1–42
reduced secretion of
inflammatory mediators
and chemokines, suppressed
chemotaxis to Aβ1–42
Liu et al.
(2015a)
isolated lignans Aβ1–42 inhibit Aβ1–42 aggregation Liu et al.
(2015e)
Panax ginseng extract from
HerbPharm,
pure
compounds
cell culture,
Tg2576 mice
reduce Aβ levels,
ginsenosides Re, Rg1, and
Rg3 selectively reduce
Aβ1–42 levels
Chen et al.
(2006)
Continued on next page
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Table 1.1 – Continued from previous page
Plant Drug Model Effect Reference
Panax ginseng ginsenoside Rg3 cell culture reduces Aβ levels, enhances
neprilysin gene expression
Yang et al.
(2009a)
fermented
water extract of
root
cell culture,
scopolamin-
induced amnesic
mice, APP/PS1
mice
memory enhancing, reduces
Aβ1–42 level
Kim et al.
(2013)
ginsenoside
compound K
mouse primary
astrocyte culture
promotes Aβ clearance
through enhancing
autophagy
Guo et al.
(2014a)
Panax notiginseng panaxynol,
panaxydol
rat cortical
primary neuron
cultures treated
with Aβ25–35
protective against apoptotic
cell death, interfere with
increases in calcium and
ROS concentration
Nie et al.
(2008)
quercetin
3-O-β-D-xylo-
pyranosyl-β-D-
galacto-
pyranoside
cell culture,
Aβ1–40,
scopolamin-
induced amnesic
mice
oestrogenic activity,
antioxidant, inhibits Aβ
aggregation, protective
against apoptotic cell death,
interferes with increase in
calcium, memory enhancing
Choi et al.
(2010)
notoginsenoside
R1
cell culture protective against apoptotic
cell death and
mitochondrial damage,
antioxidant
Ma et al.
(2014)
notoginsenoside
R1
mouse
hippocampal
primary neuron
cultures, acute
brain slices,
APP/PS1 mice
memory enhancing,
increases intrinsic
excitability of hippocampal
neurons, rescues
Aβ-induced decline in long
term potentiation
Yan et al.
(2014)
Phellodendron
chinense /
amurense
ethanol extract
of cortex
cell culture protective against apoptotic
cell death, P. amurense is
more potent than
P. chinense
Xian et al.
(2013)
Polygonum
multiflorum
water extract of
roots
mice treated with
Aβ25–35
memory enhancing, inhibits
AChE, antioxidant
Um et al.
(2006)
ethanol extract
of roots, 2,3,5,4’-
tetrahydroxy-
stilbene-2-O-β-
D-glucoside
Drosophila
melanogaster
expressing
Aβ1–42, cell
culture
ameliorated neurological
phenotypes, protective
against cell death,
antioxidant
Liu et al.
(2015c)
Punica granatum pomegranate
juice
Tg2576 mice improved learning, reduced
Aβ levels
Hartman
et al. (2006)
Rhodiola rosea salidroside cell culture protective against apoptotic
cell death, antioxidant
Zhang et al.
(2010)
Continued on next page
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Table 1.1 – Continued from previous page
Plant Drug Model Effect Reference
Rhodiola rosea salidroside rats treated with
Aβ1–40
memory enhancing,
antioxidant,
anti-inflammatory, inhibits
AChE
Zhang et al.
(2013a)
Rosa laevigata methanol
extract
cell culture,
mice treated with
Aβ1–42
antioxidant, protective
against cell death, memory
enhancing
Choi et al.
(2006)
ethanol extract,
1,2-benzenedi-
carboxylic acid
dinonyl ester
cell culture,
mice treated with
Aβ1–42
antioxidant;
1,2-benzenedicarboxylic
acid dinonyl ester: memory
enhancing, inhibits AChE
Choi et al.
(2009)
Sanguisorba
officinalis
gallic acid rat cortical
primary neuron
cultures treated
with Aβ25–35
in low concentrations
protective against apoptotic
cell death, interfere with
increases in calcium and
ROS concentration and
glutamate release
Ban et al.
(2008)
Scutellaria
baicalensis
baicalein,
baicalin
cell culture antioxidant, protective
against cell death
Heo et al.
(2004)
oroxylin A mice treated with
Aβ25–35
memory enhancing,
anti-inflammatory,
antioxidant
Kim et al.
(2008a)
stem-leaf total
flavonoid
rats treated with
Aβ25–35
protective against apoptotic
cell death
Wang et al.
(2013a)
baicalein cell culture,
mouse primary
neuron culture,
Tg2576 mice
reduces Aβ production,
increases α-secretase
activity, memory enhancing
Zhang et al.
(2013b)
Verbena officinalis water extract of
aerial parts
rat cortical
primary neuron
cultures treated
with Aβ25–35 or
Aβ1–42
protective against apoptotic
cell death and neurite
destruction
Lai et al.
(2006)
Plants with an effect on the acetylcholinergic system could also be beneficial in treatment
of AD. One such plant from TCM is Areca catechu L. (Arecaceae). This palm tree is na-
tive to south and south-east Asia, it can grow 10–25 m high, and bears hard orange fruits
with fibrous mesocarp (Van Wyk et al., 2015). Medicinally used part are the seeds, that
can be used raw (bı¯n láng), baked, or charred. Bı¯n láng is indicated for the treatment of
parasitic infections, malaria, abdominal pain, and gastrointestinal disorders (Qian, 2007).
Beyond the traditional usage, extracts of A. catechu seeds have been shown to exert several
pharmacological activities such as antioxidant, anti-inflammatory, analgesic, antidepres-
sive, regulating blood glucose and lipids, and others (reviewed in Peng et al., 2015). The
effects are in part mediated by a cholinomimetic activity due to stimulation of muscarinic
ACh receptors and inhibition of AChE (Ghayur et al., 2011; Gilani et al., 2004). The main
compounds in A. catechu are alkaloids, mainly arecoline, and polyphenols (Fig. 1.5). Arecol-
ine, while being one of the main active compounds, has also been shown to have toxic effects
including enhancement of oxidative stress and inducing apoptosis (Peng et al., 2015; Shih
et al., 2010).
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Figure 1.5: Selected compounds from Alpinia oxyphylla and Areca catechu.
1.2.2 Glycyrrhiza uralensis
Glycyrrhiza uralensis Fisch. (Fabaceae) is a perennial herb, that can grow around 1 m tall
(Fig. 1.6). It has imparipinnate leaves with 5–17 leaflets, racemose inflorescence with vi-
olet papilionaceous flowers, and a branched root system. G. uralensis naturally grows in
Asia, therefore it is traditionally used in TCM. The same can be said about Glycyrrhiza in-
flata Bat., whereas the third medicinally used species of the genus Glycyrrhiza, Glycyrrhiza
glabra L., is known both in China and in Europe, as it also grows in Mediterranean areas
(Van Wyk et al., 2015). The medicinally used part of these plants are the dried roots and
stolons. Besides their use in medicine, the roots can be also used to produce liquorice confec-
tionery because of their sweet taste that has given the genus its name (Greek ‘glukurrhiza’
means ‘sweet root’).
In both western and Chinese medicine Glycyrrhiza has been traditionally used against
cough, palpitations, and gastric pain. Other uses in Europe include other conditions of
respiratory, gastrointestinal, cardiovascular, and genital-urinary systems, and skin (Fiore
et al., 2005; Hosseinzadeh & Nassiri-Asl, 2015; Nassiri-Asl & Hosseinzadeh, 2008). Today
it is still used against cough and in treatment of gastric and duodenal ulcers. In China
ga¯n ca˘o (the drug consisting of dried roots of either three Glycyrrhiza species) is one of
Figure 1.6: Glycyrrhiza glabra
(picture taken in the botan-
ical garden of University of
Würzburg, June 2008) and
the drug ga¯n ca˘o, dried root
from Glycyrrhiza uralensis.
21
1. Introduction
Figure 1.7: Some compounds found in Glycyrrhiza spp. Glc: glucose; GlcA: glucuronic acid; Api:
apiose.
the most used herbal drug (Guo et al., 2014b). According to TCM philosophy it can har-
monize and strengthen the action of other herbs in a formula and carry its effects to all
12 meridians, making it a unique assistant drug, although it is not compatible with all
toxic herbs (Guo et al., 2014b; Kao et al., 2014). The harmonizing and detoxifying effects
can be explained by the interaction with cytochrome P450 enzymes and permeability gly-
coprotein (Wang et al., 2013b). Its indications, additionally to the common indications with
European medicine, include sores and boils, spasmodic abdominal pain, and detoxification
(Qian, 2007). Newer studies have found a potential in neuroprotection and enhancing mem-
ory for G. glabra (Dhingra et al., 2004; Parle et al., 2004; Shen et al., 2013) and in protection
against Aβ toxicity for G. uralensis (Ahn et al., 2006; Kanno et al., 2013).
Roots of Glycyrrhiza spp. contain triterpene saponins, flavonoids, coumarines, and some
other minor compounds (Fig. 1.7) (Nassiri-Asl & Hosseinzadeh, 2008). The most abundant
compounds in all three medicinally used species are the triterpene saponin glycyrrhizic
acid (GA), and flavonoid glycosides liquiritin apioside and isoliquiritin apioside (Farag et al.,
2012; Kondo et al., 2007a; Montoro et al., 2011). Most triterpenes found are derivatives of
GA or its aglycon glycyrrhetinic acid (GRA). G. uralensis has higher content of liquiritin,
isoliquiritin, and liquiritigenin than the other two species and a higher ratio of flavanones
to chalcones. Some compounds like glycycoumarin, glabridin, and licochalcone A are specific
to G. uralensis, G. glabra, and G. inflata, respectively (Kondo et al., 2007a; Simmler et al.,
2015). The roots also contain considerable amounts of sugars and starch, the aerial parts of
the plant contain high amounts of flavonoids (Hayashi et al., 2000; Lutomski, 1983).
GA as the most abundant compound is also responsible for many of the therapeutic effects
of Glycyrrhiza species. The best studied of those is the anti-inflammatory effect, that arises
from the competitive inhibition of 11β-hydroxysteroid dehydrogenase and consequent rise
in cortisol activity (Krähenbühl et al., 1994; Monder et al., 1989). The aglycon GRA, that is
produced from GA by intestinal bacteria (Hattori et al., 1983), is thereby a stronger inhibitor
than GA. Other mechanisms mediating the effects of GA and GRA are modulation of phos-
phoinositide 3-kinase (PI3K) activity and consequent suppression of transcription factors
like nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB). Modula-
tion of PI3K activity leads to changes in different pathways and contributes to the anti-
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inflammatory and antioxidant activities (Kao et al., 2009, 2013; Wang et al., 2011). This,
inhibition of the NF-κB, as well as an anti-excitotoxic effect also lead to neuroprotection
in models for AD, Parkinson’s disease and epilepsy (Kao et al., 2009; Luo et al., 2013; Zhao
et al., 2013). The effect of GRA on NF-κB has also been suggested as a protective mechanism
in liver diseases (Chen et al., 2014). Furthermore, GRA has been shown to be beneficial in
metabolic disorders, since it can improve glucose tolerance, increase insulin secretion, and
has an anti-adiposity effect (Ko et al., 2007; Park et al., 2014). Recent studies have shown
that GRA can also activate protective autophagy which contributes to the anti-viral activity
of this compound (Laconi et al., 2014; Tang et al., 2014). Some additional effects of GA and
GRA as well as their side effects (mostly arising from 11β-hydroxysteroid dehydrogenase
inhibition) are reviewed in Ming & Yin (2013).
The major phenolic constituents liquiritigenin (LG) and isoliquiritigenin (ILG) have a
number of biological activities, too. Both of them are phyto-oestrogens, whereby LG is a
selective agonist of the β type of oestrogen receptor (Mersereau et al., 2008). They are also
antioxidants via inducing NRF2 (Gong et al., 2015; Wang et al., 2015). The antioxidant ac-
tivity and protection against mitochondrial dysfunction prevents cell damage and apoptosis
in different models, including glutamate induced neuronal toxicity (Choi et al., 2014; Denzer
et al., 2016; Teng et al., 2014; Yang et al., 2012, 2013a; Zeng et al., 2013). ILG is further-
more an antagonist of NMDAR (Kawakami et al., 2011). Liquiritin and isoliquiritin both
have antidepressant properties, mediated by antioxidant effects and modulation of neuro-
transmitters (Wang et al., 2008; Zhao et al., 2008). Additionally, LG has beneficial effects on
learning and memory and can attenuate Aβ-induced neurotoxicity (Liu et al., 2011, 2010,
2009; Zeng et al., 2013). ILG has anti-diabetic properties and improved memory in a dia-
betes model (Gaur et al., 2014; Ma et al., 2015b). It is also protective against Aβ toxicity
and inhibits Aβ aggregation (Chen et al., 2013; Lee et al., 2012b). The anti-inflammatory
properties of ILG have been shown to involve NF-κB and toll-like receptor 4 suppression
(Kim et al., 2008b; Park & Youn, 2010; Wang et al., 2015). Due to reduction of prostaglandin
E2 and interleukin 6 signalling, ILG can induce apoptosis in different cancer cells (Li et al.,
2013a; Takahashi et al., 2004; Zhao et al., 2014).
1.2.3 Carlina acaulis
Carlina acaulis L. (Asteraceae) is a perennial plant that can be found in central and south-
ern Europe. It has a fleshy taproot and pinnatilobate, spiny leaves, arranged as a rosette.
The common name ‘silver thistle’ derives from the white silvery involucral bracts that sur-
round the flowerhead (Fig. 1.8). The bracts react to changes in air humidity and close to
protect the flowers from rain—a feature that has been used to predict weather (Junghans,
2003). The flowerhead is sessile (C. acaulis ssp. acaulis) or with a short stem (C. acaulis
ssp. simplex ), which has given the plant another common name: stemless carline thistle.
The medically used part is the root, Carlinae radix. It is traditionally used as diuretic,
diaphoretic and anthelmintic drug (Meusel & Kästner, 1990). The essential oil from the root
and also traditional decocts have antibacterial activity, especially against Staphylococcus
aureus (Ðord¯evic´ et al., 2012; Herrmann et al., 2011a; Jovic´ et al., 2012; Schmidt-Thomé,
1950). Furthermore, antioxidant (Ðord¯evic´ et al., 2007, 2012), anti-inflammatory, anti-ulcer
(Ðord¯evic´ et al., 2012), and anti-trypanosomal effects (Herrmann et al., 2011a) have been
reported. The drug Carlinae radix is supposed to contain C. acaulis, but often also the
roots of Carlina acanthifolia are sold (Schilcher & Hagels, 1990; Stojanovic´-Radic´ et al.,
2012). The roots from these two plants have a similar morphology, chemical composition,
and pharmaceutical properties (Ðord¯evic´ et al., 2012; Schilcher & Hagels, 1990; Stojanovic´-
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Figure 1.8: Carlina acaulis flower
head and leaf rosette, and the
main active compound Carlina
oxide. The picture was taken
in botanical garden of Heidel-
berg University, July 2014.
Radic´ et al., 2012), therefore C. acanthifolia is considered a substitute drug.
Carlinae radix contains 1–2 % essential oil with the main compound Carlina oxide (Fig. 1.8).
This alkyne was first isolated by Semmler (1906), who identified the benzyl and furan
groups but considered it unlikely to have a triple bond in a natural product. His attempts to
synthesize the 1-phenyl-3-α-furyl-allene that he believed to be Carlina oxide failed, so the
theoretical structure could not be proven (Semmler & Ascher, 1909). The correct structure,
2-(3-phenylprop-1-ynyl)furan, was discovered almost 30 years later by Gilman et al. (1933).
The biosynthesis of Carlina oxide results from the fatty acid metabolism (Bohlmann &
Mannhardt, 1957; Bohlmann & Rode, 1967; Meusel & Kästner, 1990). Next to Carlina oxide
the essential oil contains the sesquiterpenes ar-curcumene, farnesene, and β-sesquiphellan-
drene (Chalchat et al., 1996; Meusel & Kästner, 1990; Semmler, 1906; Stojanovic´-Radic´
et al., 2012). Additionally, the roots contain inulin as a reserve polysaccharide (Vitkova &
Evstatieva, 2002).
The aerial parts of the plant contain flavonoids such as the C-glycosylflavones vitexin,
isoschaftoside, orientin, and isoorientin (Ðord¯evic´ et al., 2012; Raynaud & Rasolojaona,
1979), apigenin, apigenin-7-O-glucoside (Ðord¯evic´ et al., 2012), and chlorogenic acids (Jaiswal
et al., 2011). Herb extracts of C. acaulis and C. acanthifolia have higher antioxidant and
anti-inflammatory activities than the respective root extracts (Ðord¯evic´ et al., 2012).
1.3 Caenorhabditis elegans
Caenorhabditis elegans is a free-living roundworm (phylum Nematoda) of the family Rhab-
didae. It was first described by Maupas (1900), who gave it the name Rhabditis elegans.
There are two sexes: hermaphrodites and males, although males occur only with a fre-
quency of 1.5 per 1000 and the hermaphrodites are able to survive for many generations
without mating. Figure 1.9 shows the anatomy of an adult hermaphrodite. Its about 1 mm
long transparent body is filled with the intestine, starting at the pharynx that marks the
head region, and reproductive organs. The males are slightly smaller and can be recognized
by the bursa—a sensitive organ surrounding their tails that is needed for mating.
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Figure 1.9: Anatomy of an adult C. elegans hermaphrodite. Picture taken with Keyence BZ9000,
scale bar corresponds to 100 µm.
Brenner (1974) introduced it as a model organism for genetic studies on the development
and function of nervous system. He chose this organism because of the simplicity of han-
dling and a manageable amount of cells. Together with H. R. Horwiz and J. E. Sulston, Sid-
ney Brenner became the Nobel Prize in Physiology or Medicine in 2002 for his work concern-
ing organ development and programmed cell death that they had done on this model system.
C. elegans became the first multicellular organism with completely sequenced genome (The
Caenorhabditis elegans Sequencing Consortium, 1998) and mapped connectome (Albertson
& Thomson, 1976; White et al., 1986), and the entire cell lineage of this organism is known
(Sulston et al., 1983). The genome of C. elegans consists of five autosomal chromosomes
and one sex chromosome with a constitution XX in hermaphrodites and OX in males. The
haploid genome contains 97 megabase DNA with over 19,000 genes. 36 % of the proteins
in C. elegans have a homologue in Homo sapiens (The Caenorhabditis elegans Sequencing
Consortium, 1998). The availability of the complete sequence and high homology to hu-
man genome together with the ease of handling make this nematode an excellent model
organism.
The normal lifespan of C. elegans is about three weeks, depending on temperature and
food concentration (Klass, 1977). After hatching from the egg, the larvae pass through four
moults (larval stages L1–L4) before they become fertile adults (Fig. 1.10) (Cassada & Rus-
sell, 1975). Each moult is preceded by a short period called lethargus, during which the
larvae stop feeding and are less agile. The time between moults is dependent on tempera-
ture. At lower temperatures the larvae grow slower and therefore need more time to reach
the size at which the moult occurs (Byerly et al., 1976; Cassada & Russell, 1975). The young
adult hermaphrodites produce sperm during the first hours of adulthood, then eggs begin
to form. The sperm remains stored in spermatheca. It fertilizes the ripe eggs as they pass
from ovary to uterus. One hermaphrodite can lay about 280 eggs before all the sperm is
used, unless it mates with a male and gets additional sperm (Byerly et al., 1976). After that
it can lay unfertilized eggs. The eggs are laid shortly before the larvae hatch. In some cases
the larvae hatch already in the uterus where they feed on unfertilized eggs and eventually
break through in the body cavity of their mother, thereby killing it (Maupas, 1900). This
phenomenon is referred to as ‘bagging’, because the dead hermaphrodite looks like a bag of
larvae.
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Figure 1.10: Lifecycle of C. elegans at 20 °C. Pictures taken with Keyence BZ9000, moulting times
after Byerly et al. (1976), scale bar corresponds to 100 µm.
When the food is limited or the population density too high, the L2 larvae can form a
dormant survival stage called dauerlarva. This stage has similar length as the L2 larva but
is much thinner. The dauers do not feed, their pharynx is closed, and they have an altered,
thicker cuticle. This stage is more resistant to desiccation, high temperatures, and harmful
chemicals than normal worms (Cassada & Russell, 1975). In convenient environmental
conditions the dauerlarvae can resume normal development by a moult to L4 larvae. The
time spent in dauer stage does not affect the residual lifespan of the worm, so that going
through a harsh period can more than double its lifespan.
1.3.1 Insulin-like signalling pathway
Genes involved in regulating dauer formation in C. elegans were named daf (abnormal
dauer formation) in an early genetic study (Riddle et al., 1981). The same genes were later
observed to play a role in ageing and regulation of lifespan. The gene daf-2 was described by
Kimura et al. (1997) as coding for a receptor tyrosine kinase homologous to human insulin
and IGF-1 receptors. Mutations in this gene lead to dauer formation or increased lifespan in
worms. The life lengthening activity of daf-2 is dependent on DAF-16 (Kenyon et al., 1993),
a transcription factor homologous to human FOXO1, FOXO4 (Lin et al., 1997; Ogg et al.,
1997), and FOXO3 (Lee et al., 2001). DAF-16 can translocate to the nucleus under stress-
ful conditions such as starvation, oxidative stress, and heat (Henderson & Johnson, 2001).
Together daf-2, daf-23 that was later described as ageing alteration 1 (age-1), coding for a
homologue to PI3K catalytic subunit p110 (Morris et al., 1996), and daf-16 form a distinct
pathway among the daf-genes (Gottlieb & Ruvkun, 1994)—the insulin-like signalling (ILS)
pathway (Fig. 1.11).
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Figure 1.11: The ILS pathway in C. elegans. Activation of DAF-2 leads to auto-phosphorylation
and recruits IST-1. IST-1 interacts with AAP-1 that recruits AGE-1 to the plasmamembrane
where it can produce PIP3. This is antagonized by the phosphatase DAF-18. PIP3 activates
PDK-1 and together they activate AKT-1 and 2. SGK-1 is also activated by PDK-1. AKT-1, AKT-
2, and SGK-1 phosphorylate DAF-16, thereby inhibiting its translocation into nucleus. DAF-2
antagonists lead to nuclear localization of DAF-16. ILS and DAF-16 interact with other pathways
and transcription factors to achieve differential gene expression.
The ILS pathway is conserved throughout evolution. Most of the genes involved have ho-
mologues in humans and other organisms (Tab. 1.2) (Papatheodorou et al., 2014). Addition-
ally to the three named genes, others have been found to be associated with this pathway.
The proteins insulin receptor substrate (IST-1) (homologue to human insulin receptor sub-
strate (IRS)) and AGE-1 adaptor protein (AAP-1) (homologue to human PI3K adaptor sub-
unit p55) help to recruit AGE-1 to plasma membrane upon DAF-2 activation (Wolkow et al.,
2002). The phosphatidylinositol-3,4,5-trisphosphat (PIP3) produced by AGE-1 leads to acti-
vation of 3-phosphoinositide-dependent kinase-1 (PDK-1) (Paradis et al., 1999), protein ki-
nase B (AKT)-1 and AKT-2 (Paradis & Ruvkun, 1998). This process is antagonized by DAF-
18, a PIP3 phosphatase homologous to human phosphatase and tensin homologue (PTEN)
(Ogg & Ruvkun, 1998). Serum- and glucocorticoid-inducible kinase 1 (SGK-1) is activated
through phosphorylation by PDK-1 and forms a possibly temporary complex with AKT-1
and 2 (Hertweck et al., 2004). These three kinases are responsible for phosphorylating
DAF-16 and preventing its translocation to nucleus.
DAF-16 activation is regulated by environmental signals via sensory neurons (Apfeld &
Kenyon, 1999), by reproductive system (Hsin & Kenyon, 1999), and by stress such as heat
shock (Lin et al., 2001b). Insulin related peptides (INSs) (Pierce et al., 2001) and DAF-28
(Li et al., 2003) are produced in neurons and possibly released upon sensory input. Some
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Table 1.2: Homologous genes of the C. elegans ILS pathway in Drosophila melanogaster, Mus mus-
culus, and Homo sapiens.
C. elegans D. melanogaster M. musculus H. sapiens
daf-2 InR Insr, Insrr, Igf1r INSR, INSRR, IGF1R
ist-1 chico Irs1, Irs2, Irs3,
Irs4
IRS1, IRS2, IRS4
aap-1 Pi3K21B Pik3r1, Pik3r2,
Pik3r3
PIK3R1, PIK3R2, PIK3R3
age-1 Pi3K68D, Pi3K92E Pik3cd, Pik3cb,
Pik3ca, Pik3cg
PIK3CA, PIK3CG, PIK3CB,
PIK3CD
daf-18 Pten Pten PTEN
pdk-1 Pk61C Pdpk1 PDPK1
akt-1, akt-2 Akt1 Akt1, Akt2, Akt3 AKT1, AKT2, AKT3
sgk-1 − Sgk1, Sgk2, Sgk3 SKG1, SKG2, SKG3
daf-16 foxo Foxo1, Foxo3,
Foxo4, Foxo6
FOXO1, FOXO3, FOXO4,
FOXO6
of these peptides like INS-1 are antagonists of DAF-2, others like DAF-28 act as agonists.
Some of the INSs are also found in other tissues and may have different targets. ILS is an
important pathway in regulation of ageing and growth, but apparently there are other me-
diators whose signals converge on DAF-16 such as c-Jun N-terminal kinase 1 (JNK-1) that
can phosphorylate DAF-16 and thereby promote its translocation into nucleus (Oh et al.,
2005). Also, different signals result in different activation patterns of DAF-16 (Lin et al.,
2001b). This can be explained by the fact that there are three isoforms of DAF-16 (Kwon
et al., 2010; Lin et al., 2001b), that have different expression patterns in specific tissues and
differential response to the upstream kinases (Kwon et al., 2010; Lee et al., 2001).
ILS affects lifespan and stress resistance by regulating the expression of stress related
genes, genes involved in metabolism, development, intra- and extracellular signalling, and
also genes for antimicrobial proteins (Lee et al., 2003; McElwee et al., 2003; Murphy et al.,
2003; Oh et al., 2006). For expression of some genes interactions between DAF-16 and other
transcription factors are necessary. Small HSPs can lengthen the lifespan and possibly pro-
tect for age related diseases. To activate these genes both DAF-16 and HSF-1 are needed
(Hsu et al., 2003; Morley & Morimoto, 2004) and the activity of HSF-1 is modulated by
ILS (Chiang et al., 2012). Oxidative stress is involved in ageing and age related diseases.
The transcription factor skinhead 1 (SKN-1) (orthologous to human NRF2) is required for
detoxification of free radicals (An & Blackwell, 2003) and is regulated via ILS by the same
kinases that phosphorylate DAF-16 (Tullet et al., 2008). Together these transcription fac-
tors regulate the expression of partly the same, partly different genes. Dietary restriction
can increase lifespan independent of DAF-16 via defective pharynx development 4 (PHA-4),
although those two transcription factors have overlapping binding sites and both of them
can regulate the expression of some SOD proteins (Panowski et al., 2007). Yeast silent infor-
mation regulator related 2.1 (SIR-2.1) is also involved in the ageing regulation (Tissenbaum
& Guarente, 2001) by interacting with 14-3-3 family protein 1 (FTT-1) and DAF-16, thereby
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activating the stress related gene expression in a DAF-16 dependent manner (Berdichevsky
et al., 2006; Wang et al., 2006). FTT-1 can also bind the phosphorylated form of DAF-16 in
the cytoplasm, inhibiting its entry into the nucleus (Berdichevsky et al., 2006).
Taken together the ILS is a central pathway in a complex network that regulates age-
ing and stress resistance. The evolutionary conservation of this pathway suggests that it is
important for normal function of a multicellular organism. It also opens the possibility to in-
vestigate these signals and the impact of modifications to them in a simple model organism
such as C. elegans.
1.3.2 Nervous system
The nervous system of C. elegans consists of 302 neurons. Their cell bodies are organized
into 11 ganglia and connected by processes that are concentrated in the circumpharyngeal
nerve ring and the ventral and dorsal chords (Ware et al., 1975; White et al., 1986). The
ganglia and process bundles are highly organized and symmetrical. The neurons can be
divided into sensory, moto-, and interneurons. They have a simple morphology with few
branches and connect to each other via gap junctions or chemical synapses. As neurotrans-
mitters acetylcholin (Lewis et al., 1987), biogenic amines (Alkema et al., 2005; Horvitz et al.,
1982; Sulston et al., 1975), γ-aminobutyric acid (GABA) (McIntire et al., 1993), glutamate
(Arena et al., 1992; Schaeffer et al., 1990), and various neuropeptides are described. The
pharynx and its 20 neurons form a separated, nearly self-contagious system, which gets in-
put from somatic nervous system only by one pair of interneurons (Albertson & Thomson,
1976). Additionally to the neurons, 56 glial cells support the functions of the nervous system
(Oikonomou & Shaham, 2011).
The body wall muscles of C. elegans are obliquely striated and allow dorso-ventral con-
tractions of the body, leading to the sinuous movement of the worms. The muscle cells send
arms towards motoneurons in the nerve ring or ventral chord to meet their innervating neu-
ral processes that make synapses en passant. Gap junctions between the muscle cells might
ensure the uniform distribution of a signal in adjacent cells (White et al., 1986). Some mo-
toneurons have also sensory properties that mediate a withdrawal in response to a touch or
help to maintain the oscillating body movement by monitoring the stretch of one side of the
body (McIntire et al., 1993; White et al., 1986). In contrast to the rest of the body, the head
can also be moved in lateral directions. The head muscles are innervated by neurons from
the nerve ring which probably allows for finer adjustment of movements than the relatively
simple ventral and dorsal chords. One sensory neuron is also found to synapse directly on a
muscle cell in the head (Ware et al., 1975; White et al., 1986).
C. elegans is able to sense different chemical and mechanic stimuli. The main chemosen-
sors are organized in the amphids, that are located on the lateral lips of the mouth (Fig. 1.12).
Each amphid contains 12 neurons and two glial cells that form the amphid channel. Most of
the neuronal endings lie in this channel and are in contact with the outer medium through
a pore in the cuticula, some are buried in one of the glial cells called the sheath cell. The
nerve ending of AFD, a thermosensory neuron (Mori & Ohshima, 1995), is also buried in
the sheath cell, but outside of the amphid channel (Ward et al., 1975). The tree neurons
which are not directly exposed to the environment—AWA, AWB, and AWC—are responsible
for the chemotaxis to volatile molecules, therefore they can be considered olfactory neu-
rons (Bargmann et al., 1993). The exposed neurons can sense water-soluble molecules like
cAMP and several ions, ASE being the most important chemosensory neuron in this set
(Bargmann & Horvitz, 1991; Dusenbery, 1974; Ward, 1973). Several of these neurons play
a role in dauer formation (Schackwitz et al., 1996; Vowels & Thomas, 1992).
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Figure 1.12: Scematic longitudinal
section through an amphid. The
sensory neurons are surrounded
by a sheath cell (sh) and socket
cell (so) that form the amphid
channel. Five of the 12 neurons
are shown. The cilia of the neu-
rons sensitive for water-soluble
substances are in direct contact
with surrounding medium. They
have either a single cilium (ASE,
ASG, ASH, ASI, ASJ, ASK) or
a branched dendrite with two
cilia (ADF, ADL). The olfactory
neurons AWA, AWB, and AWC
have their dendrites buried in the
sheat cell. AFD has its den-
drites outside the amphid chan-
nel. The scale bar corresponds
to 1 µm. Adapted from (Perkins
et al., 1986).
Detection of chemicals can help the worms find possible food sources (microorganisms),
but also some mechanic stimuli are involved in feeding behaviour. The mechanosensory
dopaminergic neurons CEP, ADE, and PDE are required for basal slowing response—the
behaviour observed when a C. elegans encounters food. Due to slower movement the worm
will stay longer at the food source. If a worm has been deprived from food for some time, it
reacts even stronger by completely stopping its movements. This behaviour—the enhanced
slowing response—is mediated by a pair of serotonergic neurosecretory neurons called NSM
(Sawin et al., 2000). The NSM neurons are located in the pharynx and have mechanosen-
sory endings under the cuticle of pharyngeal lumen (Albertson & Thomson, 1976). Exoge-
nous dopamine and serotonin can trigger the respective behaviours in mutants defective in
catecholamine synthesis (Sawin et al., 2000). In wildtype animals these neurotransmitters
also inhibit locomotion (Horvitz et al., 1982; Schafer & Kenyon, 1995).
1.3.3 Caenorhabditis elegans as a model for AD
C. elegans has a homologue to human APP called APP-like 1 (APL-1) (Daigle & Li, 1993) that
is involved in sensory responses and plasticity, development and metabolism of the worms
by interacting with ILS and other related signalling pathways (Ewald et al., 2012a,b). There
are also homologues for α- and γ-secretases, but no BACE1 activity has been found in the
worms and APL-1 lacks the Aβ sequence (reviewed in Alexander et al., 2014). Therefore,
the C. elegans strains used as models for AD are mostly transgenic. The strains best char-
acterized are CL2006 and CL4176 that express a human Aβ peptide in their muscle cells,
and CL2355 that expresses the same peptide in nervous system (see Tab. 2.2 for detailed
genotype information). A strain with Aβ expression in glutamatergic neurons and three
strains expressing tau have also been described (reviewed in Lublin & Link, 2013).
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CL2006 was the first transgenic C. elegans strain expressing human Aβ. It was made in
the lab of Link (1995). This strain expresses Aβ constitutively in its body wall muscles,
where it aggregates and forms plaques. The transgenic construct contains a signal peptide
for secretion, so the model was expected to produce extracellular Aβ1–42. Further exami-
nation of this model, however, showed that Aβ fibrils were formed intracellularly and the
peptide produced was Aβ3–42, probably due to cleavage of the signal peptide at a different
site than expected (Link et al., 2001; McColl et al., 2009). The aggregates can be stained
with anti-Aβ antibodies or amyloid specific dyes like thioflavin S, Congo red, or X-34 (Fay
et al., 1998; Link, 1995; Link et al., 2001). These dyes can also be used to stain senile plaques
in AD brains, indicating that the plaques in worms have a similar structure to the plaques
found in humans. This was also confirmed by electron microscopy (Link et al., 2001). There-
fore, this model is suitable for investigating Aβ aggregation and possible modulators of this
process. Aβ expression and aggregation in muscles of these worms leads to progressive
paralysis. This phenotype is more pronounced in the strain CL4176 that also expresses Aβ
in muscles, but the expression can be induced by temperature change (Link et al., 2003).
These worms paralyse and suffer under oxidative stress without the formation of fibrillar
amyloid deposits, suggesting that the toxicity of Aβ in this strain is mediated by oligomers
(Drake et al., 2003). Hence, this model can be used to study the effects on oligomers and
oligomer toxicity. Both of these strains express Aβ in their muscles, representing rather
inclusion body myositis (a disease with Aβ aggregates in muscles) than AD. To better re-
capitulate the neuronal disease, the strain CL2355 with pan-neuronal Aβ expression was
developed. These worms have deficits in chemotaxis, associative memory, and serotonin sig-
nalling (Dosanjh et al., 2010; Wu et al., 2006), being therefore useful for testing effects on
the nervous system.
In addition to the Aβ aggregation and toxicity, these models share some similarities with
the human disease. As already mentioned, Aβ dependent oxidative stress is observed in
these worms (Drake et al., 2003). This is accompanied by higher levels of iron (Wan et al.,
2011), copper can have protective or enhancing activity on the toxicity depending on its
concentration as also seen in other models (Luo et al., 2011; Rebolledo et al., 2011). Oxi-
dation of specific proteins involved in several cellular functions corresponding to defects in
AD have been identified (Boyd-Kimball et al., 2006). Aβ causes synaptic dysfunction and
mislocalisation of ACh receptors (Rebolledo et al., 2011). It induces expression of HSPs in
worms and also in AD brain (Link et al., 2003). HSP-16.2 can interact with Aβ oligomers
and reduce their toxicity in C. elegans model (Fonte et al., 2002, 2008; Wu et al., 2010). Aβ
toxicity is also reduced by a proteasomal protein, also upregulated by Aβ expression, and
its human homologue (Hassan et al., 2009). Defective autophagy has also been observed in
the C. elegans model of Aβ toxicity as well as in AD neurons (Florez-McClure et al., 2007).
Aβ is degraded through autophagy in this model. The degradation can be enhanced and
Aβ toxicity reduced by decreasing the activity of the ILS pathway (Cohen et al., 2006, 2010;
Florez-McClure et al., 2007). The same pathway in humans is impaired in diabetes melli-
tus, a risk factor for AD, and is also involved in Aβ clearance (see section 1.1.4). The first
metabolomic study in a C. elegans AD model could also draw parallels to human disease
(Van Assche et al., 2015).
Despite these similarities, C. elegans is obviously not a perfect model for AD. Due to the
lack of BACE1 activity this model has no relevance to APP processing and Aβ production.
It also lacks processes comparable to neuroinflammation, several pathways relevant to Aβ
clearance in humans, and even cell types and organs like astrocytes, microglia, or the blood
brain barrier. These models are still useful for studying the aggregation of Aβ in an in
vivo environment, the response of a single cell to Aβ toxicity, or the effect of compounds
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interacting directly with Aβ, independent of an vertebrate organism. In the pan-neuronal
Aβ strain also effects on neurons, neurotransmission, and simple behaviour can be studied.
In contrast to mammalian models like mice or rats C. elegans has a short life span, making
it a good model organism for ageing and age related diseases. The short reproduction cycle
and easy handling of these worms make it possible to carry out high throughput screens,
that would not be possible in mammalian models. On the other hand, this is an in vivo
system, having the advantage over cell culture where usually only one cell type is kept in
an artificial medium. Hence, C. elegans can be seen as a bridge between in vitro experiments
and more complex vertebrate models.
1.4 Objectives
Neurodegenerative diseases are a growing social and medical problem in our ageing soci-
ety. Although neurodegeneration can be caused by different mechanisms, the diseases tend
to share many features like protein aggregation, oxidative stress, neuroinflammation, or
defects of lysosomal degradation. For this work AD was chosen as a representative neu-
rodegenerative disease, since it is becoming a major health problem and new medications
for its treatment are desperately needed. Phytotherapy can be beneficial in such complex
disorders because of the multitarget action and good tolerability, which is important in old,
fragile patients. Identifying active extracts and secondary metabolites is therefore imperial.
C. elegans was chosen as a model organism for this study because of its easy handling and
availability of several strains that can model aspects of AD.
The objectives of the present work are:
• Screening different extracts of selected plants for their activity on Aβ aggre-
gation to identify active extracts
25 potentially effective plants from TCM were identified via literature research. Meth-
anol and dichloromethane extracts of these plants will be studied on the C. elegans
strain CL2006. Most active extracts will be chosen for further analysis.
• Testing the chosen extracts for their ability to counteract Aβ-induced toxic-
ity
An effect on Aβ aggregation in CL2006 does not verify a reduction of Aβ toxicity,
if the toxic species are oligomers, not fibrils. To study the effect on oligomers, two
other strains will be used: CL4176, to identify the general potential to counteract
Aβ-induced toxicity, and CL2355, to study the effect on neurons.
• Phytochemical characterization of active extracts
In order to identify active constituents, the extracts will be analysed via HPLC, LC-
MS, or GLC-MS. Major constituents will be tested for their activity on Aβ aggregation
and toxicity in the systems mentioned before.
• Evaluation of in vivo antioxidant activity
Since oxidative stress is an important feature in neurodegenerative disease, the an-
tioxidant activity of the extract and of the major compounds will be studied. The
C. elegans strain TJ375 will be used to detect HSP expression, a marker for general
stress resistance.
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• Testing effects on ILS pathway and lifespan
ILS pathway is highly conserved throughout evolution, which makes it possible to
draw conclusions about the effects in humans based on the study in C. elegans. Insulin
signalling in disturbed in AD, therefore the extracts and compounds will be tested for
their ability to activate DAF-16, the downstream transcription factor of ILS. Activa-
tion of DAF-16 leads to lengthened lifespan in C. elegans, hence this effect will be also
tested.
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2 Material and methods
2.1 Material
2.1.1 Instruments
Bioblock Scientific Thermolyne Corp.
BioDoc-It™ Imaging System UVP
Biofuge pico Heraeus
Certoclav EL Certoklav Sterilizer GmbH
Centrifuge Rotina 380R Hettich
Cooling incubator IPP Memmert
DS-Qi1Mc black and white camera Nikon
Degasser ERC-3215α Shodex
Electrophoresis Power Supply E452 Consort
Fluorescence microscope Ni-E Nikon
Fluorescence microscope BZ9000 Keyence
Freezer −20 °C Liebherr
Freezer −80 °C Fryka
GLC system HP5890 Series II Hewlett Packard
HPLC system 9100 (YL9110 quaternary pump,
YL9101 vacuum degasser, YL9160 photo diode
array detector)
Young Lin
HPLC system Gold (125P solvent module, 168
detector)
Beckman
Incubating Mini Shaker VWR
Incubator Heraeus
Ion trap mass spectrometer LCQ-Duo Finnigan
LAS 3000 Imaging system Brennan & Company
Marathon autosampler Spark
Microplate reader Asys UVM340 Anthos Mikrosysteme GmbH
MP120 pH meter Mettler-Toledo
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NanoPhotometer Implien
PerfectBlue™ Dual Gel Twin S Peqlab
Quadrupole mass spectrometer SSQ 7000 Finnigan
Refrigerator Liebherr
Rotary evaporator Heidolph
Sartoblot® II Satorius
Shaker GFL
Stereomicroscope SM 22-AD 24 Hund
Sterile bench Labortechnik Fröbel
Thermocycler TGradient Biometra
2.1.2 Laboratory material
8-Chambre slides BD Biosciences
96-Well plates Greiner Bio-One
Cellstar® tubes (15, 50 ml) Greiner Bio-One
Cover slips Marienfeld
GLC column Zebron (30 m × 0.25 mm, film thick-
ness 0.25 µm)
Phenomenex
LiChroCART (4-4) RP-18e (5 µm) guard column Merck
LiChroCART RP-18 column (250 × 4 mm, 5 µm) Merck
Object slides Menzel-Gläser
Petri dishes (35 × 10, 60 × 15, 100 × 20 mm) Greiner Bio-One
pH indicator Macherey-Nagel
Preparative TLC plates (30 × 30 cm, silica gel 60,
F254 0.5 mm)
Merck
Round filter Schleicher & Schuell
Safe-lock tubes (0.1, 0.5, 1.5, 2 ml) Eppendorf
Semi-micro cuvettes 10 × 4 mm Sarstedt
2.1.3 Chemicals
2,2-Diphenyl-1-picrylhydrazyl Sigma-Aldrich
β-Mercaptoethanol Sigma-Aldrich
λ-DNA Fermentas
Acetic acid J.T. Baker
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Acetonitrile (ACN) J.T. Baker
Acrylamide/bisacrylamide (30:1) Roth
Actin antibody C11 Santa Cruz Biotechnology
Agarose Sigma-Aldrich
Ammonium acetate (NH4Ac) Grüssing
Ammonium persulfate (APS) Amersham Biosciences
Bacto™ Agar Beckton, Dickinson and Company
Bacto™ Tryptone Beckton, Dickinson and Company
Bacto™ Yeast Extract Beckton, Dickinson and Company
Benzaldehyde Merck
Bovine serum albumin (BSA) Sigma-Aldrich
Beta-amyloid 1-42, human PeptaNova
Beta-amyloid monoclonal antibody 6E10, horse
radish peroxidase (HRP) labelled
Signet
Bromphenolblue Fulka
Calcium chloride (CaCl2) Merck
Cholesterol Sigma-Aldrich
Citric acid monohydrate Applichem
Complete PCR reaction buffer, 10 × Bioron
Coomassie blue G-250 Fulka
Copper sulphate pentahydrate (CuSO4·5H2O) Grüssing
Cyclohexane Grüssing
Deoxynucleotides Bioron
Dichlormethane Sigma-Aldrich
Dimethyl sulfoxide (DMSO) VWR
Dipotassium hydrogen phosphate (K2HPO4) Merck
Disodium hydrogen phosphate (Na2HPO4) Sigma-Aldrich
Ethylenediaminetetraacetic acid (EDTA)
disodium salt dihydrate
Applichem
(−)-Epigallocatechin gallate (EGCG) Sigma-Aldrich
Ethanol Berkel
Ethidium bromide Serva
Ethylacetate University Heidelberg
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Formic acid (HCOOH) Merck
Glycerin AppliChem
Glycin AppliChem
Glycyrrhizic acid Northeast Forestry University, China
Glycyrrhizic acid monoammonium Northeast Forestry University, China
Glycyrrhetinic acid Northeast Forestry University, China
Hydrochloric acid (HCl) AnalaR Normapur
Isoliquiritigenin Phytolab
Iron sulphate septahydrate (FeSO4·7H2O) Sigma-Aldrich
Juglone (5-hydroxy-1,4-naphthochinon) Sigma-Aldrich
Liquiritigenin Phytolab
Methanol Sigma-Aldrich
Magnesium sulphate (MgSO4) Merck
Milk powder Granovita
Manganese chloride tetrahydrate (MnCl2·4H2O) Merck
Nitocellulose blotting membrane Satorius
Nitrogen Air Liquide
Paraformaldehyde (PFA) Sigma-Aldrich
Phosphoric acid Roth
Poly-L-lysin Sigma-Aldrich
Primers ITS4, ITS5 NWG
Protease inhibitor cocktail Complete Mini Roche
PST I Fermentas
Potassium chloride (KCl) Merck
Potassium dihydrogen phosphate (KH2PO4) Applichem
Sodium azide Applichem
Sodium chloride (NaCl) Applichem
Sodium dodecyl sulphate (SDS) Merck
Sodium hydroxide (NaOH) Sigma-Aldrich
Sodium hypochlorite (NaClO) Grüssing
Spectra™ Multicolor low range protein
ladder
Fermentas
Taq polymerase Bioron
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Tetramethylethylenediamine (TEMED) Roth
Thioflavin S Sigma-Aldrich
Thioflavin T Sigma-Aldrich
Tricine Roth
Tri-potassium citrate monohydrate Roth
Tris(hydroxymethyl)aminomethane (Tris) Roth
Triton® X-100 Fulka
Tween® 20 Roth
Water HiPerSolv Chromanorm® VWR
WEST-ZOL™ Plus Western blot detection
system
iNtRON Biotechnology
Whatman™ blotting paper, 0.34 mm GE Healthcare
Zinc sulphate septahydrate (ZnSO4·7H2O) Merck
2.1.4 Buffers, solutions, media
Phosphate buffered saline (PBS), 1 ×
• 140 mM NaCl
• 2.7 mM KCl
• 10 mM Na2HPO4
• 1.8 mM KH2PO4
pH was adjusted to 7.4 with HCl.
4 % Paraformaldehyde (PFA) solution
50 ml H2O was heated to about 60 °C. 4 g PFA was added and stirred, to get a suspension.
Then 1 M NaOH was added until the PFA was dissolved and the solution turned transpar-
ent. It was let to cool down and filtered. 10 ml of 10 × PBS was added to the solution and it
was then filled up to 100 ml with H2O. The pH value was checked using a pH indicator and
adjusted with HCl to be between 7 and 8.
S-basal
• 5.85 g NaCl
• 1 g K2HPO4
• 6 g KH2PO4
• 1 ml 5 mg/ml Cholesterol in ethanol
• H2O to 1 litre
The solution was autoclaved for 15 min at 125 °C .
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Trace metals solution
• 1.86 g Disodium EDTA
• 0.69 g FeSO4·7H2O
• 0.2 g MnCl2·4H2O
• 0.29 g ZnSO4·7H2O
• 0.025 g CuSO4·5H2O
• H2O to 1 litre
The solution was autoclaved for 15 min at 125 °C.
1 M Potassium citrate pH 6
• 20 g Citric acid monohydrate
• 293.5 g Tri-potassium citrate monohydrate
• H2O to 1 litre
The solution was autoclaved for 15 min at 125 °C.
S-Medium
• 1 l S-Basal
• 3 ml 1 M CaCl2
• 3 ml 1 M MgSO4
• 10 ml 1 M Potassium citrate pH 6
• 10 ml Trace metals solution
1M Potassium phosphate (kpo4), pH 6
• 35.6 g K2HPO4
• 108.3 g KH2PO4
• H2O to 1 litre
The solution was autoclaved for 15 min at 125 °C.
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NGM
• 17 g Agar
• 3 g NaCl
• 2.5 g Tryptone
• 975 ml H2O
The solution was autoclaved for 15 min at 125 °C. After cooling down to 55 °C the following
ingredients were added:
• 1 ml 1 M CaCl2
• 1 ml 1 M MgSO4
• 25 ml 1 M KPO4
• 1 ml 5 mg/ml Cholesterol in ethanol
Test-agar for chemotaxis assay
• 19 g Agar
• 975 ml H2O
The solution was autoclaved for 15 min at 125 °C. After cooling down to 55 °C the following
ingredients were added:
• 1 ml 1 M CaCl2
• 1 ml 1 M MgSO4
• 25 ml 1 M KPO4
M9-Buffer
• 5 g NaCl
• 6 g Na2HPO4
• 3 g KH2PO4
• 1 ml 1 M MgSO4
• H2O to 1 litre
The solution was autoclaved for 15 min at 125 °C.
LB Medium
• 10 g Tryptone
• 5 g Yeast extract
• 10 g NaCl
• 950 ml H2O
The solution was autoclaved for 15 min at 125 °C.
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LB Agar
• 10 g Tryptone
• 5 g Yeast extract
• 10 g NaCl
• 15 g Agar
• 950 ml H2O
The solution was autoclaved for 15 min at 125 °C and poured into 100 mm petri dishes.
TE Buffer
• 10 mM Tris
• 1 mM EDTA
Sample buffer for agarose gel electrophoresis
• 500 µl Glycerin
• 2.5 mg Bromphenolblue
• 500 µl H2O
TAE-Buffer, 50 ×
• 2420 g Tris
• 186 g EDTA
• 571 ml Acetic acid
• H2O to 10 litre
Bradford reagent
• 25 mg Coomassie blue G-250
• 12.5 ml Ethanol
• 25 ml Phosphoric acid
• H2O to 250 ml
Coomassie solution
• 0.5 % Coomassie blue G-250
• 50 % Ethanol
• 10 % Acetic acid
• 39.5 % H2O
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Destaining solution
• 20 % Ethanol
• 10 % Acetic acid
• 70 % H2O
4 × Laemmli buffer
• 5 ml 1 M Tris, pH 6.8
• 40 ml Glycerin
• 5 g SDS
• 5 mg Bromphenolblue
• H2O to 100 ml
10 % β-Mercaptoethanol were added prior to use.
Gels for SDS-PAGE
15 % resolving gel 5 % stacking gel
H2O 2.3 ml 3.4 ml
30 % Acrylamide mix 5 ml 0.8 ml
1.5 M Tris (pH 8.8) 2.5 ml -
1 M Tris (pH 6.8) - 0.6 ml
10 % SDS 0.1 ml 0.05 ml
10 % APS 0.1 ml 0.05 ml
TEMED 4 µl 5 µl
Cathode buffer
• 12.11 g Tris
• 17.92 g Tricine
• 1 g SDS
• 1 l H2O
Final concentrations: 0.1 M Tris, 0.1 M tricine, 0.1 % SDS.
Anode buffer, 5 ×
• 121.1 g Tris
• 500 ml H2O
The pH was adjusted to 8.9 with HCl, then water was added to 1 l.
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Transfer buffer
• 25 mM Tris
• 196 mM glycin
• 20 % methanol
2.1.5 Plants
Most of the plants investigated in the present study are used in TCM. They were obtained
commercially in China and kindly provided to our institute by Prof. Thomas Efferth. The
unripe fruits of G. biloba were gathered on university campus in Heidelberg, Germany.
Other suppliers are indicated in Table 2.1. Voucher specimens of the plants are deposited
at IPMB, Department of Biology, Heidelberg University, Germany.
Table 2.1: Plant material used in this work including plant part, supplier and respective IPMB
accession numbers (IPMB-nr).
Name Family Used part IPMB-nr. Supplier
Alpinia galanga Zingiberaceae Fruit P6837 China
Alpinia oxyphylla Zingiberaceae Fruit P6917 China
Areca catechu Arecaceae Seed P6840 China
Capsella
bursa-pastoris
Brassicaceae Herb P6846 China
Carlina acaulis Asteraceae Root P8212 Caesar & Loretz
Centella asiatica Apiaceae Herb P6849 China
Cnidium monnieri Apiaceae Seed P6854 China
Coptis chinensis /
deltoidea / teeta
Ranunculaceae Root P6855 China
Eleutherococcus
senticosus
Araliaceae Root P6919 Russia
Epimedium
brevicornum /
sagittatum / pubescens
/ wushanense /
koreanum
Berberidaceae Leaves P6865 China
Evodia rutaecarpa /
rutaecarpa var.
officinalis / rutaecarpa
var. bodinieri
Rutaceae Fruit P6870 China
Ginkgo biloba Ginkgoaceae Leaves P8075 Heinrich Klenk
Continued on next page
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Table 2.1 – Continued from previous page
Name Family Used part IPMB-nr. Supplier
Ginkgo biloba Ginkgoaceae Nuts P6872 China
Ginkgo biloba Ginkgoaceae Unripe
seeds
P8517 Im Neuenheimer
Feld, Heidelberg
Ginkgo biloba Ginkgoaceae EGb761® Dr. Willmar
Schwabe
Glycyrrhiza uralensis Fabaceae Wood P6873 China
Magnolia officinalis /
officinalis var. biloba
Magnoliaceae Bark P6882 China
Berberis bealei Berberidaceae Wood P6883 China
Paeonia
lactiflora / veitchii
Paeoniaceae Root P6886 China
Panax ginseng Araliaceae Root P8077 Kräuter Schulte
Panax notoginseng Araliaceae Root P6887 China
Phellodendron
chinense / amurense
Rutaceae Wood P6890 China
Polygonum
multiflorum
Polygonaceae Root P6895 China
Punica granatum Lythraceae Fruit P6897 China
Rhodiola rosea Crassulaceae Root P6920 Kräuterparadies
Lindig
Rosa laevigata Rosaceae Fruit P6900 China
Sanguisorba
officinalis / officinalis
var. longifolia
Rosaceae Root P6901 China
Scutellaria
baicalensis
Lamiaceae Wood P6903 China
Verbena officinalis Verbenaceae Herb P6910 China
2.1.6 Caenorhabditis elegans strains
The C. elegans strains used in this work (Tab. 2.2) and their food source Escherischia coli
OP50 were obtained from Caenorhabditis Genetics Center (CGC) at University of Min-
nesota, which is funded by NIH Office of Research Infrastructure Programs (P40 OD010440).
An exception are the strains CL2355 and PD8120 that were a kind gift from Dr. Christopher
D. Link, University of Colorado.
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Table 2.2: C. elegans strains used in the present work.
Strain Genotype Description from CGC
N2 wildtype C. elegans var. bristol. Isolated from mushroom compost
near Bristol, England by L.N. Staniland.
CL2006 dvIs2 dvIs2 [pCL12(unc-54::Aβ1–42) + pRF4(rol-6(su1006))].
Adult onset paralysis and egg-laying deficiency when
raised at 20 °C.
CL4176 smg-1(cc546) I;
dvIs27 X
dvIs27 [pAF29(myo-3::Aβ1–42::let UTR) + pRF4(rol-
6(su1006))]. Temperature sensitive: needs to be propa-
gated at 16 °C. At 25 °C expression of human Aβ in muscle
cells, leading to paralysis.
CL802 smg-1(cc546) I;
rol-6(su1006) II
Temperature sensitive with roller phenotype.
CL2355 smg-1(cc546) I;
dvIs50 I
dvIs50 [pCL45(snb-1::Aβ1–42::let UTR + mtl-2::GFP]. Tem-
perature sensitive: needs to be propagated at 16 °C. At
23 °C pan-neuronal expression of human Aβ. Shows
deficits in chemotaxis, associative learning, and thrashing
in liquid. Also has incomplete sterility due to germline pro-
liferation defects and embryonic lethality.
PD8120 smg-1(cc546) I Temperature sensitive.
TJ375 gpIs1 gpIs1 [hsp-16.2::GFP]. Insertion not mapped. GFP fluores-
cence after > 1 hour heat shock at 35 °C.
TJ356 zIs356 IV zIs356 [daf-16::GFP]. Roller strain, increased resistance to
heat and UV. Grows and reproduces slowly. Integrated by
gamma irradiation of extrachromosomal (Ex daf-16::GFP)
line.
2.1.7 Software
32 Karat™ 5.0 Beckman Coulter, Inc.
Bioedit Ibis Biosciences
DigiRead V 1.8.0.2 Biochrom
ImageJ 1.43u public domain
MEGA 5.1 Tamura et al. 2011
NIS-Elements Nikon
SigmaPlot 13.0 Systat Software, Inc.
StatView 5.0.1 SAS Institute Inc.
YL-Clarity Young Lin
Xcalibur™ 2.0 Thermo Scientific
46
2.2. Methods
2.2 Methods
2.2.1 Preparation of extracts
Extraction of TCM plants
The dried plant material from plants listed in Table 2.1 (with exception of C. acaulis) was
extracted with methanol and dichloromethane. For G. uralensis also a water extract was
prepared. 50 g of the plant material was heated under reflux with the respective solvent
for 4 h, then filtrated. The extracts were concentrated in a rotary evaporator and stored at
−20 °C. Small amounts of these crude extracts were dried in a heating block and dissolved
in methanol or DMSO to the desired concentration.
Some of these extracts were prepared earlier in the same manner by Dorothea Kaufmann
and Florian Hermann during their PhD thesis at Heidelberg University, IPMB, Department
of Biology.
Extraction of Carlina acaulis
This extract was prepared by Frank Sporer, a scientific assistant at Heidelberg University,
IPMB, Department of Biology. The dried roots of C. acaulis were extracted with dichlor-
methane in a Soxhlet extractor. The crude extract was dried under nitrogen flow and dis-
solved in methanol for further experiments.
2.2.2 Isolation of Carlina oxide
Carlina oxide was isolated from the dichloromethane extract of C. acaulis using preparative
thin layer chromatography (TLC) plates with silica gel and a mixture of 90 % ethylacetate
and 10 % cyclohexane as eluent. The Carlina oxide fraction was separated from all other
fractions. Both the Carlina oxide fraction and the residual extract were extracted from
silica gel with methanol. The amount of obtained Carlina oxide and residual extract from
three preparative TLC plates was 7.4 and 5.2 mg, respectively. The isolation was carried
out by Kevin Roth, a Master of Science student of Molecular Biotechnology at Heidelberg
University, during his laboratory practical at IPMB, Department of Biology.
2.2.3 HPLC analysis
The G. uralensis extracts were analysed with a high pressure liquid chromatography (HPLC)
system from Young Lin on a reversed phased column using gradient elution of 3 % acetic
acid in water and ACN (Zeng et al., 1990). The gradient is shown in Table 2.3. Detection
was performed at different wavelengths: 245, 310, 365, 276, 231, and 520 nm and evalu-
ated using the YL-Clarity software. The substances LG, ILG, GA, and GRA were identified
by comparison of the retention time (RT) and absorption pattern with external standards.
Calibration curves for quantification of these compounds were prepared with following con-
centrations: 150, 100, 50, 25, and 17.5 µg/ml for GA; 60, 40, 20, 10, and 5 µg/ml for LG and
GRA; 30, 20, 10, 5, and 2.5 µg/ml for ILG. GA, GRA, and ILG were quantified at 254 nm,
LG at 310 nm.
2.2.4 LC-MS/MS analysis
For LC-MS analysis of water and methanol extracts of G. uralensis the HPLC system Gold
from Beckman was used. A gradient of ACN with 0.1 % formic acid (A) and 0.1 % formic
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Table 2.3: Gradient used for HPLC analysis of G. uralensis extracts.
Time in min % H2O with 3 % acetic acid % ACN Flow rate in ml/min
0 80 20 1
13 80 20 1
15 50 50 1.2
25 20 80 1.2
30 20 80 1.2
acid in water (B) was used at a constant flow rate of 1 ml/min. The gradient from 80 % B to
20 % B in 20 min was applied, followed by 10 min at 20 % B and a 10 min equilibration at
80 % B. The run was detected at 254 nm and 365 nm using 32 Karat™ software and with
the ion trap mass spectrometer (MS) LCQ-Duo equipped with an electrospray ionisation
source. The spectra were acquired in negative ion mode over a mass range of 50–2000 m/z
with highly purified nitrogen as sheath and auxiliary gas, capillary voltage −10 V, capillary
temperature 200 °C. The Xcalibur™ software was used to analyse the data.
2.2.5 GLC-MS analysis
Work on gas-liquid chromatography (GLC)-MS was carried out by Frank Sporer, a scientific
assistant at Heidelberg University, IPMB, Department of Biology. For the GLC analysis of
C. acaulis extract following temperature gradient was applied: isotherm at 40 °C for 2 min,
8 °C/min to 300 °C, isotherm at 300 °C for 10 min. For the Carlina oxide and extract without
Carlina oxide the temperature gradient was started at 100 °C and increased in 3 °C/min for
better resolution. Data acquisition was started after 3 min. The injector temperature was
250 °C, head pressure 15 hPa, carrier gas helium, split 1:100. The separated substances
were ionized by electron ionisation with an electron energy of 70 eV and source temperature
175 °C. Detection followed via SSQ 7000 MS. The spectra were analysed using Xcalibur™
software.
2.2.6 Identification of Glycyrrhiza uralensis via DNA barcoding
Variable sites in four DNA regions have been described in Glycyrrhiza species by Kondo
et al. (2007b). Here one of them, the internal transcribed spacer (ITS) sequence, was ex-
amined. DNA was extracted from the dried plant material of ga¯n ca˘o earlier by Florian
Hermann during his work on his PhD thesis at Heidelberg University, IPMB, Department
of Biology. It was stored in Tris-EDTA (TE) buffer at 4 °C. The ITS sequence containing
ITS1, 5.8S ribosomal ribonucleic acid (rRNA) gene, and ITS2 was amplified by polymerase
chain reaction (PCR) with the primers ITS4 (TCC TCC GCT TAT TGA TAT GC) and ITS5
(GGA AGT AAA AGT CGT AAC AAG G). 0.5 µl of each primer, 1.5 µl of mixed deoxynu-
cleotides, 2.5 µl 10 × reaction buffer, 0.5 µl 20 mg/ml BSA, 0.2 µl Taq polymerase, 16.3 µl
H2O, and 3 µl DNA were pipetted together in a PCR tube. The PCR program is shown in
Table 2.4.
The amplified DNA was tested for the right size by agarose gel electrophoresis. 6 µl of the
PCR product with 1.5 µl sample buffer were loaded on a 1 % agarose gel in TAE buffer with
0.01 % ethidium bromide. The separation was performed at 90 V for 40 min. The bands
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Table 2.4: PCR program for ampli-
fying ITS.
Temperature Duration
94 °C 5 min
38 cycles:
94 °C 45 s
45 °C 50 s
72 °C 50 s
72 °C 5 min
4 °C 5 min
were compared to a λ-marker (λ-DNA cut by PST I enzyme).
Finally the samples containing correct PCR product were purified and sequenced. For
the purification DNA was precipitated with NH4Ac and ethanol and centrifuged for 30 min
at 13,000 rpm. The solvent was discarded, the pellet washed with 70 % ethanol. The sol-
vent was completely removed and the pellet dried at 56 °C. The dry pellet was then dis-
solved in sterile H2O and sent for sequencing to StarSEQ® GmbH. The raw sequences were
edited using Bioedit and a divergence analysis was performed using MEGA 5.1. For the
divergence analysis the sample P6873 was compared to sequences retrieved from GenBank,
Glycyrrhiza astragalina was used as an outgroup (Tab. 2.5).
2.2.7 DPPH• assay
2,2-Diphenyl-1-picrylhydrazyl (DPPH•) is a free radical that can be reduced by hydrogen
donors. This reaction can be quantified photometrically, since DPPH• has a strong ab-
sorbance at 517 nm but the reduced form, hydrazine, does not. DPPH• free radical scaveng-
ing assay was performed using a modified version of the method described by Blois (1958).
DPPH• was prepared as a 0.2 mM solution in methanol. Equal volumes of the tested sub-
stance and DPPH• solution were mixed and incubated for 30 min at room temperature.
After the incubation the absorbance of each sample in duplicates was measured at 517 nm
in a microplate reader. For each tested substance concentration a blank without DPPH•
was prepared and measured in the same manner. DPPH• free radical scavenging effect was
calculated using the following equation:
% DPPH• scavenging effect= A0−A1
A0
×100
A0: absorbance of DPPH•
A1: absorbance of DPPH• with the tested compound
2.2.8 SDS-PAGE and Western blot analysis of Aβ
To separate the different forms of Aβ present in the worms and evaluate the effect of the
extracts on the amount of oligomers and monomers of this peptide, a Western blot analy-
sis was conducted. CL2006 worms were treated the same way as for the quantification of
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Table 2.5: Sequences used for the divergence analysis.
GenBank accession nr. Species Encoded region
JF778868 G. inflata 5.8S rRNA, partitial sequence; ITS2;
26S rRNA, partitial sequence
AB280740 G. inflata ITS1; 5.8S rRNA; ITS2
AY065623 G. glabra 18S rRNA, partitial sequence; ITS1;
5.8S rRNA; ITS2; 26S rRNA, partial
sequence
JF778867 G. glabra 5.8S rRNA, partitial sequence; ITS2;
26S rRNA, partitial sequence
HE602402 G. glabra ITS1; 5.8S rRNA; ITS2
AB280739 G. glabra ITS1; 5.8S rRNA; ITS2
JF421504 G. uralensis 5.8S rRNA, partitial sequence; ITS2;
26S rRNA, partitial sequence
JF778869 G. uralensis 5.8S rRNA, partitial sequence; ITS2;
26S rRNA, partitial sequence
HQ229003 G. uralensis 5.8S rRNA, partitial sequence; ITS2;
26S rRNA, partitial sequence
GQ246129 G. uralensis ITS1; 5.8S rRNA; ITS2
AB280738 G. uralensis ITS1; 5.8S rRNA; ITS2
EU418258 G. uralensis ITS1, partitial sequence; 5.8S rRNA;
ITS2, partitial sequence
AB649775 G. uralensis 18S rRNA, partitial sequence; ITS1;
5.8S rRNA; ITS2; 26S rRNA, partitial
sequence
JF421503 G. uralensis 5.8S rRNA, partitial sequence; ITS2;
26S rRNA, partitial sequence
GQ246133 G. astragalina ITS1; 5.8S rRNA; ITS2
GQ246134 G. astragalina ITS1; 5.8S rRNA; ITS2
plaques (see section 2.2.10). Instead of fixing the worms at the end of the treatment, they
were collected in a Eppendorf tube, washed twice with 1 × PBS, and resuspended in 100 µl
PBS with protease inhibitor cocktail. These samples were frozen and kept at −80 °C until
further use.
The samples were thawed on ice and homogenized. The protein concentration was mea-
sured after Bradford (1976). Briefly, 2 µl of the sample were mixed with 1 ml diluted Brad-
ford reagent (1:5 in water) and the absorption was measured at 595 nm after 5 min incu-
bation at room temperature. A standard curve was prepared using BSA in a concentration
range of 0.5–3 mg/ml.
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A SDS-tricine polyacrylamide gel electrophoresis (PAGE) was performed with 15 % re-
solving gel and 5 % stacking gel. The samples (final concentration of 50 µg/ml protein) were
heated at 100 °C for 3 min in Laemmli buffer prior to loading on the gel. A low range protein
ladder was used as marker. 0.5 µg Aβ were used as positive control. The gel was run for
approximately 1 h at 100 V in tricine containing cathode buffer and anode buffer without
tricine.
For detection either a Coomassie staining or Western blot were used. For the Coomas-
sie staining the gel was covered with Coomassie solution and stained on shaker for several
hours followed by destaining with the destain solution. For Western blot analysis the pro-
teins were blotted on a nitrocellulose membrane in transfer buffer for 2 h at 48 mA . Then
the membrane was blocked with 5 % milk powder in phosphate buffered saline containing
0.05 % Tween® 20 (PBST) over night at 4 °C. On the next day the membrane was incubated
with either anti-Aβ or anti-actin antibodies coupled with HRP (1:1000 dilution in 2.5 %
milk powder in PBST) for 2 h. The membrane was washed 3× 10 min in PBST and detected
with WEST-ZOL™ Western blot detection system. The blots were documented by LAS 3000
Imaging system.
2.2.9 Caenorhabditis elegans culture conditions
The temperature sensitive strains CL4176, CL802, CL2355, and PD8120 were cultivated at
16 °C, all others at 20 °C. The worms grew on nematode growth medium (NGM) and were
fed with E. coli OP50, an uracil deficient E. coli strain (Brenner, 1974). The bacteria were
cultured in liquid LB medium at 37 °C overnight. This overnight culture was stored at 4 °C
for further use. Aliquots of it were spread on LB agar plates and left at 37 °C overnight
prior to resuspension in S-medium. Most of the experiments were conducted in S-medium
containing 109 cells/ml E. coli OP50 (OD600 ≈ 1).
To obtain eggs for the experiments the hypochlorite treatment described earlier (Sulston &
Hodgkin, 1988) was used. Briefly, the worms were treated with 0.5 M NaOH and 1 % NaClO
for 10 minutes or until the worms were dissolved. The eggs were pelleted by centrifuging at
1300 × g for 40 s and washed with sterile water.
2.2.10 Quantification of Aβ aggregates in CL2006
To see the effect of the treatments on Aβ aggregation, the C. elegans strain CL2006 was
used. These worms constitutively express human Aβ in their muscle cells where the pep-
tides aggregate causing difficulties in movement (Link, 1995). The eggs of CL2006 worms
were isolated, placed in S-medium with E. coli OP50 and kept at 20 °C. The worms were
treated on day 2 after hatching. 100 µg/ml of the methanolic TCM extracts were used,
except for Magnolia officinalis, Rhodiola rosea, and Ginkgo biloba unripe seeds, where
50 µg/ml was used. For the dichloromethane extracts different concentrations were used
depending on the solubility of the extracts: 100 µg/ml for Ginkgo biloba nuts, Berberis
bealei, Panax notoginseng, Phellodendron spp., and Alpinia oxyphylla; 50 µg/ml for Alpinia
galanga, Coptis spp., Epimedium spp., Evodia rutaecarpa, Rosa laevigata, Sanguisorba of-
ficinalis, Ginkgo biloba leaves and unripe seeds; 25 µg/ml for Capsella bursa-pastoris, Cen-
tella asiatica, Glycyrrhiza uralensis, Magnolia officinalis, Paeonia spp., Punica granatum,
Scutellaria baicalensis, Panax ginseng, and Rhodiola rosea; 10 µg/ml for Areca catechu,
Cnidium monnieri, Polygonum multiflorum, Verbena officinalis, and Eleutherococcus sen-
ticosus. As a positive control the worms were treated with 100 µg/ml EGCG, which has
been shown to be effective in this assay (Abbas & Wink, 2010). The negative controls were
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treated with the respective amount of solvent, maximum 1 % as final concentration. Addi-
tionally, the compound thioflavin T (ThT), that has been shown to decrease the number of
Aβ aggregates in C. elegans by Alavez et al. (2011), was tested.
For G. uralensis and the pure compounds GA, glycyrrhizic acid monoammonium (GAA),
GRA, LG, and ILG dose-dependence curves were prepered by testing different concentra-
tions of these substances. The G. uralensis extract was tested in a range from 0 to 500 µg/ml,
the pure compounds from 0 to 100 µg/ml. This experiment was repeated several times at
different time points with the G. uralensis extract.
On day 6 after hatching the worms were collected and fixed in 4 % PFA in 1 × PBS over
night. Then the PFA was removed and the worms were permeabilized in a solution con-
taining 1 % Triton® X-100 and 5 % β-mercaptoethanol in 125 mM Tris-buffer for 24 h at
37 °C. The permeabilization solution was removed by washing with 1 × PBS twice. The per-
meabilized worms were transferred in a well of a 8-chamber microscope slide coated with
poly-L-lysin and air-dried. The Aβ aggregates were stained with 0.0125 % thioflavin S (ThS)
solution in 50 % ethanol for 1 minute, the excess stain was washed away with 50 % ethanol,
2 × 1 minute. The Aβ aggregates were quantified on fluorescence microscope Ni-E (excita-
tion wavelength 480 nm, emission wavelength 525 nm) by counting the aggregates in the
head region of 25 worms per sample.
2.2.11 Paralysis assay in CL4176
The paralysis assay was described by Dostal & Link (2010) as a method for assaying Aβ tox-
icity. For this assay the strains CL4176 and CL802 are used. CL4176 expresses human Aβ
peptide in its muscle cells, similar to CL2006 (section 2.2.10), but the expression is temper-
ature inducible and the paralysis phenotype is more penetrative than in the latter strain.
The temperature sensitivity is accomplished via a mutation in the smg-1 (suppressor with
morphogenetic effect on genitalia) gene and a long 3’ untranslated region on the messenger
ribonucleic acid (mRNA) of the Aβ minigene. SMG-1 is a key component of the non-sense
mediated mRNA decay (NMD) pathway. At 16 °C it functions normally despite the mutation
and the AβmRNA is degraded. At temperatures higher then 20 °C the SMG-1 protein loses
its function and so in this strain Aβ can be expressed. The control strain CL802 has the
temperature sensitive mutation in the smg-1 gene and the roller transfection marker but
no transgenic Aβ.
Eggs from the worms of the strains CL4176 and CL802 were isolated and placed on small
NGM plates containing the test substances and E. coli OP50. In this assay the used con-
centration for the methanol extract of A. catechu and the control EGCG was 100 µg/ml.
The methanol extract of G. uralensis was used in concentrations of 200 and 500 µg/ml, for
the water extract of G. uralensis and methanol extract of A. oxyphylla a concentration of
200 µg/ml was used. For the pure substances GA, GRA, LG, and ILG the concentration
was 50 µg/ml. The dichloromethane extract of C. acaulis, the residual extract without Car-
lina oxide, and Carlina oxide were tested in concentrations of 25 and 50 µg/ml each. As a
negative control the respective amount of methanol or water was used.
The worms were cultivated at 16 °C for 36 h. Then the temperature was risen to 25 °C.
After 24 h the worms on each plate were counted, and paralysed worms were scored under
stereomicroscope every 2 h for 12 h in total. Worms were counted as paralysed when they
failed to react to a touch of platinum wire or only moved their heads creating a halo in the
bacterial lawn.
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2.2.12 Chemotaxis assay in CL2355
CL2355 worms have a similar genotype as CL4176 but with pan-neuronal expression of
the transgene. The Aβ in this strain interferes mostly with behaviours like chemotaxis,
enhanced slowing response or egg laying. In chemotaxis assay these worms fail to respond
to the attractant benzaldehyde. The control strain PD8120 has the temperature sensitive
mutation but no transgene, and therefore it has no behavioural impairments.
CL2355 and PD8120 worms were raised from eggs in S-medium at 16 °C for 36 h. Then the
temperature was risen to 23 °C and kept there for 36 h. 24 h after experiment start the test
substances GA, GRA, LG, and ILG in a concentration of 50 µg/ml, or the methanol extract
of G. uralensis in concentrations of 200 or 500 µg/ml were added to the medium. As positive
control EGCG in a concentration of 100 µg/ml was used, as negative control 1 % methanol
or water. After 72 h in total the worms were washed twice with M9 buffer and placed in
the middle of a 100 mm test plate. The test agar was prepared without NaCl, tryptone, and
cholesterol to avoid undesired chemotactic effects. 1 µl of 1 M sodium azide in water was
added to two spots on opposite sides of the plate. To one side 1 µl of ethanol and to the other
side 1 µl of 0.1 % benzaldehyde in ethanol was added. The plates were incubated at 23 °C
for 1 h. Afterwards the number of worms was counted on both sides in 2 cm radius of the
benzaldehyde and ethanol spots. The chemotaxis index (CI) was calculated with following
formula:
CI = worms on the side of benzaldehyde−worms on the side of ethanol
total number of worms on the plate
2.2.13 Serotonin sensitivity assay in CL2355
C. elegans can take up exogenous serotonin, and it can trigger physiological effects like
the enhanced slowing response. The CL2355 worms are reported to be hypersensitive to
serotonin due to the transgenic Aβ expression in the nervous system (Wu et al., 2006). The
control strain PD8120 shows a wildtype reaction.
CL2355 and PD8120 worms were raised from eggs in S-medium at 16 °C for 36 h. Then
the temperature was risen to 23 °C and kept there for 36 h. 24 h after experiment start
the test substances GA, GRA, LG, and ILG in a concentration of 50 µg/ml, or the methanol
extract of G. uralensis in concentrations of 200 or 500 µg/ml were added to the medium. The
dichloromethane extract of C. acaulis was tested in concentrations of 25, 10, and 5 µg/ml,
the residual extract without Carlina oxide with 25 µg/ml and Carlina oxide with 10 µg/ml.
Additionally, 200 µg/ml ascorbic acid was tested. As positive control EGCG in a concentra-
tion of 100 µg/ml was used, as negative control 1 % methanol or water.
After 36 h at 23 °C the worms were washed twice with M9 buffer to remove all of the
bacteria. They were placed in 1 mM serotonin solution in M9 buffer and the relative number
of active worms was determined after 5 min.
2.2.14 Heat shock protein expression
Small HSPs are molecular chaperones that are expressed under stress conditions. Here
low doses of the pro-oxidant juglone are used to induce oxidative stress. The worm strain
TJ375 with the transgenic construct hsp-16.2::GFP was used to visualize oxidative stress.
Treatment with an antioxidant, that can reduce the oxidative stress induced by juglone,
leads to decreased expression of HSP-16.2 and therefore lower fluorescence in this strain.
Eggs of TJ375 worms were raised in S-medium at 20 °C for 5 days. On day 1 after hatching
the test substances GA, GRA, LG, and ILG in a concentration of 50 µg/ml, the methanol
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extract of G. uralensis in concentrations of 200 or 500 µg/ml, the dichloromethane extract
of C. acaulis, 50, 10, or 5 µg/ml, residual Carlina extract without Carlina oxide or Carlina
oxide, 25, 10, or 5 µg/ml each, were added. As positive controls EGCG (100 µg/ml) and
ascorbic acid in concentrations of 100, 200, and 500 µg/ml were used, as negative controls
1 % methanol or water.
On day 4 after hatching 20 µM juglone in ethanol were added. 24 h after adding juglone
the worms were collected in an Eppendorf tube, the medium was removed, and the worms
were washed with 1 × PBS. After removing the PBS, 20 µl 10 mM sodium azide in PBS was
added to the worms, they were transferred to an object slide and covered with a cover slip.
The worms were observed on flourescence microscope Ni-E at excitation wavelength 480 nm,
emission wavelength 525 nm. Pictures were taken with the DS-Qi1Mc black and white
camera of 25 worms per sample. For the experiments with C. acaulis BZ9000 from Keyence
was used. The fluorescence intensity in the head region was measured using ImageJ.
2.2.15 Survival assay
Eggs of wildtype (N2) worms were cultivated in S-medium at 20 °C. On day 1 after hatching
the test substances GA, GRA, LG, and ILG in a concentration of 50 µg/ml, or the methanol
extract of G. uralensis in concentrations of 200 or 500 µg/ml were added to the medium. As
positive controls EGCG (100 µg/ml) and ascorbic acid (200 µg/ml) were used, as negative
controls 1 % methanol or water. On day 3 after hatching 80 µM juglone was added—a dose
that usually kills the worms. 24 h after that the survivors were counted.
2.2.16 DAF-16 delocalisation
DAF-16 is a transcription factor that triggers the expression of many stress related genes.
The strain TJ356 carries the transgenic construct daf-16::GFP, which makes it possible to
monitor the stress level in C. elegans. Under stress the DAF-16::GFP protein delocalises
from cytoplasm into the nuclei, which then become visible under microscope as fluorescing
dots (Henderson & Johnson, 2001).
Eggs of TJ356 worms were cultivated in S-medium at 20 °C. On day 1 after hatching
the larvae were treated with the test substances for one hour. GA, GRA, LG, and ILG in
a concentration of 50 µg/ml, the methanol extract of G. uralensis in concentrations of 200
or 500 µg/ml, the dichloromethane extract of C. acaulis, residual Carlina extract without
Carlina oxide, and Carlina oxide, 25, 10, and 5 µg/ml each, or EGCG, 100 µg/ml (dissolved
in water or in methanol), were tested. As positive controls 20 µM juglone or a heat shock at
37 °C for 15 min were used, as negative controls 1 % methanol or water. Then the worms
were collected, anesthesized with 10 mM sodium azide and transferred to an object slide.
25 worms per sample were evaluated under fluorescence microscope, excitation wavelength
480 nm, emission wavelength 525 nm. Worms with green fluorescent protein (GFP) in the
cell nuclei were counted as positive, worms with fluorescence spread through the whole body
as negative.
2.2.17 Lifespan assay
In the lifespan assay the effect of methanol extract from G. uralensis and the pure sub-
stances GA, GRA, LG, and ILG on longevity of the worms was tested. The test was carried
out with the wildtype (N2) and the Aβ expressing strain CL2006 to see possible effects re-
lated to Aβ. Eggs were placed in S-medium and cultivated at 20 °C. On day 2 after hatching
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methanolic G. uralensis extract in concentrations of 50, 200, or 500 µg/ml or the pure sub-
stances in a concentration of 50 µg/ml were added to the worms. On day 3 100 worms per
sample were transferred to a new culture dish with fresh S-medium and same treatment
as before. From days 3–10 after hatching the worms were transferred to a new dish every
day to exclude larvae from the experiment. Afterwards the worms were transferred every
second day. While transferring, the number of living and dead animals, that did not move
when touched with a platinum wire, was counted. Worms that had died from bagging or
unnatural causes like wounds taken from the platinum wire were censored.
2.2.18 Statistical analysis
Statistics were carried out using the StatView software. Treatments were compared to
their respective solvent controls in an unpaired Students t-test. Results were considered
significant when p < 0.05 . In case of the dose-dependence curves one-way analysis of vari-
ance (ANOVA) and Fisher’s protected least significant difference (PLSD) test with signif-
icance level p < 0.05 were used. For survival analysis in paralysis and lifespan assays a
life table analysis was performed. The determined median values were compared to the
respective solvent controls using an unpaired Students t-test with p < 0.05 as significance
level. For the determination of relative mean effective concentration (EC50) (Sebaugh, 2011)
values in the DPPH• assay the measured values were normalized, so that the highest gave
100 % effectiveness and the lowest 0 %. Then standard curve analysis in the software
SigmaPlot was used. All experiments, except the lifespan assay, were repeated at least 3
times.
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3 Results
3.1 Screening the TCM extracts against Aβ aggregation
To find plants that can interact with Aβ, a screening of extracts of TCM plants was con-
ducted. 25 probably interesting plants were identified through literature research. Metha-
Figure 3.1: Microscopic fluorescence pictures of C. elegans stained with thioflavin S. A) wildtype
worm; B–K) CL2006 worms treated with 1 % methanol (B), 100 µg/ml EGCG (C), methanol
extract of Areca catechu (D), methanol extract of Alpinia oxyphylla (E), methanol extract of Cni-
dium monnieri (F), methanol extract of Glycyrrhiza uralensis (G), 10 µg/ml dichloromethane ex-
tract of Areca catechu (H), 100 µg/ml dichloromethane extract of Alpinia oxyphylla (I), 10 µg/ml
dichloromethane extract of Cnidium monnieri (J), or 25 µg/ml dichloromethane extract of Gly-
cyrrhiza uralensis (K). The scale bar indicates 50 µm. Pictures were taken with DS-Qi1Mc black
and white camera on a Ni-E fluorescence microscope using FITC filter and 40× magnification.
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3.1. Screening the TCM extracts against Aβ aggregation
nol and dichloromethane extracts of these plants were tested on their ability to inhibit Aβ
aggregation (see section 2.2.10). Aβ aggregates are only seen in the transgenic CL2006
worms but not in the wildtype (Fig. 3.1 A & B). EGCG, that was used as positive control,
decreased the number of Aβ aggregates by 35 % (p < 0.01) (Fig. 3.1 C & Fig. 3.2), which
is comparable to the results of Abbas & Wink (2010). Some methanol extracts like Areca
catechu (32 % decrease, p < 0.01) and Glycyrrhiza uralensis (30 % decrease, p < 0.01) showed
a similar effect. Several other extracts were effective to a lesser extent: Alpinia oxyphylla
with 25 % decrease (p < 0.01), Sanguisorba officinalis with 23 % (p < 0.01), Rosa laevi-
gata 21 % (p < 0.01), Cnidium monnieri 18 % (p = 0.01), Eleutherococcus senticosus 15 %
(p < 0.01), Alpinia galanga 15 % (p = 0.01), Panax notoginseng 13 % (p < 0.01), Coptis spp.
13 % (p = 0.03), phellodendron spp. 12 % (p < 0.01). All tested methanol extracts of Ginkgo
biloba were effective (22 % decrease in the number of Aβ aggregates for nuts, 20 % for un-
ripe seeds, and 13 % for leaves, respectively, p < 0.01), but the special extract EGb761® had
no effect. Thioflavin T decreased the number of plaques by 37 % (p < 0.01). Representative
pictures for some treatments are shown in Figure 3.1 and the results are summarised in
Figure 3.2.
The dichloromethane extracts were poorly soluble in the aqueous culture medium, so that
for some extracts smaller concentrations had to be used (Fig. 3.4). Even so, the extracts of
Areca catechu and Cnidium monnieri had a strong effect decreasing the Aβ aggregates by
32 % and 35 %, respectively (p < 0.01). Polygonum multiflorum (21 % decrease, p = 0.01) and
Eleutherococcus senticosus (15 % decrease, p = 0.04) also showed an effect in the 10 µg/ml
treatment group (Fig. 3.4 A). Among the extracts used in the concentration of 25 µg/ml
(Fig. 3.4 B) only Magnolia officinalis had an significant effect (14 % decrease, p = 0.02).
Raw seeds of Ginkgo biloba could significantly decrease (by 20 %, p < 0.01) the number
of Aβ aggregates at 50 µg/ml (Fig. 3.4 C), whereas Sanguisorba officinalis increased the
number by 14 % (p = 0.04). Panax notoginseng and Alpinia oxyphylla showed an effect at
a concentration of 100 µg/ml (Fig. 3.4 D), decreasing Aβ aggregation by 17 % and 14 %,
respectively (p < 0.01).
Figure 3.3: Effect of DMSO on the Aβ aggregation in CL2006. * p < 0.05;
** p < 0.01 as compared to untreated control.
All values were compared to respective solvent controls. For methanol no dose-dependent
effect was observed but DMSO, that was used to solve the dichloromethane extracts, had
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an effect on the number of Aβ aggregates as shown in Figure 3.3. Concentrations above
0.25 % were significantly different from untreated worms with 18 % decrease in number of
Aβ aggregates for 0.5 % DMSO (p = 0.02) and 24 % for 1 % DMSO (p < 0.01).
Figure 3.4: Effects of the dichloromethane extracts of TCM plants on the Aβ aggregation in CL2006.
A) 10 µg/ml of the TCM extracts solved in DMSO were used; B) 25 µg/ml of the TCM extracts
solved in DMSO were used; C) 50 µg/ml of the TCM extracts solved in DMSO were used; D)
100 µg/ml of the TCM extracts solved in DMSO were used. * p < 0.05; ** p < 0.01 as compared to
respective controls.
60
3.2. Areca catechu
3.2 Areca catechu
3.2.1 Dose-dependence
Dose-dependence of the Aβ aggregation reducing effect in CL2006 was tested for A. catechu
in the concentration range from 0 to 100 µg/ml. The two highest tested concentrations of
75 µg/ml and 100 µg/ml significantly reduced the number of aggregates by 17 % (p = 0.03)
and 32 % (p < 0.01), respectively (Fig. 3.5). Higher concentrations could not be tested,
because they proved to be toxic for the worms.
Figure 3.5:Dose-dependence of the effect of methanol extract from A. catechu
on Aβ aggregation in CL2006. * p < 0.05; ** p < 0.01 as compared to
control.
3.2.2 Paralysis assay
Instead of counteracting Aβ toxicity, the methanol extract of A. catechu proved to be rather
toxic itself in the paralysis assay (see section 2.2.11). 100 µg/ml, that were not problematic
in the Aβ aggregation assay, shortened the mean time of paralysis (PT50) significantly by
1.4 h (p < 0.01) (Fig. 3.6).
3.3 Alpinia oxyphylla
3.3.1 Paralysis assay
The paralysis assay with A. oxyphylla was carried out by Mariam Baalbaki, a pharmacy
student at Heidelberg University, during her laboratory practical at IPMB, Department of
Biology, as described in section 2.2.11. No effect on the Aβ toxicity can be seen for the
methanol extract (Fig. 3.7). Also the positive control, EGCG (solved in methanol), showed
no significant difference compared to the solvent control, although there is a slight tendency
to a delay (0.4 h difference in the PT50 values).
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Figure 3.6: Results of the paralysis assay for methanol extract of A. catechu. ** p < 0.01 as
compared to control.
Figure 3.7: Results of the paralysis assay for methanol extract of A. oxyphylla.
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3.4 Glycyrrhiza uralensis
3.4.1 Identification of the species
In TCM three different species of Glycyrrhiza can be medically used under the drug name
ga¯n ca˘o. Therefore, it had to be determined from which species the material used in this
work, P6873, originated (see section 2.2.6).
The estimated evolutionary divergence (Tab. 3.1) between all three species is quite low.
The highest values are 1.2–1.5 % between the outgroup G. astragalina and the other species.
The ITS sequence is very similar between G. glabra and G. inflata with 0.05 % divergence.
The same value was observed between G. uralensis and the sample P6873, whereas it has
a divergence of 0.4 % to the other two species. The same divergence was observed between
G. uralensis and the other species G. glabra and G. inflata (0.4 and 0.3 %, respectively). This
suggests that the plant material used here comes from Glycyrrhiza uralensis.
The obtained sequence is available in GenBank, number KM588200.
Table 3.1: Estimates of evolutionary divergence over se-
quence pairs between the Glycyrrhiza species calcu-
lated from the ITS sequence data retrieved from NCBI
database and compared to the sample P6873. Data was
calculated by MEGA software using the Maximum Com-
posite Likelihood model.
P6873
G. uralensis 0.0005
G. glabra 0.0044 0.0037
G. inflata 0.0036 0.0032 0.0005
G. astragalina 0.0128 0.0124 0.0147 0.0141
3.4.2 Phytochemical analysis of the extracts
HPLC analysis
The three extracts of G. uralensis were analysed via HPLC (see section 2.2.3) and compared
to the standards GA, GRA, LG, and ILG (Fig. 3.8). The LG standard eluates first with a
RT of 17.1 min and can be best detected at 276 nm. GA follows with the RT 19.1 min and
is detected at 254 nm as is GRA that has the highest RT with 27.5 min. ILG has a RT of
19.5 min and shows a strong absorption at 365 nm. LG and ILG both also absorb at 310 nm
in contrast to the other standards. The wavelenghts 231 and 520 nm did not contribute any
additional information, therefore they are not included in the analysis.
The methanol and water extracts give a similar chromatogram, but the intensity of the
peaks is higher in methanol extract. Both extracts contain peaks that can be assigned to LG,
GA, and ILG based on their RT and absorption behaviour. Only traces of GRA were found
in these extracts. The dichloromethane extract has a completely different chromatogram.
Only trace amounts of the standard substances could be detected in this extract.
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Figure 3.8: HPLC analysis of G. uralensis extracts. A) Standards: 50 µg/ml LG (a), 50 µg/ml GA (b),
25 µg/ml ILG (c) and 50 µg/ml GRA (d); B) water extract, 1 mg/ml; C) methanol extract, 1 mg/ml;
D) dichloromethane extract, 1 mg/ml.
64
3.4. Glycyrrhiza uralensis
Quantification of selected compounds
The content of GA, GRA, LG, and ILG in the G. uralensis extract was quantified via HPLC
using an external standard. The results are summarised in Table 3.2. The highest amounts
of GA, LG, and ILG were found in the methanol extract. All the amounts are quite low, the
highest being 64.2 µg/ml for GA in the methanol extract.
Table 3.2: Quantification of the compounds detected in G. uralensis extracts. LG:
liquiritigenin; ILG: isoliquiritigenin; GA: glycyrrhizic acid; GRA: glycyrrhetinic
acid. Values given in µg/ml.
LG ILG GA GRA
Water extract 3.0 0.9 54.1 0.2
Methanol extract 9.4 1.8 64.2 0.4
Dichlormethane extract 2.9 1.5 4.6 4.1
LC-MS/MS analysis
LC-MS/MS analysis was carried out for water and methanol extracts of G. uralensis (see
section 2.2.4). Figure 3.9 shows the HPLC profiles detected at 254 and 365 nm. In methanol
extract 18 peaks were detected, in water extract 15 of them could be found. Some more
lipophilic substances seem to be missing. Also, the intensity of the detected peaks is lower
in the water extract, suggesting that most of the substances are better soluble in methanol.
The detected peaks were further analysed via MS (Fig. 3.10). The results are summarised
in Table 3.3. Some of the substances could be identified by comparing the MS and MS/MS
spectra with published data (Farag et al., 2012; Montoro et al., 2011).
The first two peaks eluting at 5.4 and 5.8 min, respectively, could be assigned to liquiritin
apioside (Tab. 3.3 1) and liquiritin (Tab. 3.3 2). The MS spectrum for liquiritin apioside
(Fig. 3.11 1) shows a negatively charged molecular ion ([M−H+]–) peak with the m/z = 549, a
peak with m/z = 1099 which corresponds to a dimer, and peaks with m/z = 617 and 662 which
are probably adducts of the [M−H+]– with formic acid and sodium ([M−2H++Na++HCOOH]–,
m/z = 617; [M−2H++Na++HCOOH+•COOH]•–, m/z = 662). Also, a small peak correspond-
ing to a sodium adduct can be detected ([M−2H++Na+]–, m/z = 571). The fragmenta-
tion via MS/MS splits the molecule in liquiritin (m/z = 417) and further in its aglycon
liquiritigenin (m/z = 255). The split off sugars could not be detected. Furthermore the
molecule can be split in the middle, at the unconjugated ring, resulting in the fragments
with m/z = 429 ([M−C7O2H5+]–) and m/z = 297 due to additional loss of the apiose residue
([M−C7O2H4+−C5O4H8]–). For liquiritin (Fig. 3.11 2) also a [M−H+]– peak and a dimer
(m/z = 835) were detected, accompanied by formic acid and sodium adducts ([M−2H++Na+
+HCOOH]–, m/z = 485; [M−3H++2 Na++2 HCOOH]–, m/z = 553). The MS/MS spectrum
shows only one peak for the aglycon liquiritigenin.
The spectra for isoliquiritin apioside (Tab. 3.3 3) and isoliquiritin (Tab. 3.3 4) are simi-
lar to the ones of their isomers, but they can be distinguished by their absorption spectra.
Isoliquiritigenin and its derivatives have a much stronger absorption at 365 nm than liquir-
itigenin derivatives (compare peaks 1 and 2 with 3 and 4 in Fig. 3.9). The MS spectrum for
isoliquiritigenin apioside (Fig. 3.12 3) shows [M−H+]– peak (m/z = 549) and the adducts with
sodium (m/z = 571), formic acid ([M−H++HCOOH]–, m/z = 595) and combinations of both
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Figure 3.9: HPLC chromatograms of the LC-MS/MS runs. A) G. uralensis water extract, 1 mg/ml; B)
G. uralensis methanol extract, 1 mg/ml. The peak numbers correspond to compounds described
in Table 3.3.
(m/z = 662 and 617 as above). The peak with m/z = 662 is much higher for 3 than for 1, prob-
ably because of the exposed double bond that can react with the formic acid radicals. The
fragmentation pattern is the same as for liquiritin apioside, but the fragment with m/z = 429
is much less intense. This is probably due to the different structure at the site of fragmen-
tation. For isoliquiritin the same adducts are observed as for liquiritin. The fragmentation
results in the aglycon and the fragment without apiose as described above ([M−C7O2H5+]–,
m/z = 297). The absorption and fragmentation pattern of these four substances concur with
those published by Farag et al. (2012).
The substances 5–11 seem to have a similar structure. Their retention times lie within
4 min, they have similar masses and fragmentation patterns, and all but number 10 absorb
more light at 254 nm then at 365 nm (Tab. 3.3). Substance number 8 could be identified as
glycyrrhizic acid by comparing its RT and mass to a standard. That suggests, that all sub-
stances in this group are saponins. The MS spectrum of glycyrrhizic acid (Fig. 3.13 8) shows
[M−H+]– peak with m/z = 821, sodium adducts ([M−2H++Na+]–, m/z = 843; [M−3H++2 Na+]–,
m/z = 865), adducts with formic acid ([M−H++2 •COOH]–, m/z = 911), combinations of
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Figure 3.10: Total ion current in MS, ESI negative. A) G. uralensis water extract, 1 mg/ml; B)
G. uralensis methanol extract, 1 mg/ml. The peak numbers correspond to compounds described
in Table 3.3.
both kinds of adducts ([M−2H++Na++•COOH]•–, m/z = 888; [M−2H++Na++2 •COOH]–,
m/z = 933; [M−2H++Na++2 •COOH+HCOOH]–, m/z = 979), and a dimer peak (m/z = 1643).
The MS/MS spectrum is dominated by a fragment with m/z = 351, which corresponds to the
negatively charged ion of the two glucuronic acid molecules (C12O12H15
–), the sugars linked
to the aglycon of glycyrrhizic acid. This fragment can be found in all detected saponins,
suggesting they all have the same sugar moiety. The same fragment was reported in all
detected saponins by Farag et al. (2012). The remaining triterpene fragment is poorly ion-
ized, there is only a very small peak with m/z = 469. The other visible peaks belong to
[M−H+−H2O]– (m/z = 803), [M−H+−H2O−CO2]– (m/z = 759) and the fragment without one
glucuronic acid moiety ([M−C6O6H9+]–, m/z = 645).
Substance 9 has the same molecular mass as glycyrrhizic acid, a very similar RT and
almost identical fragmentation pattern (Tab. 3.3 & Fig. 3.13 9). Based on this data it could
be licorice saponin H2, a stereoisomer of glycyrrhizic acid. The fragments correspond to
those reported by Montoro et al. (2011). The fragment with m/z = 583, that was not present
in the MS/MS spectrum of glycyrrhizic acid, belongs to [M−H2O−CO2−C6O6H9+]–.
Substance number 5 could be identified as licorice saponin A3 by comparison of the data
with Farag et al. (2012) and Montoro et al. (2011) (Tab. 3.3 5). It has a [M−H+]– with
m/z = 983 (Fig. 3.14 5) and adducts with sodium ([M−2H++Na+]–, m/z = 1005; [M−3H++
2 Na+]–, m/z = 1027) and formic acid ([M−2H++Na++HCOOH]–, m/z = 1051; [M−3H++2 Na+
+HCOOH]–, m/z = 1073) can be seen in the MS spectrum as for the other substances. The
MS/MS spectrum shows a base peak with m/z = 821 that corresponds to glycyrrhizic acid
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Table 3.3: Tentative identification of the compounds detected in methanol and water extracts of
G. uralensis via LC-MS/MS and comparison with the data of (a) Farag et al. (2012) and (b) Mon-
toro et al. (2011).
Nr. RT in min λmax [M−H]− MS/MS Tentative identification
1 5.4 198, 214,
277, 310
549 255, 429 liquiritin apioside a
2 5.8 199, 215,
277, 311
417 255 liquiritin a
3 7.4 206, 362 549 255, 417 isoliquiritin apioside a
4 8.0 202, 361 417 255 isoliquiritin a
5 8.9 214 983 821, 803, 351 licorice saponin A3 a,b
6 9.8 199, 215,
276, 311
879 351, 861, 703, 817 22-acetoxyglycyrrhizin
7 10.9 215 837 351, 661, 819, 775 licorice saponin G2 a,b
8 11.8 218, 250 821 351, 803, 645, 759 glycyrrhizic acid a
9 12.4 217 821 351, 803, 645, 759 licorice saponin H2 b
10 13.1 218, 370 821 351, 510, 645, 777 unknown (saponin)
11 13.5 218 823 351, 805, 647 licorice saponin J2 a,b
12 15.5 218, 348 367 298, 337 glycycoumarin
13 16.3 219 353 298, 284 unknown
14 17.3 221, 287 353 297, 285 unknown
15 18.1 221, 347 365 307, 295, 350 glycyrol
16 19.6 221 351 283, 265, 307 gancaonin G or A
17 20.6 219, 292 423 229, 193 unknown
18 21.6 222, 268 421 284 isoanguston A
(loss of the glucose moiety) and the fragments with m/z = 803 and m/z = 351 that were
already discussed for glycyrrhizic acid.
The substance 6 is probably 22-acetoxyglycyrrhizin (Tab. 3.3 6). It has a [M−H+]– with
m/z = 879 (Fig. 3.14 6) that is by 58 units higher than the m/z for glycyrrhizic acid. This mass
difference corresponds to a acetoxy group (CH2COO
–). Other peaks in this spectrum corre-
spond to sodium and formic acid adducts ([M−2H++Na+]–, m/z = 901; [M−3H++2 Na+]–,
m/z = 923; [M−2H++Na++•COOH]•–, m/z = 946; [M−3H++2 Na++HCOOH]–, m/z = 969;
[M−2H++Na++2 •COOH]–, m/z = 991). Also the fragments in MS/MS have masses that
correspond to those of glycyrrhizic acid with a mass difference of 58 (861, 817, 703), except
the glucuronic acid peak at 351. Farag et al. (2012) observed a fragment with m/z = 383
for 22-acetoxyglycyrrhizin, but this cannot be confirmed here. Still the data suggests that
substance 6 is 22-acetoxyglycyrrhizin.
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Figure 3.11: MS (upper part) and MS/MS (lower part) spectra for liquiritigenin derivatives in
G. uralensis extract. The numbers correspond to compounds described in Table 3.3. All spectra
are baseline substracted.
The next substance that could be identified is licorice saponin G2 (Tab. 3.3 7). In com-
parison to glycyrrhizic acid one of its methyl groups is hydroxylated and therefore the
molecular mass rises by 16. In accordance to that, the [M−H+]– seen in the MS spectrum
has a m/z = 837 (Fig. 3.15 7). Again, adducts with sodium ([M−2H++Na+]–, m/z = 859;
[M−3H++2 Na+]–, m/z = 881) and formic acid ([M−3H++2 Na++HCOOH]–, m/z = 927; [M
−4H++3 Na++2 HCOOH]−, m/z = 995) can be observed. The fragmentation pattern is the
same as for glycyrrhizic acid with a sugar ion peak (m/z = 351), [M−H+−H2O]– (m/z = 819),
[M−H+−H2O−CO2]– (m/z = 775), and the fragment without one glucuronic acid moiety
([M−C6O6H9+]–, m/z = 661). Farag et al. (2012) reported a fragment with m/z = 289 that
might belong to [C12O12H15
–−H2O−CO2]–. A small peak with that m/z was detected, too,
as well as the fragment with m/z = 643 (corresponding to [M−C6O6H9+−H2O]–) reported by
Montoro et al. (2011).
The last saponin, substance 11 (Tab. 3.3 11), is licorice saponin J2 which was also observed
by Farag et al. (2012) and Montoro et al. (2011). Its MS spectrum (Fig. 3.15 11) shows
a [M−H+]– peak with m/z = 823, sodium ([M−2H++Na+]–, m/z = 845; [M−3H++2 Na+]–,
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Figure 3.12: MS (upper part) and MS/MS (lower part) spectra for isoliquiritigenin derivatives in
G. uralensis extract. The numbers correspond to compounds described in Table 3.3. All spectra
are baseline substracted.
m/z = 867) and formic acid adducts ([M−H++HCOOH]–, m/z = 868; [M−2H++2 •COOH]–,
m/z = 913), and combination of both ([M−3H++2 Na+ +2 •COOH]–, m/z = 957). The frag-
ments in the MS/MS spectrum have a by 2 units higher m/z (805, 761, 647) than the respec-
tive fragments for glycyrrhizic acid due to the differences in the triterpene structure. The
peak at 351 remains same.
Substance 10 is probably a saponin, too, but it could not be identified with the given data
(Tab. 3.3 10). It has a [M−H+]– with m/z = 821 (Fig. 3.15 10), the same as for glycyrrhizic
acid. Also the fragments in MS/MS have corresponding masses. A peak with m/z = 645
was observed for glycyrrhizic acid, 777 is the mass of decarboxylated glycyrrhizic acid
([M−H+−CO2]–) and was also observed for other saponins, although in very small amounts.
Likewise, the glucuronic acid peak at 351 is present for the unknown substance, suggesting
that the difference lies in the triterpene structure and not in the sugar moiety. The fragment
with m/z = 510 is new, it cannot be explained without having further structural information.
The absorption is different for this substance as well compared to other saponins. It has a
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Figure 3.13: MS (upper part) and MS/MS (lower part) spectra for glycyrrhizic acid and licorice
saponin H2. The numbers correspond to compounds described in Table 3.3. All spectra are
baseline substracted.
strong absorption at 356 nm, pointing to a conjugated pi-electron system.
Substance 12, with the RT 15.5 min, probably belongs to glycycoumarin (Tab. 3.3 12). Its
mass and absorption match earlier data (Farag et al., 2012), although the fragmentation
pattern is different. Still, the fragments observed can be explained using the molecular
structure of glycycoumarin. The MS spectrum (Fig. 3.16 12) shows the [M−H+]– peak with
m/z = 367, an adduct with formic acid and sodium ([M−2H++Na++HCOOH]–, m/z = 435),
and a possible dimer (m/z = 734). The fragments arise from loss of the methoxy group
([M−H+−•OCH3+H•]–, m/z = 337) or, to a lesser extent, only the methyl group ([M−H+−
•CH3]
•–, m/z = 352), loss of carbon dioxide from the lactone group ([M−H+−CO2]–, m/z = 323),
and loss of the isoprenyl group ([M−H+−•C5H9]•–, m/z = 298).
Substances 13 and 14 both have a [M−H+]– with m/z = 353 and similar absorption (Tab. 3.3
13 & 14). The MS/MS fragments are similar but not identical (Fig. 3.17 13 & 14). Both have
71
3. Results
Figure 3.14: MS (upper part) and MS/MS (lower part) spectra for licorice saponin A3 and 22-
acetoxyglycyrrhizin. The numbers correspond to compounds described in Table 3.3. All spectra
are baseline substracted.
a small peak with m/z = 338 indicating the loss of a methyl group ([M−H+−•CH3]•–). A
slightly higher peak appears with m/z = 298 for substance 13 and 297 for substance 14,
followed by m/z = 284 or 285, respectively. The masses 284 and 285 could indicate the loss
of a isoprenyl group ([M−H+−•C5H9]•– or [M−C5H9+]–, respectively). The masses 298 and
297 could arise from a partitial loss of this group ([M−H+−•C4H7]•– and [M−2H+−C4H7–]–,
respectively). There are several substances with the corresponding molecular mass of 354,
such as licochalcon D and G, licoflavonol, gancaonin I, dehydroglyasperin C, or glycybenzo-
furan. All of them have a isoprenyl group and all but licoflavonol have methoxy groups that
might lose the methyl group. The first three substances all have the same conjugated pi-
electron system and absorb light at 365 nm, therefore these are probably not identical with
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Figure 3.15: MS (upper part) and MS/MS (lower part) spectra for other saponins in G. uralensis
extract. The numbers correspond to compounds described in Table 3.3. All spectra are baseline
substracted.
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Figure 3.16: MS (upper part) and MS/MS (lower part) spectra for coumarins and an unknown
substance in G. uralensis extract. The numbers correspond to compounds described in Ta-
ble 3.3. All spectra are baseline substracted.
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Figure 3.17: MS (upper part) and MS/MS (lower part) spectra for unknown substances
in G. uralensis extract and some molecules with matching mass. The numbers corre-
spond to compounds described in Table 3.3. All spectra are baseline substracted.
molecules detected here. Substances 13 and 14 could be gancaonin I, dehydroglyasperin C,
glycybenzofuran, or similar prenylated methoxybenzofurans /-pyrans.
Substance 15 is probably glycyrol. The MS spectrum shows a [M−H+]– peak with m/z = 365
(Fig. 3.16 & Tab. 3.3 15), which is fragmented into ions with m/z = 350 (loss of methyl group,
[M−H+−•CH3]•–), 307 (additional loss of carbon dioxide, [M−CH3+− CO2]–), 295 (loss of a
methyl and part of a isoprenyl group, [M−H+−•CH3−•C4H7]–) and 282 (loss of a methyl
and a isoprenyl group, [M−CH3+−•C5H9]•–). Glycyrol has a isoprenyl sidechain, a methoxy
group able to split off the methyl group, and a lactone ring that can give rise to the carbon
dioxide. Also, the observed absorption is consistent with the conjugated pi-electron system of
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Figure 3.18: MS (upper part) and MS/MS (lower part) spectra for gancaonin and isoanguston
A. The numbers correspond to compounds described in Table 3.3. All spectra are baseline
substracted.
glycyrol. Montoro et al. (2011) reported this compound in G. glabra, although unfortunately
no MS/MS data have been published.
Substance number 16 has a [M−H+]– with m/z = 351 (Fig. 3.18 16), corresponding to
a substance with a molecular mass of 352 like gancaonin A or G. The MS/MS fragments
suggest a isoprenyl chain ([M−C5H9+]–, m/z = 283) and a methyl group ([M−H+−•CH3]•–,
m/z = 336) that are present in both gancaonin isomers. The m/z = 265 suggest a loss of
water, additionally to the loss of an isoprenyl group ([M−C5H9+−H2O]–). The fragment with
m/z = 307 could result from loss of three methyl groups: one of the methoxy group, the other
two from the isoprenyl group, made possible by a ring formation between this group and the
adjacent hydroxy group ([M−C3H9+]–). In case of gancaonin G there would be the oxygen
radical of the methoxy group instead of a hydroxy group. That might facilitate the ring
formation, making gancaonin G the more probable candidate for the identity of substance
16, but there is no definite proof for either of the isomers.
The substance 17 could not be identified. It has a [M−H+]– with m/z = 423 and the spec-
trum shows also a dimer with m/z = 847 (Fig. 3.16 17). This molecule is fragmented into
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two parts with m/z = 193 and 229. Farag et al. (2012) reported a substance with m/z = 423
that was identified as kanzonol H, but the reported MS/MS fragments do not match with
substance 17.
Substance 18 has a [M−H+]– with m/z = 421 and a dimer with m/z = 843 (Fig. 3.18 18).
A compound with m/z = 421 was reported by Farag et al. (2012) but could not be identified.
The molecular mass and absorption of this compound (Tab. 3.3 18) match isoanguston A
(Lee et al., 2010b). The fragment with m/z = 284 could result from loss of the two isoprenyl
groups ([M−•C5H9−C5H9+]•–).
3.4.3 Dose-dependence
Methanolic extract of G. uralensis showed an effect in the initial screening on CL2006
worms. The dose-dependence of this effect was tested as described in section 2.2.10. In
the first test, that was conducted in May 2011, all treatments with concentrations above
50 µg/ml were significantly different from control (p < 0.01 for higher concentrations), but
for some reason the effect of 500 µg/ml extract was lower than for 400 µg/ml (40 % decrease
in number of Aβ aggregates vs. 53 % decrease, see Figure 3.19 A). In this experiment the
methanol concentration was not constant but increased with rising extract concentration.
Figure 3.19: Dose-dependence of the effect of methanolic G. uralensis extract on Aβ aggregation
in CL2006 measured at different time points. A) Dose-dependence as % of control; B) Number
of Aβ aggregates in control and 100 µg/ml treatment in the different experiments. * p < 0.05;
** p < 0.01 as compared to solvent controls.
To test the possibility that high methanol concentrations may be responsible for the drop
of effectiveness for high concentrations, the experiment was repeated in September 2011
with constant methanol concentration. Surprisingly the initial effect of 100 µg/ml extract
could not be reproduced. In fact, none of the treatments had a significant effect. At the
same time it was observed that the total number of Aβ aggregates in the control worms had
increased from 6 to 10 in average (Figure 3.19 B).
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Due to the different results gained in the previous experiments, the test was repeated
again in August 2012. This time only 400 µg/ml and 500 µg/ml extract treatments had
significant effects (16 %, p = 0.01 and 24 % decrease, p < 0.01, respectively). None of the
treatments reached the effect observed for 100 µg/ml treatment in the initial screening. The
total number of plaques was on the same level as a year ago.
In 2013 and 2014 more tests with the CL2006 strain were done to investigate the cause of
the differences. New CL2006 worms were ordered from CGC together with new E. coli
OP50. Fresh S-medium was prepared for these experiments. Even the incubator was
changed. None of this changed the result that even the positive control EGCG was not
effective any more. The number of plaques continued to rise up to 30 in untreated worms.
This number is normal for CL2006 under standard conditions, but can be reduced at lower
temperatures (Dr. Christopher D. Link, P. I. at University of Colorado, Boulder, Institute
for Behavioural Genetics, personal communication). Since the rapid increase in the number
of plaques coincided with the breakdown of our old incubator and bringing into service of a
new one in May 2011, it is possible that the low numbers of plaques in earlier experiments
resulted from a malfunction of temperature control in the old incubator.
Figure 3.20: Dose-dependence of the effect of pure compounds from G. uralensis on Aβ aggregation
in CL2006. * p < 0.05; ** p < 0.01 as compared to solvent controls.
The dose-dependence was also measured for pure compounds contained in G. uralensis
extracts: GA, its aglycon GRA and the salt GAA, LG, and ILG (Fig. 3.20). The diammonium
salt of glycyrrhizic acid showed no effect. GA had a significant effect only for the highest
tested concentration of 100 µg/ml with 14 % decrease in number of Aβ aggregates (p = 0.04).
GRA was active at 50 and 100 µg/ml with 18 % and 22 % decrease (p < 0.01), GAA had a
significant effect already for 10 µg/ml (12 % decrease, p = 0.01), followed by 16 % and 17 %
decrease for the following concentrations (p < 0.01), but the treatment with 100 µg/ml had
no significant difference to control. The strongest effect was observed for ILG by 50 µg/ml
treatment that decreased the number of Aβ aggregates by 26 % (p < 0.01), but 100 µg/ml of
this substance had a somewhat lesser effect (19 % decrease, p < 0.01). LG had its strongest
effect at 100 µg/ml with 23 % decrease and 15 % decrease at 50 µg/ml (p < 0.01). The treat-
ment with 50 µg/ml was effective for most of the substances, therefore this concentration
was used in following experiments.
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3.4.4 Western blot analysis
The Western blot method was validated using pure Aβ1–42 peptide as positive control (see
section 2.2.8). It could be detected with both the Coomassie staining of the gel and with
antibodies against Aβ (Fig. 3.21). Monomeric Aβ has a molecular weight of 4.5 kDa, so
its band should appear near the last marker band. The band detected here appears slightly
higher, so it could correspond to dimers. It has been shown that Aβ forms dimers and higher
order oligomers in presence of SDS (Bitan et al., 2005; Watt et al., 2013), in which case it
would be an artefact of the method. The two bands with higher molecular weight indicate
the presence of tri- and tetramers that might have formed due to interactions with SDS or
before the SDS-PAGE, since Aβ oligomerises rapidly in solution.
Figure 3.21: Validation of the Western blot analysis
with pure Aβ. A) Detection with Aβ antibodies; B)
Coomassie staining.
This positive control showed that the method is valid and can easily detect micromolar
concentrations of Aβ. However, in the homogenates of C. elegans no Aβ could be detected.
The control detection of actin was reproducibly positive. One possible explanation would
be, that in the worms there is not enough monomeric Aβ or low weight oligomers that
could be detected with this method. However, no bands were seen even when pure peptide
was mixed in the homogenate to make sure that there was enough protein to detect. This
indicates that something in the samples prevents the antibody from binding. Attempts to
purify the sample with different methods failed. Removing the lipids from the samples with
the purification method described by Wessel & Flügge (1984) restored the signal for Aβ
added to the sample after purification, but failed to do so for samples with Aβ added prior
to purification. This suggests, that Aβ in the samples interacts with lipids and is removed
with them during the purification.
3.4.5 Paralysis assay
The ability of G. uralensis extracts and pure compounds to ameliorate Aβ toxicity was eval-
uated in a paralysis assay using the strains CL4176 and CL802 (see section 2.2.11). The
control strain CL802 did not show paralysis for any treatments. The results with CL4176
are summarised in Figure 3.22.
Both the water extract and the methanol extract of G. uralensis could significantly prolong
the PT50. The effect for the methanol extract was dose-dependent, 200 µg/ml increased PT50
by 0.8 h, 500 µg/ml by 1.8 h (p < 0.01). The water extract (200 µg/ml) had a similar effect
increasing the PT50 by 1.8 h (p = 0.02), but the control EGCG had the highest effect with
2.7 h increase in PT50 (p = 0.03). From the pure substances only ILG had a significant effect
with 1.2 h increase in PT50 (p < 0.01). Notably, both controls treated either with water or
with 1 % methanol had 2.7 h difference in their PT50 values.
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3.4.6 Chemotaxis assay
The strain CL2355 has defective chemotaxis due to Aβ expression in nervous system. In
this assay the ability of G. uralensis to restore the normal behaviour was studied (see sec-
tion 2.2.12). Unfortunately the treatments had little effect (Fig. 3.23). Only GRA could sig-
nificantly increase the CI towards benzaldehyde by 0.1 (p = 0.05). Some other treatments
also seem to increase the CI, but due to the high standard error these values are not sig-
nificantly different from control. Some treatments also decrease the CI of the control strain
PD8120, pointing to unspecific effects on chemotaxis behaviour. This effect is significant for
EGCG solved in water (0.17 decrease, p = 0.02). The solvent methanol changes the CI in
both strains. Results for 200 µg/ml G. uralensis, ILG, and EGCG solved in methanol are not
significantly different between the Aβ expressing worms and the control strain, probably
due to the high standard error.
Figure 3.23: Results of the chemotaxis assay for G. uralensis and pure compounds.
50 µg/ml of the pure compounds solved in methanol were used and 100 µg/ml EGCG
as positive control, the negative control was treated with water or 1 % methanol.
* p < 0.05 as compared to the respective solvent control.
3.4.7 Serotonin sensitivity assay
Exogenous serotonin triggers the enhanced slowing response in normal C. elegans worms
(see section 2.2.13). Although CL2355 worms are reported to be hypersensitive to sero-
tonin (Wu et al., 2006), no difference in behaviour compared to the control strain PD8120
was observed in the present work when the worms were treated with water or substances
solved in water (Fig. 3.24 B). In presence of 1 % methanol the worms showed hyposensitivity
(Fig. 3.24 A). The number of active CL2355 worms was significantly reduced after a treat-
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Figure 3.24: Results of the serotonin sensitivity assay on Aβ expressing CL2355 worms and the
control strain PD8120. A) The used concentrations for the pure compounds were 100 µg/ml for
EGCG and 50 µg/ml for other substances; B) 200 µg/ml ascorbic acid and 100 µg/ml EGCG were
used. * p < 0.05; ** p < 0.01 as compared to controls.
Figure 3.25: Heat shock protein expression levels after treatment with A) water, the scale bar cor-
responds to 20 µm; B) 100 µg/ml ascorbic acid; C) 200 µg/ml ascorbic acid; D) 500 µg/ml ascorbic
acid; E) quantification of the fluorescence intensity. * p < 0.05; ** p < 0.01 as compared to control.
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ment of 100 µg/ml EGCG (15 % decrease, p < 0.01), 50 µg/ml GA (8 % decrease, p < 0.01),
GRA (11 % decrease, p < 0.01), LG (6 % decrease, p = 0.03), and ILG (8 % decrease, p < 0.01)
solved in methanol. Treatments with GA and GRA also significantly decreased the activity
of the control strain PD8120 (12 %, p = 0.04 and 16 %, p = 0.02, respectively). The rela-
tive number of active worms between both worm strains was significantly different for all
treatments except for 50 µg/ml LG and the substances solved in water.
3.4.8 Antioxidant properties
Heat shock protein expression
Figure 3.26: Heat shock protein expression levels after treatment with A) 1 % methanol, the scale
bar corresponds to 20 µm; B) 100 µg/ml EGCG; C) 200 µg/ml methanolic G. uralensis extract; D)
500 µg/ml methanolic G. uralensis extract; E) 50 µg/ml of GA; F) 50 µg/ml of GRA; G) 50 µg/ml of
LG; H) 50 µg/ml of ILG; I) quantification of the fluorescence intensity. * p < 0.05; ** p < 0.01 as
compared to control.
The expression of hsp-16.2::GFP construct in TJ375 worms was triggered by the pro-
oxidant juglone, a naphtochinone from Juglans regia. The antioxidant activity of the com-
pounds was assessed as the reduction of fluorescence intensity compared to a solvent con-
trol (see section 2.2.14). The well known antioxidant ascorbic acid showed a strong dose-
dependent decrease of the fluorescence intensity (Fig. 3.25) with no effect for 100 µg/ml
treatment, 45 % reduction for 200 µg/ml and 55 % for 500 µg/ml (p < 0.01 for both). The
positive control EGCG had the strongest effect among the other compounds, lowering the
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mean fluorescence intensity by 50 %, p < 0.01 (Fig. 3.26). ILG decreased the fluorescence
intensity by 26 % (p < 0.01), the treatments with 500 µg/ml G. uralensis extract, GA, and
LG had smaller effects (14 %, p = 0.04, 15 %, p = 0.03, and 23 %, p = 0.01, respectively).
Survival assay
Survival assay measures the antioxidant activity by determining the increase in survival
rate under lethal oxidative stress (see section 2.2.15). The effects are summarised in Fig-
ure 3.27. Both controls ascorbic acid and EGCG increased the number of living worms
markedly (by 72 % for ascorbic acid, by 67 % for EGCG solved in water, and by 74 % for
EGCG solved in methanol, p < 0.01 for all). The G. uralensis extract could not protect the
worms from oxidative stress, but the pure compound ILG had an even stronger effect than
the controls, increasing the survival by 82 % (p < 0.01). Its isomer LG had compared to that
only a small effect (19 % increase, p = 0.03).
Figure 3.27: Survival under lethal oxidative stress after treatment with G. uralensis and pure
compounds. A) 50 µg/ml of the pure compounds solved in methanol were used, 100 µg/ml
EGCG as positive control, as negative control 1 % methanol was used; B) control treat-
ments with 200 µg/ml ascorbic acid and 100 µg/ml EGCG solved in water. * p < 0.05;
** p < 0.01 as compared to controls.
3.4.9 DAF-16 delocalisation
Delocalisation of the transcription factor DAF-16 into the nucleus is necessary to start the
expression of several stress resistance genes (see section 2.2.16). Under normal conditions
the fluorescence in daf-16::GFP worms is spread throughout the body (Fig. 3.28 A), under
oxidative or heat stress the fluorescence concentrates in the cell nuclei (Fig. 3.28 B, C). A
treatment with methanol delocated some of the protein into the nucleus, but around 50 %
of the treated worms were still negative. Because of this solvent effect only samples with
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Figure 3.28: Representative pictures of TJ356 worms in DAF-16 delocalisation assay. Worms
treated with A) water; B) 20 µM juglone; C) 15 min at 37 °C; D) 1 % methanol; E) 200 µg/ml
methanol G. uralensis extract; F) 500 µg/ml methanol G. uralensis extract; G) 50 µg/ml gly-
cyrrhizic acid; H) 50 µg/ml glycyrrhetinic acid; I) 50 µg/ml liquiritigenin; J) 50 µg/ml isoliquirit-
igenin; K) 100 µg/ml EGCG solved in methanol; L) 100 µg/ml EGCG solved in water. The scale
bars indicate 100 µm. Pictures were taken with BZ9000 from Keyence.
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> 70 % worms with nuclear DAF-16 were considered significantly positive. The treatment
with GA showed no increase in the nuclear localisation compared with the methanol treat-
ment. Treatments with G. uralensis extract, GRA, and LG showed a small increase that
did not reach the significance level of 70 %. Also EGCG, that has been reported to be ac-
tive in this assay before (Abbas & Wink, 2010), showed no significant effect in the current
experiment. However, the EGCG solved in water had a stronger effect (15 % more posi-
tives than water control) than the substance solved in methanol (no difference to methanol
treatment). The only significantly active substance from the ones tested here was ILG that
delocated DAF-16 in about 85 % of the worms.
3.4.10 Lifespan assay
The ability of G. uralensis extracts and the pure substances found in this extract to extend
the lifespan of C. elegans was tested in this assay (see section 2.2.17). The results shown
in Figures 3.30 and 3.29 indicate, that neither the extract nor the pure substances had a
positive effect on the lifespan. The extract rather shortened the half-time of life by 9.6, 5.4,
and 1.9 days in the wildtype worms (N2) and by 7.9, 2.9, and 3.1 days in CL2006 for 500,
200, and 50 µg/ml, respectively. This effect was dose-dependent as can be clearly seen on the
survival curves and half-time values for the wildtype worms. The effect was less pronounced
for the Aβ expressing strain CL2006. From the pure substances GA had no effect, whereas
ILG shortened the half-time by 7.3 and 5.8 days in N2 and CL2006, respectively. LG had
a stronger toxic effect in CL2006 (3.5 days decrease in half-time) than in the wildtype (2.7
days), GRA had almost no effect in CL2006, but was more toxic than LG in the wildtype (3.5
days decrease in half-time).
Figure 3.29: Half-times of the lifespan assay. 50 µg/ml of the pure compounds solved
in methanol were used, 1 % methanol was used as control.
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3.5 Carlina acaulis
3.5.1 GLC-MS analysis of the extract
This analysis was carried out by Frank Sporer, a scientific assistant at Heidelberg Univer-
sity, IPMB, Department of Biology (see section 2.2.5).
Figure 3.31: GLC-MS total ion current of dichloromethane extract of C. acaulis and corresponding
MS spectra.
The extract contains mainly Carlina oxide and small amounts of benzaldehyde and ar-
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curcumene (Fig. 3.31) that have been reported as constituents of C. acaulis volatile oil before
(Chalchat et al., 1996; Stojanovic´-Radic´ et al., 2012). These compounds could be identified
by comparison of their MS-spectra to published data (Ðord¯evic´ et al., 2005; Qin et al., 2007)
and the Chemical Abstract Service database. The MS data for the other peaks in the chro-
matogram do not match any previously reported substance from C. acaulis and could not be
identified.
Figure 3.32 shows the chromatograms for isolated Carlina oxide fraction isolated from
the dichlormethane extract of Carlina acaulis (CarOx) and the residual extract of Carlina
acaulis after isolation of Carlina oxide (Car0). CarOx (Fig. 3.32 A) contains most of the
recovered Carlina oxide ( 99 % of total recovered substance calculated by peak area) but
also curcumene and some of the unidentified substances. Carlina oxide comprises 51 % of
all substances in this fraction. Car0 (Fig. 3.32 B) contains only 1.5 % Carlina oxide relative
to CarOx, and most of the other substances from the extract. Due to the low concentration
of Carlina oxide, it can be considered free of this substance.
Figure 3.32: GLC-MS total ion current of isolated Carlina oxide fraction (A) and residual extract
(B). Scale relative to Carlina oxide in A.
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3.5.2 Paralysis assay
Figure 3.33: Results of the paralysis assay for C. acaulis extract (Carlina), the extract without
Carlina oxide (Car0) and Carlina oxide (CarOx) in the concentrations of 25 µg/ml (A) and 50 µg/ml
(B). C) PT50 values for all treatments. * p < 0.05 as compared to control.
The paralysis assay was first conducted with 25 µg/ml of C. acaulis extract, Car0 and
CarOx (see section 2.2.11). No significant differences were observed (Fig. 3.33 A). The ex-
tract was most effective with a PT50 value of 36.7 h compared to 36 h in a control treated
with 0.5 % methanol (p = 0.05). Therefore a higher concentration of 50 µg/ml for all treat-
ments was tested (Fig. 3.33 B). Here the extract could increase the PT50 from 35 h (control
treated with 1 % methanol) to 36.6 h (p = 0.04). CarOx (PT50 = 36 h) had a slightly stronger
effect than Car0 (PT50 = 35.5 h), but both were not significant compared to control. Inter-
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estingly, the control treatments with 0.5 and 1 % methanol were also significantly different
(p < 0.01), differing by 1 h.
3.5.3 Chemotaxis assay
The chemotaxis assay (see section 2.2.12) produced no evaluable results. The extract and
especially CarOx seem to be toxic for the worms. Since the CL2355 strain is more sensitive
than other worms, there were mostly not enough individuals to evaluate. The observed
worms showed no increased chemotaxis.
3.5.4 Serotonin sensitivity assay
The serotonin sensitivity assay (see section 2.2.13) showed a significant difference to the
solvent control only for 10 µg/ml C. acaulis extract (p = 0.03) (Fig. 3.34). No dose-dependent
effect was observed. In case of 10 µg/ml CarOx there was a significant difference to methanol
treatment in the control strain PD8120 (p = 0.02), suggesting an action mechanism inde-
pendent of Aβ expression.
Figure 3.34: Results of the serotonin sensitivity assay for C. acaulis on Aβ expressing
CL2355 worms and the control strain PD8120. The used concentration for Carlina
oxide was 10 µg/ml and for the residual extract 25 µg/ml. * p < 0.05 as compared to
control.
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3.5.5 Antioxidant properties
The antioxidant properties of C. acaulis were studied by Kevin Roth, a Master of Science
student of Molecular Biotechnology at Heidelberg University, during his laboratory practical
at IPMB, Department of Biology.
DPPH• scavenging
The in vitro antioxidant activity was tested via DPPH• scavenging assay (see section 2.2.7).
The results showed a typical sigmoidal curve, although only the highest tested concentration
reached the upper plateau (Fig. 3.35). Relative EC50 in this assay was 122 µg/ml.
Figure 3.35: DPPH• scavenging activity of C. acaulis
Heat shock protein expression
The antioxidant activity in vivo was tested in C. elegans as effect on the HSP expression (see
section 2.2.14). EGCG and ascorbic acid were used as positive controls and both showed a
significant decrease in fluorescence intensity, that corresponds to HSP expression levels
(Fig. 3.36 E and F, respectively). The extract of C. acaulis showed an dose-dependent effect,
where only the highest tested concentration (50 µg/ml) resulted in a significant decrease by
47 % (Fig. 3.36 B, p < 0.01). This value is similar to the effect of 200 µg/ml ascorbic acid
(41 % decrease, p < 0.01). Car0 showed no effect for all tested concentrations (Fig. 3.36
C), whereas a strong dose-dependent effect was observed for CarOx. The highest tested
concentration, 25 µg/ml, reduced the fluorescence intensity significantly by 64 % (Fig. 3.36
D, p < 0.01). This value is only slightly smaller than the strongest effect, observed for the
control 100 µg/ml EGCG: 75 % decrease in the fluorescence intensity (p < 0.01).
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Figure 3.36: Heat shock protein expression levels after treatment with A) 0.5 % methanol; B)
50 µg/ml C. acaulis extract (Carlina); C) 25 µg/ml C. acaulis extract without Carlina oxide
(Car0); D) 25 µg/ml Carlina oxide (CarOx); E) 100 µg/ml EGCG; F) 200 µg/ml ascorbic
acid; G) quantification of the fluorescence intensity. The scale bar corresponds to 100 µm.
Pictures were taken with BZ9000 from Keyence. ** p < 0.01 as compared to control.
3.5.6 DAF-16 delocalisation
The data for this experiment was gathered by Kevin Roth, a Master of Science student
of Molecular Biotechnology at Heidelberg University, during his laboratory practical at
IPMB, Department of Biology, as described in section 2.2.16. DAF-16 delocalisation into
the nuclei was observed after the treatment with C. acaulis extract and with CarOx but
not for Car0 (Fig. 3.37). The effect was dose-dependent for both treatments and stronger
for CarOx, where already 5 µg/ml caused significant DAF-16 delocalisation (63 % of the
worms positive, p < 0.01; 69 % and 85 % positives for 10 and 25 µg/ml, respectively). The
extract showed a significant activation of the DAF-pathway for the concentrations of 10 and
25 µg/ml (60 % (p = 0.05) and 77 % (p < 0.01) positives, respectively). The positive controls
juglone and a heat shock at 37 °C also activated the pathway (84 and 100 % positives, re-
spectively, p < 0.01), the untreated worms showed significantly less DAF-16 delocalisation
(7 %, p < 0.01) than the control treated with methanol (48 % positives).
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Figure 3.37: DAF-16 localisation in an untreated worm (A) and after treatment with 25 µg/ml
C. acaulis extract (B), 25 µg/ml extract without Carlina oxide (C) or 25 µg/ml Carlina oxide
(D). The scale bars indicate 100 µm, the pictures were taken with BZ9000 from Keyence; E)
quantification and dose-dependence of the treatments in this assay. * p < 0.05; ** p < 0.01 as
compared to control.
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4.1 Screening of TCM drug extracts
For this screen 25 plants were chosen based on earlier reports of neuroprotective activity. As
a control EGCG was used because of its proven activity in the used C. elegans model (Abbas
& Wink, 2010) and known mechanism of action (Bieschke et al., 2010; Ehrnhoefer et al.,
2008; Hyung et al., 2013). In the study by Abbas & Wink (2010) 220 µM EGCG lowered
the number of Aβ aggregates by 33 %, which is in good accordance to the 35 % decrease for
100 µg/ml (≈ 220 µM) EGCG observed in the present study (Fig. 3.2). Thioflavin T showed
an even stronger effect than EGCG in the present study. This substance was reported to
decrease amyloid pathology in C. elegans strain CL4176 (Alavez et al., 2011). These worms
develop only a few small plaques before they paralyse, which makes it difficult to image
them, and therefore this strain is usually not used for quantification of Aβ aggregates. Due
to the different methods these results are not directly comparable to the present work, but
in both cases thioflavin T treatment led to decrease in the number of Aβ aggregates.
Of the 55 tested extracts 12 methanol and 9 dichloromethane extracts showed significant
activities. The effects of methanol extracts reached a maximum effect of 32 % decrease in Aβ
deposits for A. catechu. Two other methanol extracts reduced the number of Aβ aggregates
by at least 25 %, namely G. uralensis (30 %) and A. oxyphylla (25 %). These three extracts
were pursued further and are discussed in the following sections. The effect of other extracts
was smaller but still noteworthy. S. officinalis and R. laevigata have not had much atten-
tion in relation to AD, but both of them decreased Aβ deposition in the C. elegans model.
Gallic acid from S. officinalis has shown neuroprotective effects against Aβ toxicity (Ban
et al., 2008). Although the substances underlying the effect on Aβ aggregation were not fur-
ther elucidated, the dichloromethane extract of this plant was not effective, suggesting that
the active compounds are rather hydrophilic like gallic acid. In case of R. laevigata the one
compound reported to be neuroprotective (1,2-benzenedicarboxylic acid dinonyl ester; Choi
et al., 2009) is more lipophilic and would be expected to be contained in dichloromethane ex-
tracts. The methanol extract was more effective though, indicating other active substances
in this plant. This result is in accordance with the study of Choi et al. (2006), who showed
protective effects against Aβ toxicity for the methanol extract of R. laevigata in cell culture
and mice.
Four of the seven extracts tested for G. biloba were significantly effective. The seed ex-
tracts were more effective than leaves with 22 % decrease in the number of Aβ aggregates
for the methanol extract of the TCM drug and 20 % for both extracts of raw seeds, although
only half the concentration was used for the dichloromethane extract. This indicates that
there are several active ingredients. Some of them are rather lipophilic and are lost either
when the seeds ripen, when the sacrotesta is removed, or when the nuts are baked to pre-
pare bái guo˘. Other compounds remain in the nuts or are produced during the preparation
of bái guo˘. To our knowledge there are to date no studies of the effects of G. biloba seeds
or bái guo˘ on AD published in international journals. The results presented here, however,
suggest that the seeds, either raw or prepared, are possibly more potent than the leaves and
deserve further study.
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The methanol extract of G. biloba leaves showed moderate activity, decreasing the num-
ber of Aβ aggregates by 13 %. The dichloromethane extract as well as the special extract
EGb761 had no significant effect. The result for EGb761 was unexpected, since many stud-
ies have shown its effectiveness in different models (see Tab. 1.1). Two studies have also
used the C. elegans model CL2006. Smith & Luo (2003) examined the ROS content in this
model and found that single compounds found in EGb761 can lower the ROS concentration,
but the results for the extract itself were not significant. Wu et al. (2006) performed the
same Aβ aggregation assay, that was also used in the present work, although with some
modifications in treatment protocol and data analysis. The treatment was started at day 4
in contrast to day 2 in the present study, the worms were evaluated on day 6 in both studies.
Therefore it is possible that EGb761 has some immediate effects that can be seen after two
days, but have vanished after four days. To check this possibility, the experiment should be
repeated with different treatment times to compare the effects. Due to limited availability
of EGb761 this was omitted in the present study.
Two of the most studied plants besides G. biloba in context of cognitive enhancement
are P. ginseng and P. notoginseng. While P. ginseng had no effect on Aβ aggregation in the
present study, both extracts of P. notoginseng had moderate activity. In previous studies
the compound quercetin 3-O-β-D-xylopyranosyl-β-D-galactopyranoside has been reported
to inhibit Aβ aggregation (Choi et al., 2010). Other substances like notoginsenoside R1 and
the polyacetylenes panaxynol and panaxydol could counteract Aβ toxicity in cell culture
and mouse models (Ma et al., 2014; Nie et al., 2008; Yan et al., 2014). These reports are
in accordance with the present study, indicating that P. notoginseng contains several sub-
stances that are able to ameliorate Aβ pathology. Since the activity of the extracts was not
so high, it would be advisable to identify these active compounds and use them in higher
concentrations. Further studies should reveal the suitability of this plant for patients with
AD.
E. senticosus, the Siberian ginseng, showed positive results for both methanol and dichlor-
methane extracts. The decrease in Aβ deposits was 15 % for both extracts, but a ten times
lower concentration was used for the dichloromethane extract, so mostly lipophilic com-
pounds seem to be the active ingredients. The methanol extract has been tested before on
primary neuron culture, where it could protect the cells from Aβ-induced neurotoxicity (Bai
et al., 2011; Tohda et al., 2008). Bai et al. (2011) noted activity against axonal and neuritic
atrophy mostly in more hydrophilic fractions, whereas hexane fraction of the extract had
no effect. They isolated some compounds that were responsible for the protective effect like
eleutherosides E and B, isofraxidine, and stigmasterol and sitosterol glycosides. Although
aglycons of these compounds might be contained in a dichloromethane extract, it seems
more likely that some other compounds are responsible for the effect on Aβ aggregation
observed in the present study. This underlines the benefits of using plant extracts in a com-
plex disease like AD, where several compounds can lead to synergistic effects by influencing
different targets.
Significant, although low activity was also observed for the methanol extracts of Phel-
lodendron spp. (huáng ba˘i), A. galanga, and Coptis spp. (huáng lían). P. amurense and
P. chinense, both species used in the TCM drug huáng ba˘i, have been reported to counteract
Aβ toxicity in cell culture (Xian et al., 2013). It is possible that this protection is at least
partly conferred by inhibiting Aβ aggregation. Same can be said for A. galanga that has
shown memory enhancing and antioxidant activities in mice treated with Aβ25–35. Berber-
ine, the active ingredient of Coptis spp., has been shown to lower Aβ levels in a mouse
model of AD. This activity was replicated in the present study in the C. elegans model with
methanol extract of huáng lían. The Phellodendron species also contain berberine, although
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in smaller amounts than Coptis spp. (Van Wyk et al., 2015). Therefore, the effect of huáng
ba˘i extract might be due to this compound, too. Berberine has several effects besides low-
ering Aβ levels, including AChE inhibition and should therefore be considered as a possible
lead drug for AD therapy (Ji & Shen, 2011).
C. monnieri yielded the most effective dichloromethane extract that decreased the num-
ber of Aβ aggregates by 35 %. The methanol extract of this plant had lower but still signif-
icant activity with 18 % decrease. This activity might be due to osthole, a rather lipophilic
coumarine derivative, that would be expected to be contained mostly in dichloromethane
extract. This compound can improve memory in a mouse model of AD via enhancing neu-
rogenesis (Liu et al., 2015b). However, in the study of Liu et al. (2015b) no decrease in
Aβ deposition was detected. Therefore the present study is the first to report this effect
for C. monnieri extracts and further research is needed to identify the active compounds.
Two other dichloromethane extracts, namely P. multiflorum and M. officinalis, showed a
significant effect. For both only the dichloromethane but not methanol extract was effective,
indicating lipophilic substances as active compounds. In M. officinalis these compounds
could be magnolol and honkiol, that have been reported to counteract Aβ-induced toxicity
before (Hoi et al., 2010). For P. multiflorum water and ethanol extracts have been studied
earlier in context of Aβ toxicity (Liu et al., 2015c; Um et al., 2006). The water extract had
a memory enhancing effect in mice and inhibited AChE (Um et al., 2006). The ethanol ex-
tract and its active compound 2,3,5,4’-tetrahydroxystilbene-2-O-β-D-glucoside were tested
on a Drosophila model, where they could counteract Aβ toxicity, but no effect on Aβ levels
was observed (Liu et al., 2015c). The lipophilic compounds, shown here to act against Aβ
aggregation, complement the actions of hydrophilic compounds, making P. multiflorum an
interesting plant for AD research.
The most effective dichloromethane extract (C. monnieri) had stronger activity than the
methanol extracts with only tenth of the amount used for the treatment. This might in-
dicate that lipophilic compounds are more active then the hydrophilic substances. They
are able to penetrate biomembranes and could therefore have higher bioavailability. How-
ever, since the culture medium for C. elegans is water based, these substances are poorly
soluble and difficult to test. This might account for the fact that there are more methanol
extracts showing significant activity. On the other hand, several dichloromethane extracts
also lead to an increase in the number of Aβ aggregates. It has to be considered that the
solvent DMSO, in which these extracts were solved, has itself a plaque decreasing effect
(Fig. 3.3). This observation is in accord with a study showing that 0.8 % DMSO can increase
the lifespan of C. elegans and even lower concentrations reduce paralysis in CL4176 worms
(Frankowski et al., 2013). To account for additive effects, all extracts were compared with
the respective concentration of DMSO as control, but a possible synergistic interaction can
not be excluded. Interactions counteracting the effect of DMSO could also explain the appar-
ent increase in number of Aβ aggregates for extracts that have no anti-aggregation activity.
Due to the complications with dichloromethane extracts and the fact that there were more
highly active methanol extracts, further work concentrated on the latter.
Some of the plants tested here were reported to have effects on Aβ levels or toxicity in
earlier studies (see Tab. 1.1) but showed no activity in the C. elegans model. Many of the
other studies tested pure compounds rather than extracts, which might explain the differ-
ent results. The content of active compounds in the extract is often low, so their effects can
be missed. Most studies working with extracts used water as a solvent, hence these extracts
also have different composition compared to methanol and dichloromethane extracts used
in the present study, making them not directly comparable. Another difference is also the
model used. Compared to cell culture C. elegans is a more complex model. Some substances
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might be active on cells, but fail in the C. elegans model due to low bioavailability, intesti-
nal metabolism, or other factors that are not present in cell culture. On the other hand,
mice and rats are much more complex animals than a nematode like C. elegans. They have
developed organs, cell types, and signalling cascades that are not present in nematodes.
Therefore, the C. elegans model is only suitable for testing direct interactions with Aβ or
effects on basic, evolutionary conserved signalling pathways. To detect interactions with
specific targets that are only found in vertebrates, other models are needed. These differ-
ences in the methodology have to be considered when comparing different studies and are
probably responsible for the differing results.
4.2 Areca catechu
A. catechu is known for its antiparasitic and cholinomimetic activities, but to date there are
no studies about its effects on amyloid aggregation. In the present study both methanol
and dichloromethane extracts showed high reduction in number of Aβ aggregates in the
C. elegans model. The methanol extract, that was studied further, showed a dose-dependent
effect (Fig. 3.5), but concentrations higher than 100 µg/ml could not be tested due to toxicity
for the worms. A. catechu contains mainly alkaloids and polyphenols. To clarify, which of
these groups is responsible for the effect, arecoline as the main alkaloid was also tested
in the Aβ aggregation assay. It showed no significant activity for concentrations up to
125 µg/ml (data not shown), suggesting that the effect of the extract is due to the polyphe-
nols or some other minor compound.
To examine whether A. catechu can also counteract Aβ toxicity, the paralysis assay with
the C. elegans strain CL4176 was conducted. 100 µg/ml of the extract were used, since this
concentration was effective in the first experiment and showed no toxic effects. However, in
the paralysis assay this treatment significantly shortened the time until paralysis (Fig. 3.6)
and also some worms of the control strain CL802, that do not express Aβ, appeared paral-
ysed after the treatment. The CL4176 and CL802 strains seem to be more sensitive to the
toxicity of A. catechu, possibly because the worms were treated earlier in this assay. The
extract might interact with important processes during development of the worms, making
them more vulnerable to the Aβ toxicity or toxic substances in general. Another possibility
is that the extract and Aβ both interact with the same target in CL4176, leading to an ad-
ditive or even synergistic toxicity. A direct interaction with Aβ is also possible and would
lead to higher toxicity, if the toxic oligomers were stabilised and further aggregation to less
toxic plaques prevented. In this case, however, the toxicity should have also been observed
in the CL2006 worms.
The organoselenium compound diphenylselenide, that has shown several positive effects
in different AD models, also increased the paralysis rate in C. elegans (Zamberlan et al.,
2014). Zamberlan et al. (2014) showed, that the effect on paralysis is due to muscle inhibi-
tion via increased AChE activity. A. catechu has cholinomimetic activity and might inhibit
AChE (Gilani et al., 2004). Diphenylselenide has shown AChE-inhibitory activity as well
in mammalian models, but activated the enzyme in C. elegans (Zamberlan et al., 2014).
Whether a similar effect could be the cause of increased paralysis after treatment with
A. catechu needs further testing. Until then other causes of toxicity cannot be excluded.
The toxicity could have been prevented by using lower concentrations of the drug. In
the Aβ aggregation assay the concentration 75 µg/ml also showed a significant decrease
in the number of deposits, but the effect size was only a half of the higher concentration.
Therefore, lowering the concentration would lead to loss of therapeutic effect. If the extract
has an effect on larval development, treating the worms later, when they are fully developed,
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would also solve the problem. This would be a mechanism specific for C. elegans that is not
relevant for AD therapy. In the case of an effect on acetylcholinergic neurotransmission, the
effect might also be specific for C. elegans and further studies in mammals are required to
evaluate it. In the present study the work with A. catechu was discontinued in favour of the
less toxic extract of G. uralensis.
For possible usage of A. catechu in AD therapy it would be important to further charac-
terise the toxicity of this plant. The effects seen in C. elegans might be specific for nematodes
and not affect humans or they might be more general. Arecoline has been shown to cause
neurotoxicity (Shih et al., 2010), to be cytotoxic, and chewing the seeds can cause oral can-
cer (Peng et al., 2015). On the other hand, a small study on patients with mild to moderate
AD reported no adverse effects for low doses of arecoline that improved the memory of re-
sponders (Soncrant et al., 1993). Arecoline acts as a cholinomimetic but had no effect on Aβ
aggregation. Therefore, the role of polyphenols and other constituents of Areca nuts in the
beneficial and toxic activity of the extract should be further clarified. If the toxic compounds
can be separated from the beneficial ones, the development of a modified extract or using
pure compounds would be advisable.
4.3 Alpinia oxyphylla
The methanol extract of A. oxyphylla decreased the number of Aβ aggregates by 25 %, being
the third most effective methanol extract in the present study. The chloroform fraction of
an ethanol extract has been reported before to decrease Aβ levels in mice (Shi et al., 2014).
This extract was rich in sesquiterpenes like nootkatone, had antioxidant effects, and inhib-
ited AChE. The decrease in Aβ aggregates shown in the present study is in accordance with
these results. The methanol extract probably contains at least some of the sesquiterpenes
but also other constituents like protocatechuic acid and 5-hydroxymethylfurfural. Both lat-
ter substances have been shown to decrease Aβ levels and have other neuroprotective prop-
erties (Liu et al., 2014; Song et al., 2014; Zhang et al., 2015). Based on this initial positive
activity the extract of A. oxyphylla was studied further.
The paralysis assay, however, did not show a significant difference between treatment
with the methanol extract of A. oxyphylla and control (Fig. 3.7). There was also no signifi-
cant difference between control and treatment with EGCG (solved in methanol), in contrast
to the results obtained with EGCG solved in water (Fig. 3.22). The effect of EGCG on the
CL4176 strain has only been investigated in one study before (Brown et al., 2006). There the
compound was solved in ethanol and a small, not significant effect in the paralysis assay was
observed. A tendency to longer time until paralysis was also observed in the present study
for EGCG solved in methanol. The EGCG solved in water, on the other hand, had a strong,
significant effect. In the light of this data it seems possible that the used solvent modulates
the activity of EGCG. The main mode of action for EGCG as a polyphenol is building un-
specific hydrogen bonds with proteins. The possible interaction with solvent molecules and
its impact on the hydrogen bond building ability of EGCG would be an interesting topic for
further studies.
Assuming, that the lack of activity for the positive control EGCG was because of a spe-
cific solvent effect that does not affect other substances, then the results indicate that the
methanol extract of A. oxyphylla has no activity against Aβ toxicity. It is possible, that the
compounds in this extract only interact with Aβ fibrils, but not the oligomers that cause
toxicity in CL4176. However, other studies have shown that this plant can ameliorate cog-
nitive deficits in mice treated with Aβ1–42 (Liu et al., 2014; Shi et al., 2014). The lack of a
corresponding effect in the present study might be due to a different model organism. It is
99
4. Discussion
also possible, that a higher dose of the extract or a pure active compound is needed to see an
effect. Given the promising activity of A. oxyphylla in the Aβ aggregation experiment and
its low toxicity compared to some other plants, e.g. A. catechu, the possible beneficial effects
of this plant on AD pathology should be studied more intensively in the future.
4.4 Glycyrrhiza uralensis
4.4.1 Determination of the used Glycyrrhiza species
The TCM drug ga¯n ca˘o can contain three different species of Glycyrrhiza: G. uralensis,
G. glabra, and G. inflata. Therefore, DNA barcoding was used to determine the exact species.
The comparison of ITS sequences from the drug and sequences from known species from
database showed the highest similarity with G. uralensis (Tab. 3.1). The ITS sequence
does not differ between G. glabra and G. inflata, but compared to G. uralensis there are two
variable sites: one single nucleotide polymorphism in ITS1 and a substitution of three nu-
cleotides in ITS2 (Kondo et al., 2007b). Hence, in this case the analysis of the ITS sequence
was sufficient for the identification.
DNA of the same plant material has been used before to analyse the chloroplast gene for
ribulose bisphosphate carboxylase large chain (rbcL) (Herrmann et al., 2011b). According to
Kondo et al. (2007b), there are two genotypes for rbcL in Glycyrrhiza species. The first one
is found in all three species (G. glabra, G. inflata, G. uralensis), the second one (GenBank
accession number AB012126) was only found in G. uralensis in the study of Kondo et al.
(2007b). In contrast to that, Hayashi et al. (2000) reported that the rbcL sequence is iden-
tical in G. uralensis and G. inflata (GenBank accession numbers AB012126 and AB012127,
respectively). Herrmann et al. (2011b) reported the Glycyrrhiza species used to be G. inflata
(GenBank accession number JF950025). The two rbcL genotypes differ by two nucleotide
substitutions at the bases 706 and 736 (based on the sequence AB012126). By comparing
the sequences from Kondo and Hayashi to the sequence reported by Herrmann, it occurs
that the latter sequence only contains 698 base pairs and is lacking the essential bases.
Hence, this sequence cannot be used for identification.
The identity of the plant material as G. uralensis is also supported by the phytochemical
analysis. Glycycoumarin, a compound specific for the species G. uralensis (Kondo et al.,
2007a), was found in the methanol extract of the plant (peak 12 in Fig. 3.9, Fig. 3.16)
whereas no masses corresponding to glabridin (324 g/mol) or licochalcone A (338 g/mol)
were observed (Tab. 3.3). Also the ratio of flavanones to chalchones seems to match most
closely the conditions reported for G. uralensis (Kondo et al., 2007a; Simmler et al., 2015),
although this ratio was not quantitatively determined in the present study. Altogether, both
the genetic and phytochemical analysis point to G. uralensis, and this result is also consis-
tent with the fact that the drug was purchased in China, where G. uralensis is the most
common species.
4.4.2 Glycyrrhiza uralensis and its major compounds decrease Aβ
aggregation
The methanol extract of G. uralensis decreased the number of Aβ aggregates in the initial
screening by 30 % (Fig. 3.2) and was therefore chosen for further study as one of the most
potent extracts. The dichloromethane extract had no significant activity, possibly because
due to poor solubility only 25 µg/ml of this extract could be used or because of the differ-
ent composition of the extracts. Water and ethanol extracts have been studied before on
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mice and primary neuron culture (Ahn et al., 2006; Lee et al., 2012b). Memory enhancing
and neuroprotective activities were reported, but the effects on Aβ aggregation were not
investigated in these studies. The compound LG has been shown to reduce Aβ secretion
from neurons and ILG can inhibit Aβ aggregation by binding to this peptide (Chen et al.,
2013; Liu et al., 2009). The phytochemical analysis of the extract showed that the methanol
extract—in contrast to the dichloromethane extract (Fig. 3.8)—contains glycosylated forms
of these compounds (peaks 1–4 in Fig. 3.9). Therefore, these substances could be responsible
for the effect seen for the extract.
Quantification of the compounds in the different extracts showed, that 54–64 µg/ml GA
is present in water and methanol extracts, 9 µg/ml of LG were found in methanol extract,
the other studied compounds were present only in traces (Tab. 3.2). The dichloromethane
extract contained only trace amounts of all four compounds in correlation with the lack
of significant activity in the aggregation assay. In the LC-MS/MS analysis the aglycons
could not be recovered, but liquiritin, liquiritin apioside, isoliquiritin, isoliquiritin apioside,
and GA were present in high amounts (Fig. 3.9, Fig. 3.10). Glycosides often function as
prodrugs that have to be activated by bacteria in the gut. It is known that the active form
of GA in humans is GRA that is produced form GA by intestinal bacteria (Hattori et al.,
1983; Krähenbühl et al., 1994; Monder et al., 1989). The C. elegans model system used
here contains living E. coli as a food source for the worms. These bacteria probably also
metabolise the extracts, so it can be expected that the worms are exposed to more aglycons
than originally present in the extract. Therefore, although only trace amounts were found
in the extract, the high amount of glycosides can lead to higher concentrations of LG, ILG,
and GRA, and these compounds can significantly contribute to the activity of the extract.
Most of the saponins found in the methanol extract are derivatives of GRA. Assuming
that the sugar residues are removed by the bacteria, the aglycon GRA should be represen-
tative for possible activity of these compounds. Besides the already mentioned substances,
isoprenylated flavonoids and coumarins were found. Glycycoumarin has shown protective
activity against Aβ toxicity before (Kanno et al., 2015), but since only a small amount of
coumarins was found in the active extract, it is unlikely that these are the main active con-
stituents. Of the isoprenylated flavonoids only isoangustone A could be identified (Tab. 3.3,
Fig. 3.18) and there are to date no reports about this substance interacting with Aβ. There-
fore, GA as the major compound (peak 8 in Fig. 3.10) and the aglycons LG, ILG, and GRA
were chosen for further study.
In the Aβ aggregation assay in CL2006 GA showed a significant effect only for the highest
tested dose (100 µg/ml), the other substances were already active at 50 µg/ml, decreasing
the number of Aβ aggregates by up to 26 % (Fig. 3.20). LG and ILG had slightly higher
activity than the other compounds. These results are in accordance with earlier reports
(Chen et al., 2013; Liu et al., 2009), but they also suggest that LG and ILG are not the only
active compounds in G. uralensis in respect of Aβ aggregation. For further experiments all
four compounds were tested in addition to the methanol extract.
4.4.3 Glycyrrhiza uralensis and isoliquiritigenin counteract Aβ
toxicity
Protective effects against Aβ-induced neurotoxicity have been reported before for different
G. uralensis extracts, ILG, and LG (Ahn et al., 2006; Lee et al., 2012b; Liu et al., 2009). Here
the effects of methanol and water extract as well as the pure compounds GA, GRA, LG, and
ILG were tested in C. elegans models expressing Aβ in muscles and neurons. The paraly-
sis assay with the strain CL4176 produced the most significant results. Both G. uralensis
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extracts and ILG delayed the time until paralysis (Fig. 3.22). The control substance EGCG
was also active in this assay and had the highest activity of all tested compounds with 2.7 h
delay in PT50. This activity is much stronger pronounced than the moderate delay reported
by Brown et al. (2006). As discussed in section 4.3, there might be an effect of solvent modi-
fying the action of EGCG.
Regarding solvent effects, it was also observed that the treatment with 1 % methanol alone
had a significantly different PT50 compared to the water-treated control. This effect was
dose-dependent, since there was also a significant difference between 0.5 and 1 % methanol
(Fig. 3.33; p < 0.01). That confirms the observation made by the treatment with A. catechu
extracts (see section 4.2) that the CL4176 strain is more sensitive than CL2006. Methanol
had no effect on the latter strain in concentrations up to 1 % (data not shown). In contrast to
A. catechu, the effect observed for methanol was not toxic but beneficial. The solvent alone
could delay paralysis to the same extent as EGCG. Possibly this activity was mediated by
a hormetic effect of early life exposure to a low concentration of a toxin, since methanol has
shown hormetic effects at concentrations below 1 % before (Qin et al., 2010). To account for
this effect, all treatments were compared to the respective solvent control.
From the two G. uralensis extracts tested, the water extract showed higher activity. At a
concentration of 200 µg/ml it led to the same delay in paralysis as 500 µg/ml of the methanol
extract. The water extract contains slightly more saponins than the methanol extract (com-
pare peaks 5, 6, and 7 in Fig. 3.10), so this could be the cause of higher activity. However,
the only saponin tested as a pure compound—GA—showed no difference to the control.
Saponins have an amphiphilic structure which allows them to interact with biomembranes
and increase their permeability. Therefore, if saponins are not the active ingredients them-
selves, they can still lead to higher activity of an extract by increasing the bioavailability of
the active compounds. Same can be said for the aglycon GRA which showed only minimal,
non-significant activity in this assay. Although this molecule has no hydrophilic sugars, the
lipophilic triterpene structure can still interact with the lipids and cholesterol molecules in
the biomembrane.
ILG was the only pure compound with significant activity in this assay. This result is in
accordance with an earlier report of a protective effect against Aβ-induced neuronal death
(Lee et al., 2012b). Similar activity has been reported for its isomer LG (Liu et al., 2009).
In the paralysis assay, however, LG rather shortened the time until paralysis, although
this effect was not significant. The worms of the control strain CL802 did not react to the
treatment with LG, suggesting that this compound is not toxic in general. ILG has been
reported to interact directly with Aβ (Chen et al., 2013) and similar interactions have been
observed for other flavonoids (Bu et al., 2015). ILG and LG are polyphenols like EGCG, so
they share a possible mechanism of action. ILG has one more hydroxy group compared to
LG, allowing it to build more hydrogen bonds. Hence, if this is the mechanism of action, ILG
would be expected to be more potent. This, however, does not explain the opposite activity of
LG. Possibly, the unspecific binding via hydrogen bonds is not the only mechanism of action
for these flavonoids in the paralysis assay.
The common properties these flavonoids share with EGCG also suggest, that if the sol-
vent affects the action of EGCG (section 4.3), this would also be the case with ILG and LG.
The effects of methanol and EGCG are clearly not additive, but rather lead to an abolish-
ment of any visible effect (Fig. 3.7). If the same happens to ILG and LG, then the small
negative effect of LG could be interpreted as an abolishment of the methanol effect. It was
suggested, that the latter arises from a hormetic response. In this case the antioxidant and
neuroprotective effects of LG could protect the worms from methanol toxicity and prevent
the induction of hormesis. The same should happen with ILG, but apparently ILG has a
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higher protective capacity, so that the delay in paralysis still reaches significance above the
methanol control.
Aβ is degraded via autophagy in the CL4176 worms and this process is regulated by the
transcription factors HSF-1 and DAF-16 (Cohen et al., 2006; Florez-McClure et al., 2007).
Therefore, ILG or other compounds in the G. uralensis extract can lower its toxicity also by
interacting with proteins involved in autophagy or its regulation. Fluoxetine, a selective
serotonin reuptake inhibitor, has been shown to delay paralysis in this model dependent on
DAF-16 activation and serotonin (Keowkase et al., 2010). ILG induced DAF-16 delocalisa-
tion in the present study (Fig. 3.28), indicating that this transcription factor may be involved
in the mechanism of action for this compound as well. However, G. uralensis extract failed
to activate DAF-16 significantly, although it could delay paralysis. Therefore, there must be
other mechanisms underlying its activity.
ILG and LG can modulate serotonin and norepinephrine concentrations (Wang et al.,
2008) and several compounds in G. uralensis have antioxidant activity. These properties,
besides the direct interaction with Aβ peptide, could counteract the downstream toxic ef-
fects triggered by Aβ. To further elucidate the mechanisms behind the effects seen in the
paralysis assay, the antioxidant activity in C. elegans (discussed in section 4.4.4) and the
effects on behaviour in the strain CL2355, that expresses Aβ in neurons, were investigated.
Neuronal toxicity in CL2355 leads to impaired chemotaxis behaviour. As can be seen in
Figure 3.23, the control strain PD8120 has a CI of about 0.4, whereas CL2355 worms show
no chemotaxis at all. This defect is rescued to some extent by the treatments, most signifi-
cantly by GRA. GRA also showed a small protective effect in the paralysis assay, although it
was not statistically significant. Still, these results suggest, that GRA could have protective
properties against Aβ toxicity, maybe at higher concentrations. It is also evident, that the
chemotaxis behaviour of the control strain is affected as well. This indicates, that the sub-
stances have unspecific effects on the behaviour that are not related to Aβ expression. This
assay is very sensitive to all environmental factors, leading to high standard deviations.
Therefore the effects of G. uralensis extract, ILG, or EGCG are not significant, although
there is a tendency for higher CI in CL2355 worms after these treatments (p É 0.1).
In the serotonin sensitivity assay an unexpected hyposensitivity in CL2355 worms treated
with methanol was observed (Fig. 3.24). By control treatment with water there was no dif-
ference between CL2355 and the control strain. It has been reported before that the CL2355
strain is hypersensitive to serotonin (Wu et al., 2006). In later experiments this effect was
also observed in our lab (Felix Heiner, PhD student at Heidelberg University, IPMB, Depart-
ment of Biology, personal communication). To date there is no logical explanation, why the
worms behaved differently during the present study. However, there is a difference in sensi-
tivity to serotonin between CL2355 and the control strain, when the worms are treated with
methanol. Therefore, the results were evaluated as positive, if a treatment could reduce this
difference.
Significant activity was observed for EGCG, LG, and ILG, suggesting that these sub-
stances can normalise the serotonergic neurotransmission in this model. ILG and LG
have been reported before to modulate serotonin concentrations in mice, resulting in an
antidepressant-like effect (Wang et al., 2008), and the antidepressant fluoxetine delays Aβ-
induced paralysis in C. elegans dependent on serotonin (Keowkase et al., 2010). Similarly,
green tea extract containing EGCG has been shown to elevate serotonin concentration in
human plasma (Hodgson et al., 2014). Therefore, the effect on serotonergic transmission
reported here could also be involved in the mechanism of action of the active compounds in
counteracting Aβ toxicity in the paralysis assay.
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The compounds GA and GRA can significantly suppress the activity of both the Aβ ex-
pressing strain and the control strain. This indicates, that the effect is not specifically
related to Aβ. It also suggest that these substances have a general effect on neurotrans-
mission or the enhanced slowing response in C. elegans. The inhibition of gap junctions by
GRA (Davidson & Baumgarten, 1988) may play a role in this effect. The muscle cells of
C. elegans are connected by gap junctions (White et al., 1986), therefore GRA could disturb
signalling between these cells, leading to reduced mobility. However, such an effect was not
observed in other assays following treatment with GRA. On the contrary, in paralysis assay
this compound slightly delayed paralysis. Therefore, effects related to serotonin cannot be
ruled out and may play a role in the small protective effect of GRA observed in the other
assays.
In summary, it can be said that ILG was the most potent substance in counteracting Aβ
toxicity. It had a highly significant activity in paralysis and serotonin sensitivity assays
and a positive tendency in enhancing chemotaxis. Serotonergic neurotransmission may
play a role in this protective effect. The extracts of G. uralensis as well as the substances
LG and GRA also showed protective effects, although smaller than the effect seen for ILG.
G. uralensis extracts probably contain several protective compounds that may have additive
or synergistic activitiy. ILG as one of the more potent protectors deserves further investi-
gation, weather as pure compound or in combination with other active substances found in
G. uralensis.
4.4.4 Isoliquiritigenin has antioxidant activity via activating DAF-16
Oxidative stress is one of the important characteristics of AD and ageing in general. Aβ
increases the production of ROS (Huang et al., 1999; Opazo et al., 2002). Therefore, one way
to counteract Aβ toxicity downstream of the peptide aggregation is antioxidant therapy.
The antioxidant capacity of G. uralensis extract and its active compounds in C. elegans was
investigated using two assays. In the HSP expression assay the worms are exposed to low
doses of the prooxidant juglone that induces mild oxidative stress. The survival assay is a
more rigorous test of antioxidant activity, where the worms are subjected to lethal oxidative
stress by high concentrations of juglone.
In the HSP expression assay all substances except the lower concentration of G. uralensis
extract and GRA showed a moderate activity (Fig. 3.26). As a positive control this ex-
periment was also conducted with ascorbic acid, a well known antioxidant, that exhibited
dose-dependent antioxidant activity with up to 55 % reduction in fluorescence intensity
(Fig. 3.25). The control substance EGCG reached similar values in accordance with earlier
studies in C. elegans (Abbas & Wink, 2009, 2010). The effects of other substances were much
lower in this assay. In the survival assay only ascorbic acid, EGCG, and the flavonoids LG
and ILG showed a significant effect.
From all test substances ILG had the strongest effect in both assays. This is the first
report of antioxidant activity of ILG in C. elegans, although such effects have been reported
before in cell culture systems (Gong et al., 2015; Lee et al., 2012b). In HSP expression assay
the fluorescence was decreased only by 26 %, whereas in the survival assay ILG increased
the survival rate by 82 %, being even more effective than EGCG. EGCG showed a strong
antioxidant effect in both assays. This illustrates, that both compounds act via different
mechanisms. EGCG is a radical scavenger, it can directly react with the ROS generated by
juglone and thereby prevent damage to the cells. ILG has shown radical scavenging activity
in in vitro assays as well (Chin et al., 2007; Vaya et al., 1997), but due to the differences
in structure it is a less potent radical scavenger than EGCG. Instead it can activate the
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cells own protective mechanisms via the transcription factor NRF2 (Gong et al., 2015). This
pathway may be combined with the activation of other protective mechanisms like HSP
expression, so that the effect is not so strongly seen in the HSP-expression assay, but is
highly effective under severe oxidative stress as in survival assay. Since the activity of
HSF-1, that controls the expression of HSPs, is necessary to counteract Aβ toxicity (Cohen
et al., 2006), the rather small effect of ILG in suppressing HSP expression may be related
to the effective delay of paralysis in CL4176.
LG had only a small effect in the antioxidant assays. The antioxidant activity of LG and
ILG has been attributed to the activation of NRF2. Wang et al. (2015) have shown, that ILG
has a much stronger effect on the expression of genes that are under the control of NRF2
than LG. This correlates well with the results of antioxidant activity in C. elegans and also
with the results in Aβ toxicity assays. NRF2 and its C. elegans homologue SKN-1 regulate
the expression of stress related genes that could also be involved in detoxification of the Aβ
oligomers. In AD patients the function of NRF2 has been shown to be impaired (Mota et al.,
2015). Since ILG can activate NRF2 and also influences the expression of some antioxidant
genes independent of NRF2 activation (Wang et al., 2015), this compound could be useful
for counteracting oxidative stress in early stages of AD.
In C. elegans SKN-1 activation is regulated by the same kinases that also control DAF-16
and both transcription factors share some of their target genes (Tullet et al., 2008). The
effect of G. uralensis and its compounds on DAF-16 nuclear translocation was studied using
the C. elegans strain TJ356. As shown in Fig. 3.28, the treatment with ILG led to activation
of DAF-16, other Glycyrrhiza compounds and the extract had no significant effect. EGCG
showed also no significant activity in both tested solvents, although it has been reported to
be active before. Methanol alone had an effect in this assay, therefore low activities of some
compounds like LG might have gone unnoticed.
Treatment with GRA or GA did not lead to nuclear localisation of DAF-16 although they
are reported to modulate the activity of PI3K, the human homologue of AGE-1 (Kao et al.,
2009, 2013; Wang et al., 2011). In C. elegans inhibition of AGE-1 leads to longer lifespan
of the worms which is dependent on DAF-16 (Lin et al., 1997; Morris et al., 1996). Kao
et al. (2009, 2013) have reported activation of PI3K by GA and GRA. This is in accordance
with the result that no DAF-16 activation was observed for these treatments in C. elegans.
Wang et al. (2011) reported inhibition of PI3K in active macrophages, contributing for the
anti-inflammatory activity of GA and GRA. This shows, that this effect is dependent on
the inflammatory state of the organism. Since in the present study no inflammation was
induced in the worms, the treatment did not lead to DAF-16 activation. This result is also
in line with the lack of antioxidant activity for GA and GRA.
The controls juglone and heat treatment in this test are active because they cause stress
to the worms. This rises the question, weather the activity of ILG indicates a protective or
a toxic effect? DAF-16, when active, prolongs the lifespan of C. elegans (Kenyon et al., 1993)
and activates the expression of stress resistance genes (Lee et al., 2003; McElwee et al.,
2003; Murphy et al., 2003). This activity is triggered by environmental stimuli that suggest
the need of such protection—stressors and toxins (Henderson & Johnson, 2001). Therefore,
it is a matter of concentration weather a toxin overpowers the protective effects and kills
or damages the worm or is warded off effectively. In the latter case it comes to a hormetic
response—a low concentration of the toxic substance leads to higher fitness of the organism,
making it more resistant to stress and, at least in C. elegans, prolonging its life. Both heat
and mild oxidative stress induced by juglone have been shown to trigger a hormetic response
(Cypser & Johnson, 2002).
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ILG was shown to be protective against the proteotoxicity of Aβ aggregates and against
oxidative stress in the previously discussed experiments. Hormesis is a frequent mechanism
of action for phytochemicals that is especially important for healthy ageing (Murugaiyah
& Mattson, 2015; Son et al., 2008). Hormetic pathways include transcription factors like
NRF2, that has been shown to be activated by ILG before, or FOXO. Therefore, it can be
assumed that at the used concentration ILG evokes a hormetic response by activating the
C. elegans homologue of FOXO, DAF-16. Furthermore, this may be the mechanism of action
also in other organisms, since NRF2 activation has been reported in mice and human cell
cultures (Gong et al., 2015; Wang et al., 2015). To test this hypothesis, a dose-response
analysis with a wide range of doses should be conducted.
Prolonged activity of FOXO can lead to AD-like symptoms (Manolopoulos et al., 2010).
This is in contrast to the positive effects seen for ILG via activation of DAF-16. In the exper-
iments conducted for the present work, the worms were treated with the substances once,
so the activation of DAF-16 was only transitional. It is possible that in an organism with
constitutive stress and FOXO/DAF-16 activation an additional induction of this transcrip-
tion factor has no beneficial effect (see section 4.4.5). If the activity of ILG is mediated by
the suggested hormetic effect, it is probably better suited for prevention than treatment of
fully developed dementia. However, the role of insulin signalling and FOXO in AD is not
entirely established yet. Therefore, further studies with ILG in mammalian models are
needed, to test the effect on FOXO, probable interactions with other signalling pathways,
and the resulting consequences on AD.
4.4.5 Toxicity of long-term treatment with Glycyrrhiza uralensis
DAF-16 activity leads to longer lifespan in C. elegans. To test, if G. uralensis and its com-
pounds are able to prolong life, lifespan assays were conducted with wildtype worms and
CL2006. The experiment was discontinued after the observation that the compounds rather
shortened the lifespan in the first run (Fig. 3.30). This effect was dose dependent for the
G. uralensis extract and more pronounced in wildtype than in CL2006 worms. Possibly the
protective effect of this extract against Aβ aggregation and toxicity has some benefits in the
CL2006 worms that can counterbalance the toxicity resulting in shorter lifespan.
It is also notable that the lifespan of control worms was about twice as long than the
three weeks reported before for worms growing at 20 °C (Klass, 1977). Several factors
like temperature or food restriction can influence the lifespan of the worms but could be
excluded as a cause for lifespan extension here. One possible explanation that could be
determined was a measurable electromagnetic field in the incubator that led to DAF-16
activation in TJ356 worms (data not shown). C. elegans contains biogenic magnetite and
static magnetic fields have an effect on gene expression of proteins related to development
and ageing (Cranfield et al., 2004; Hung et al., 2010). Weather the long lifespan observed
was related to the electromagnetic field was not further investigated. Another possibility
is, that the treatment with 1 % methanol prolonged the lifespan. To our knowledge the
effects of this solvent on C. elegans lifespan have not been studied before, but as discussed
above, low methanol concentrations have an hormetic effect (Qin et al., 2010). Therefore
this treatment could affect stress resistance and lifespan.
From the pure compounds ILG shortened the half-time of life by 7 days and the maxi-
mum lifespan by 18 days in the wildtype worms. Its effect in CL2006 was smaller, but still
stronger than for other treatments. LG had a similar effect in CL2006 but was closer to
the control in the wildtype worms. GA and GRA were rather neutral in CL2006, although
GRA shortened the lifespan in wildtype worms by 3.5 days. In wildtype this pattern resem-
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bles the activity in DAF-16 delocalisation assay: ILG had the highest activity, followed by
LG and GRA, GA had no effect. Hence, the toxicity might be related to prolonged activa-
tion of DAF-16, similar to the effects observed for FOXO (Manolopoulos et al., 2010). ILG
and LG had an effect against Aβ toxicity and showed antioxidant activity upon a single
treatment, whereas GA and GRA did not. ILG and probably also LG act at least in part
via hormetic pathways as discussed in section 4.4.4. Therefore, long-term treatment with
these compounds would lead to constant activation of stress-related transcription factors
like DAF-16/FOXO. That could explain why these compounds are more toxic, especially in
the CL2006 strain that is already under stress because of Aβ toxicity, compared to the other
compounds.
The results of the lifespan assay demonstrate, that long term treatment with high doses of
G. uralensis or ILG might be toxic. This might be related to prolonged activation of DAF-16,
but it could also have other causes. Therefore this possible toxicity needs further investiga-
tion to determine the concentration and time range in which these treatments are non-toxic.
It would be also important to establish, weather this toxicity is specific to C. elegans or is
also found in other species. Liquorice has been used in confectionery and as a food additive
for a long time without adverse effects in humans. However, a medicinal preparation with
high concentration of the plant extract or a pure compound that is used regularly over a
long period of time might have different toxicological effects.
4.4.6 Is isoliquiritin a viable drug candidate?
The results for ILG in the present study prove efficacy against Aβ aggregation, Aβ toxicity,
and oxidative stress that are prominent factors in the pathogenesis of AD. These results
are in accordance with earlier studies in vitro as well as on cell cultures and mice (Chen
et al., 2013; Gong et al., 2015; Lee et al., 2012b; Vaya et al., 1997). Additionally, ILG has
anti-inflammatory (Kim et al., 2008b; Park & Youn, 2010; Takahashi et al., 2004; Wang
et al., 2015) and anti-diabetic properties (Gaur et al., 2014; Ma et al., 2015b) that would
help against inflammation and insulin resistance in AD. The antidepressant-like activity
reported for ILG (Wang et al., 2008) could also be beneficial, since depression is one of the
most frequent co-morbidities in patients with AD. Taken together, these evidence show
reasonable efficacy and suggest ILG for further drug development.
Next to the efficacy bioavailability is an important factor in developing a drug. ILG has
shown good permeability in a human colon carcinoma cell line (Caco-2) and a blood-brain-
barrier model (Yang et al., 2014). The permeability resulted mostly from passive diffusion.
Studies in rats and humans with formulations containing ILG have reported low plasma
concentrations (Sadakane et al., 2015; Wu et al., 2013). The absorption of ILG is rapid, and
92 % of the drug are absorbed after per oral administration (Choi et al., 2015; Lee et al.,
2013; Qiao et al., 2014; Sadakane et al., 2015). However, the bioavailability is low due to
high rate of metabolism in gastrointestinal tract and liver, and high protein binding was
reported (Choi et al., 2015; Lee et al., 2013). In contrast to the results of Yang et al. (2014),
only small amounts of ILG were found in the brain of rats and mice (Choi et al., 2015; Lee
et al., 2013; Qiao et al., 2014), suggesting a low permeability over the blood-brain-barrier in
vivo.
In the current study the bioavailability in C. elegans was not investigated, but it has been
reported before that the drug concentration in worms is similar to that in mice (Zheng et al.,
2013). The usage of live E. coli could have also mimicked some of the metabolic effects found
in intestine of mammals. Therefore, it can be assumed that about 20 % of the substance
reached its targets. This may explain, why only relatively small effects were seen in some
107
4. Discussion
assays. On the other hand, a treatment of about 100 worms with 50 µg/ml still yielded
significant improvement, suggesting that at least in C. elegans only small amounts of the
drug are necessary for the desired activity.
The low bioavailability might be overcome by higher doses or alternative administration
methods. However, a treatment with high concentrations of a substance needs careful con-
sideration of drug safety. Glycyrrhiza spp. have been used for a long time in medicine
and food industry, they are generally considered to be safe, and there are little toxicologi-
cal studies available. Still, using high concentrations of a single compound can have side
effects, especially considering the much higher tissue concentrations of ILG in gastroin-
testinal tract, liver, and kidney than in brain as target organ (Choi et al., 2015; Lee et al.,
2013; Qiao et al., 2014). Yang et al. (2014) found ILG to be cytotoxic to rat brain microves-
sel endothelial cells in concentrations higher than 20 µM. In the present study long term
treatment of C. elegans shortened its lifespan. Therefore, further studies to determine safe
concentrations in mammals are needed.
ILG is a promising drug candidate, but before it can be used for human treatment the
issues of bioavailability and drug safety need to be solved. Derivatives of the substance
might be useful and could also lead to better efficacy (Chen et al., 2013). Also a combination
with other substances that can alter the metabolism of ILG or add to its efficacy should be
considered. Anyhow, this substance deserves further investigation in other model systems
for AD.
4.5 Carlina acaulis
4.5.1 Isolation of Carlina oxide
Carlina oxide is the major compound in the dichloromethane extract, as can be seen in Fig-
ure 3.31. Small amounts of benzaldehyde and ar-curcumene were also detected, consistent
with previous analysis of the essential oil of C. acaulis (Chalchat et al., 1996; Stojanovic´-
Radic´ et al., 2012). The extract also contains some other substances that could not be identi-
fied. Based on their masses, these might be oxidation products of Carlina oxide. Since there
is no published data about such substances, further analytical characterisation would be
necessary to confirm this assumption. Chalchat et al. (1996) have reported the presence of
small amounts of farnesene and sesquiphellandrene in the essential oil of C. acaulis. These
highly lipophilic compounds were not found in the dichloromethane extract.
The purification via TLC yielded two fractions. Figure 3.32 shows that the first fraction
contains most of the Carlina oxide, ar-curcumene and some of the unknown substances. The
second fraction contains negligible amounts of Carlina oxide, but mostly other unidentified
substances. Since the small amount of ar-curcumene in the first fraction is not likely to have
any notable effect over Carlina oxide, and the unknown compounds are probably related to
Carlina oxide, this fraction was handled as a pure substance. The second fraction containing
more other substances than Carlina oxide was tested as a control to see, if a possible effect
is attributable to Carlina oxide alone.
4.5.2 Dichlormethane extract of Carlina acaulis but not Carlina oxide
has an effect against Aβ toxicity
C. acaulis has not been studied in context of AD before. It was chosen for the present study
because of unexpected activity in the paralysis assay in a preliminary experiment. The effect
against Aβ toxicity could be reproduced for 50 µg/ml. The lower concentration of the extract
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and both fractions had no activity (Fig. 3.33). This was unexpected, because the C. acaulis
extract comprises of over 80 % Carlina oxide. Therefore, this compound would be expected to
have some activity, or else the extract without Carlina oxide should be active. Instead both
fractions showed a small, not significant delay in paralysis. Apparently Carlina oxide and
other compounds in the extract have an additive or even synergistic effect. Further research
should identify all compounds responsible for the effect and elucidate their interactions.
The effect of C. acaulis was further studied in the C. elegans strain CL2355 with neuronal
Aβ expression. Unfortunately, Carlina oxide seemed to be toxic in the chemotaxis assay
and no meaningful results could be produced. In serotonin sensitivity assay lower concen-
trations were used, reducing the toxic effects. However, there seems to be no specific effect
on serotonergic neurotransmission. C. acaulis extract showed a small significant effect for
10 µg/ml, but both a higher and a lower concentration had no activity. Carlina oxide had no
effect on the CL2355 worms but affected the control stain. This suggests that the observed
effects were unspecific and not related neither to Aβ toxicity nor to serotonin signalling.
The extract and Carlina oxide could activate DAF-16. This suggests, that Carlina oxide
could have hormetic effects at low concentrations, similar to ILG. There are however no
reports that would support or refute this assumption. It would also not explain the small
effect of the extract without Carlina oxide in the paralysis assay, since this fraction could
not activate DAF-16. C. acaulis is known to have antioxidant activity that could play a role
in delaying paralysis and is discussed in the next section. Further research is needed to
elucidate other possible mechanisms of action.
4.5.3 Carlina oxide exhibits in vivo antioxidant activity
Antioxidant activity of Carlina extracts and the essential oil has been observed before
(Ðord¯evic´ et al., 2007, 2012), but only in vitro tests have been deployed. In the present
work we showed the antioxidant activity of the dichloromethane extract of C. acaulis and
proved that Carlina oxide is the active compound.
The extract has an EC50 of 122 µg/ml in the DPPH• assay (Fig. 3.35). Ðord¯evic´ et al. have
reported an EC50 of 13.6 µl/ml for the essential oil of C. acanthifolia (Ðord¯evic´ et al., 2007)
and 208 and 155 µg/ml for the methanol extracts of C. acaulis and C. acanthifolia roots,
respectively (Ðord¯evic´ et al., 2012). Our result lies between the reported values for essential
oil and methanol extracts. Since the essential oil only contains lipophilic compounds in high
concentration, whereas a methanol extract can also include more hydrophilic compounds
like flavonoids, these values are not directly comparable with the dichloromethane extract
studied here. Nevertheless, the results for the dichloromethane extract are in the same
range as earlier reported values. This data suggest, that the active antioxidant compound
is rather lipophilic.
The main constituent of the extract is Carlina oxide (Fig. 3.31), leading to the assumption
that it is also the active ingredient. Ðord¯evic´ et al. (2007) showed via TLC that Carlina oxide
has radical scavenging activity. Its antioxidant activity was confirmed in this work by the
experiments with the isolated Carlina oxide and the extract without Carlina oxide. Both the
full extract and Carlina oxide showed dose-dependent activity in HSP-16.2 expression and
DAF-16 delocalisation assays. DAF-16 activation possibly contributes to the antioxidant
activity by triggering the expression of SOD, glutathione S-transferase, catalase, metalloth-
ioneine, and other protective proteins, including HSP-16.2. Carlina oxide is slightly more
active in both assays, whereas the extract without Carlina oxide has no effect. This would
be expected when Carlina oxide is the active compound.
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Carlina oxide was identified as the responsible compound for antioxidant activity, but
was not significantly active in the paralysis assay. This suggests, that antioxidant activity
and activation of DAF-16 alone are not sufficient to counteract the Aβ toxicity in CL4176
worms. Drake et al. (2003) have proposed that the Aβ-induced toxicity in CL4176 is related
to build-up of free radicals and the resulting oxidative stress. The results presented here
argue that this is not the only mechanism. The transcription factors DAF-16 and HSF-1,
that regulates the expression of HSPs, are both needed to achieve the detoxification of Aβ
and protect ageing worms (Cohen et al., 2006; Hsu et al., 2003). Carlina oxide activated
DAF-16, but could also effectively prevent HSP expression, indicating that its antioxidant
action is not related to HSF-1 activity. In contrast to that, ILG, that could counteract Aβ
toxicity, had only a small effect on the HSP expression (see section 4.4.4).
4.5.4 Toxicity of Carlina acaulis and Carlina oxide
C. acaulis is a known antimicrobial drug with Carlina oxide as the main active compound
(Schmidt-Thomé, 1950), it is also toxic to Trypanosoma burcei burcei (Herrmann et al.,
2011a) and 0.1 ml of the oil can be deadly to rats (Schmidt-Thomé, 1950). This poses the
questions, if there might be toxic effects against C. elegans, if the extract is toxic to E. coli
used as a food source in experiments with C. elegans, and if there might be problems con-
sidering usage of the drug in humans.
Ðord¯evic´ et al. (2007, 2012) report good antimicrobial effects against several species in-
cluding E. coli, but in general the activity is stronger against gram positive bacteria. This
was also observed by Schmidt-Thomé (1950), who reported an initial bacteriostasis but nor-
mal growth after 24 h incubation for the gram negative bacteria. Since the bacteria used as
food source for C. elegans are not supposed to grow during the experiments, the treatment
with C. acaulis and Carlina oxide is not problematic.
Carlina oxide has been reported to be toxic for small organisms like trypanosomes (Her-
rmann et al., 2011a). The authors suggest, that it inhibits trypanothione reductase, an
enzyme found only in trypanosomes. Still, there might be other not so specific mechanisms.
Carlina oxide in higher concentrations (> 50 µg/ml) was also toxic to C. elegans, therefore
lower concentrations had to be used. In case of paralysis assay, where the worms are exposed
to the drug from hatching, and in chemotaxis assay, which is in general more sensitive, a
delay in development was observed. Otherwise the worms seemed to tolerate the treatment
well, so there is no toxicity to C. elegans at tested concentrations. Interestingly, less toxic-
ity was observed in a dichloromethane extract, that had been stored at −20 °C for several
months. This extract was still effective in paralysis assay (data not shown), indicating that
the active compounds are not necessarily the toxic ones.
Schmidt-Thomé (1950) planned to test the antimicrobial activity of C. acaulis essential oil
on infected rats but failed because of the toxic effects of intraperitoneal and subcutaneous
injections. The rats died in 10 hours. Ðord¯evic´ et al. (2007, 2012) administered the oil
or extracts to rats orally and reported no adverse effects. Herrmann et al. (2011a) tested
extracts of the drug and Carlina oxide against HeLa cells and found no notable toxicity. In
traditional medicine the drug is usually applied topically. Therefore it can be said, that
the topical and oral administration of C. acaulis poses no threat to mammals, but injections
should be avoided.
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4.6 Conclusion
In the present study G. uralensis and ILG were identified as promising drug candidates for
the prevention or treatment of AD. ILG exhibited protective properties against Aβ toxicity
and oxidative stress possibly via hormetic pathways and by modifying serotonergic neuro-
transmission. It activated DAF-16, the C. elegans homologue of FOXO, that is responsible
for several anti-stress reactions and extends lifespan in C. elegans. However, the treatments
with G. uralensis and ILG shortened the life of worms, pointing to a possible long-term tox-
icity of these treatments. Further research should elucidate the efficacy and therapeutic
dosage in mammals, and eventually in humans, allowing for metabolism and bioavailability
of ILG and other active substances from G. uralensis.
C. acaulis was studied in the context of AD for the first time. A dichlormethane extract
of this plant could counteract Aβ toxicity, but the main constituent Carlina oxide was not
alone responsible for this effect. This compound, however, was the active constituent in
antioxidant assays. The in vivo antioxidant activity for C. acaulis and Carlina oxide was
reported for the first time. Further research is needed to clarify the active constituents and
mechanism of action against Aβ toxicity and to elucidate possible toxicological issues in
mammals.
The screening identified several other plants that modified Aβ aggregation and may there-
fore have beneficial effects for people with AD. ILG as well as other secondary metabolites
from the effective plants may serve as useful lead structures for the development of new
drugs. The plant extracts containing several active compounds can also be effective multi-
target therapeutics, especially since there might be still unknown targets in AD. Since
finding a cure for AD has proven to be difficult, maybe even impossible for the advanced
stages of the disease, prevention is gaining more and more importance. Adding effective
plants like G. uralensis to the regular diet might be a practical option for prevention.
Some secondary metabolites have specific targets, but more often the mechanism of action
is more general. For example, ILG can activate transcription factors related to stress resis-
tance and was suggested to act via hormetic pathways in the present work. Since protein
aggregation, oxidative stress, and inflammation are not limited to AD but rather a common
theme in many age related neurodegenerative diseases, the plants identified here might
also be helpful in Parkinson’s disease, dementia with Lewy bodies, or other similar condi-
tions. Therefore, the identified plants and active secondary metabolites should be studied
further in other models. Their usage for prevention and treatment of diseases as well as for
healthy ageing in general should be considered.
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